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Abstract
Infection remains a major cause of morbidity and hospitalisation in children receiving 
chemotherapy treatment for cancer. Among patients with the same diagnosis and treatment 
regimen, not all suffer equally from infectious complications. This suggests that as yet 
unidentified host factors may contribute to increased susceptibility to infection. Deficiency 
of mannose binding lectin (MBL), a pattern recognition receptor o f the innate immune 
system, has been proposed as one such factor but clinical studies have been inconclusive. 
MBL works in concert with MBL associated serine proteases (MASPs) to activate the 
lectin pathway of complement. Functional activity of the pathway has not been 
investigated in children with cancer to date.
Children undergoing chemotherapy were recruited to cross sectional observational and 
longitudinal studies with details of febrile neutropenia (FN) episodes recorded 
prospectively. MBL gene polymorphisms were characterized by heteroduplexing and 
reverse hybridization. MBL protein and MASP levels were measured and functional 
activity of the lectin pathway was quantified. High oligomer structure of MBL was 
analysed by Western blotting. Transcriptional regulation of MBL in response to infection 
and inflammation was studied. The MBL promoter was cloned and its activity investigated 
using luciferase assays.
A major finding is that individuals in possession of MBL variant alleles suffered from more 
frequent and longer episodes of FN over the study period compared to wildtype individuals. 
Functional analysis enabled identification of specific deficiencies within the pathway in 
patients deemed MBL sufficient by their genotype and protein level. Changes in MASP 
levels were noted in response to chemotherapy and complement function was observed to 
increase during FN episodes. Structural analysis revealed variability in MBL higher order 
oligomer structure during the acute phase of FN and promoter studies further highlighted 
the complexity o f MBL regulation.
The results presented in this thesis provide further evidence that MBL deficiency increases 
the frequency and the duration of FN in the largest paediatric cancer cohort studied to date. 
The complex interplay between other pathway components appears crucial to MBL 
function but their influence on clinical outcome is not yet fully understood.
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1.0 Introduction
In the western world approximately 1 in every 600 children develops a malignancy in 
the first 15 years of life (Stiller, 2007). During the past 30-40 years there have been 
marked improvements in outcome and now over 70% of children diagnosed with cancer 
enjoy disease free survival in excess of 5 years (Sankila et al., 2006). Improvements in 
the prevention and treatment of infections have contributed to the reduction in mortality. 
However infection related to immunosuppression is still a cause of treatment-related 
death and remains a major cause of morbidity and hospitalisation in children receiving 
chemotherapy (Basu et al., 2005).
Children with the same underlying disease and on the same treatment protocol vary in 
their susceptibility to infection; the reasons for this are currently unknown (Graubner et 
al., 2008). This thesis aims to explore the influence of host innate immunity, particularly 
the role of Mannose Binding Lectin (MBL) and the lectin pathway of complement 
activation, to increased susceptibility to infection in children with cancer.
1.1 Susceptibility to infection during chemotherapy treatment
Establishing the fine balance between effective treatment and tolerable toxicity is an 
ongoing challenge in oncology because the intensive treatment protocols employed to 
achieve improvements in outcome are complicated by such profound 
immunosuppression. Therapy induced neutropenia is considered the most important risk 
factor for infection in cancer patients. The relationship between the degree of 
neutropenia and the risk of bacterial and fungal infections was first recognised nearly 
forty years ago. Bodey et al studied the infectious complications experienced by 52 
patients treated with cytotoxic chemotherapy for acute leukaemia (Bodey et al., 1966).
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They observed that as granulocyte counts fell (particularly below 0.5x109/L), the 
frequency, duration and severity of infections dramatically increased (Figure 1.1).
Figure 1.1 Incidence of severe infection by absolute neutrophil count (ANC x l0 9/L) 
and duration of neutropenia (adapted from Bodey et al., 1966).
The degree and duration of neutropenia is generally determined by the intensity of 
treatment and the patient’s underlying disease. Clinical observations show that the 
majority of patients experience neutropenic episodes but interestingly not all suffer 
equally from associated complications implying that neutropenia is just one of many 
contributingjactors. The various modalities of treatment used to conquer the underlying 
disease have different effects on host defence. Alterations in skin/mucosal barriers, such 
as occur with the use of central venous catheters (CVCs), defects in adaptive immunity 
and in other arms of innate defence are all likely to play a role in susceptibility to 
infection (Figure 1.2).
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Figure 1.2 Alterations in host defence in patients receiving treatment for cancer
(from Lehmbecher et al., 1997).
When managing children, the situation is complicated further by the maturity (or 
immaturity) of their underlying immune system (Schultz et al., 2004; Hartel et al., 
2005). The younger the patient the more immunologically naive he/she is and the more 
susceptible to both common and opportunistic infections. In a well child, development 
of the immune system results from exposure to common ‘wild-type’ infections and 
following vaccination. At present the effect of cancer and subsequent chemotherapy 
treatment on a developing immune system is not fully understood.
1.2 M anagement o f treatm ent related infection
Many infections in cancer patients result from microorganisms that form part of the 
normal host flora colonizing the skin and the gastrointestinal (GI) mucosa. In the 1960s 
and 1970s gram-negative bacteria were responsible for the majority o f infections seen
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and mortality rates were as high as 70% (Bodey et al., 1978). In 1971, Schimpff 
introduced the use of empirical intravenous broad spectrum antibiotics which resulted in 
a marked reduction in infection related mortality (Schimpff et al., 1971). More recent 
studies suggest that gram-positive organisms have become more common, especially 
coagulase-negative Staphylococcus (Duncan et al., 2007), which is thought to be 
associated with increasing use of indwelling catheters. Current management dictates 
that when a patient with known neutropenia (ie. absolute neutrophil count < 0.5-1.0 x 
109/L) develops a fever (ie. > 38.0°C for more than 4h or > 38.5°C on one occasion) 
he/she is admitted to hospital for intravenous antibiotic treatment. Duration of 
admission is influenced by the speed of fever resolution, isolation of microorganisms 
and clinical wellbeing of the patient. With such an approach, mortality from infection in 
paediatric febrile neutropenic episodes is now around 1% (Hann et al., 1997).
In 1997, Hann et al reported that no micro-organism could be isolated in 49% of the 
febrile episodes in children on chemotherapy (Hann et al., 1997), raising the question of 
whether a significant number of patients were being overtreated. Ongoing debate about 
which antibiotics to use, the role of monotherapy and the potential role of outpatient 
based therapy coupled with increasing acknowledgement of the heterogenous nature of 
the patient group has resulted in efforts to modify management.
Attention has turned to the area of risk stratification (RS), by which patients at high risk 
of serious infection may be selected for intensive treatment and patients at low risk of 
serious infection may have their antimicrobial treatment appropriately reduced. The 
identification of prognostically different groups in oncology is not new e.g. the use of 
minimal residual disease testing (Goulden et al., 2001), but the use of RS in the 
management of infection in paediatric patients is still in its infancy. Such an approach 
potentially reduces the risk of nosocomial infection and the development of bacterial 
resistance and it has obvious cost benefits. It would also enable children to spend more
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time at home with their families with the aim of improving quality of life. Such 
strategies are discussed in detail in Chapter 3.
The safe application of alternative management strategies in clinical practice is 
dependent on the ability to accurately identify Tow risk’ patients. Current strategies rely 
on clinical variables, neutrophil count and microbiological evidence of infection. 
Improved understanding of the complex interplay between other immunological risk 
factors and their specific contribution to infection susceptibility would be invaluable. 
The identification of specific “host defence factors” which may influence infection risk 
in these patients, would enable us to tailor management and potentially reduce further 
the burden of infection treatment in appropriate patients. Potential therapeutic options 
for the future may lie in the replacement of these immunomodulatory factors.
1.3 The immune system
The immune system is composed of innate and adaptive components, which together 
form major interactive defence forces in the fight against infection. The adaptive 
immune system is highly specific in response to both host and foreign antigens utilising 
B and T lymphocytes and generating immunological memory (Janeway et al., 2004; 
Medzhitov 2007). However, this response to foreign antigens is slow, since it takes 
three to seven days before clonal selection and expansion of lymphocytes occurs 
ensuring a specific immune response. In contrast, the innate immune system forms the 
first line of host defence and offers protection within the first minutes, hours or days of 
exposure to a potential pathogen (Beutler 2004; Medzhitov 2007). It is an evolutionarily 
ancient form of immunity originally thought to be non-specific in its action. However it 
is becoming increasingly apparent that this response has considerable specificity and is 
able to discriminate between pathogens and self. Defects in the adaptive immune system
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are likely to influence the way we deal with an infection but defects in the innate 
response are more likely to influence susceptibility and is the focus o f the present study.
1.4 The innate immune system
Unlike the adaptive immune response the innate response does not recognise every 
antigen it encounters. Instead it utilises an array of pattern recognition receptors (PRRs) 
to recognise highly conserved structures present on pathogens termed pathogen 
associated molecular patterns (PAMPs) or more appropriately microbe associated 
molecular patterns (MAMPs). PAMPs/MAMPs are unique to microbes and therefore 
prevent recognition o f self. PAMPs/MAMPs share a number o f common features and 
are usually essential for the survival or pathogenicity o f microorganisms (Janeway, Jr., 
1989; Akira et al., 2006). Examples of PAMPs/MAMPs include bacterial 
lipopolysaccharide (LPS), peptidoglycan and mannans.
1.4.1 Pattern recognition receptors (PRRs)
PRRs are expressed on effectors cells of both the immune and non-immune system 
(Medzhitov and Janeway, Jr., 1997; Medzhitov 2007). Once a PAMP/MAMP is 
recognised the PRR is able to signal to its effectors enabling an appropriate response. 
PRRs can be distinguished structurally, according to their protein family of origin or 
relating to their function i.e. signalling, endocytic or secreted. The main functions of 
PRRs include: opsonization, activation of complement and coagulation cascades, 
phagocytosis, production o f antimicrobial peptides (AMPs), activation of pro- 
inflammatory signalling pathways and induction of apoptosis (Medzhitov and Janeway, 
Jr., 2000; Hoebe et al., 2004). Examples of the different PRRs and their functions are 
illustrated in Table 1.1.
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1.4.2 Effector mechanisms of innate immunity
The innate response is rapid leading to activation of effector mechanisms immediately 
after exposure to a potential pathogen. These mechanisms consist of two major 
components: recruitment and/or activation of leukocytes (eg. neutrophils,
monocytes/macrophages, mast cells and eosinophils) which are capable of combating 
invading pathogens and the release and/or activation of a variety of extracellular 
humoral mediators (eg. complement, cytokines and antimicrobial molecules). Evidence 
suggests that cellular effectors of innate responses ie. neutrophils, macrophages, 
dendritic cells (DCs) and natural killer (NK) cells are all affected by cancer treatment 
and diminished. At times of immunosuppression, it has been proposed that non-cellular 
and/or humoral innate host defences which are less affected by disease and treatment 
may assume greater importance (Lehmbecher et al., 1997).
The predictive value of innate inflammatory markers such as C-reactive protein (CRP), 
procalcitonin and cytokines including Interleukins (IL) such as IL-6 and IL-8, tumour 
necrosis factor alpha (TNF-a) and interferon gamma (INF-y) during febrile neutropenic 
episodes has been explored in a number of studies (Abrahamsson et al., 1997; de Bont 
et al., 1999; Lehmbecher et al., 1999; Fleischhack et al., 2000; Oude Nijhuis et al., 
2002; Lehmbecher et al., 2004; Stryjewski et al., 2005). As yet no single marker with 
sufficient predictive value or discriminative power to be used in clinical practice has 
been identified (Hartel et al., 2007).
Many studies to date have investigated the potential role of immune candidate genes in 
susceptibility to infectious diseases. For example; genetic variability in cytokine loci 
has been shown to influence both the risk of acquiring infection and the risk of 
developing severe complications in many non-malignant and malignant diseases (van 
Deventer, 2000; Dickinson et al., 2004; Lu et al., 2005). IL-10 gene polymorphisms 
have been associated with severity of illness in patients with community acquired
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pneumonia (Gallagher et al., 2003), pneumococcal septic shock (Schaaf et al., 2003) 
and rate of progression of Human Immunodeficiency Virus (HIV) (Shin et al., 2000; 
Smolnikova and Konenkov, 2002). An association between a high producing IL-6 
promoter polymorphism and frequency and type of infection in patients with Acute 
Myeloid Leukaemia (AML) has been reported but a number of other innate genes 
explored in the same patient group showed no effect (Lehmbecher et al., 2005).
There is a growing body of evidence to suggest that genetic deficiency of the humoral 
innate defence molecule and PRR, Mannose Binding Lectin (MBL), influences 
infection susceptibility and severity in patients undergoing treatment for cancer and the 
specific studies are discussed in detail in Section 1.8. Despite somewhat conflicting 
results and a number of unanswered questions about its specific role; MBL replacement 
therapy has been developed and is currently being investigated in this patient population 
(Petersen et al., 2006). Further work is required to establish exactly how this protein is 
operating in these patients in order to ensure the safe and appropriate application of 
MBL replacement in the future.
MBL is now known to have a number of different functions and does not work in 
isolation. In combination with MBL associated serine proteases (MASPs) it activates 
the lectin pathway of complement, also activated by Ficolins, which are a structurally 
and functionally related protein family. This thesis describes investigations of MBL and 
the lectin pathway of complement in children undergoing treatment for cancer. The 
components of the pathway and their effect on health and disease are now discussed in 
more detail.
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1.5 M annose Binding Lectin (MBL)
MBL is a member of the Collectin family; collagenous calcium-dependent lectins with a 
C-terminal lectin or carbohydrate-recognition domain (van de Wetering et al., 2004; 
Holmskov et al., 2003). The existence of mammalian serum lectins was first predicted 
by Robinson and colleagues (Robinson et al., 1975) and MBL protein was first isolated 
in cytosolic fractions of rabbit liver (Kawasaki et al., 1978). Subsequently, MBL was 
isolated from both human and rat liver (Wild et al., 1983). More recently extra-hepatic 
transcription of MBL in the small intestine and testis tissue has also been reported 
(Seyfarth et al., 2006).
Other human collectins include; Surfactant proteins A and D (SP-A, SP-D) which 
possess similar structural characteristics to MBL and are found predominantly in the 
lung and other mucosal sites (Holmskov et al., 2003), collectin liver 1 (CL-L1) (Ohtani 
et al., 1999) and collectin placenta 1 (CL-P1) (Ohtani et al., 2001) (Figure 1.3). Two 
other collectins: conglutinin, collectin of 43kDa (CL-43) and collectin of 46 kDa (CL- 
46) have so far only been detected in bovidae (Hansen et al., 2002).
Figure 1.3 The subunit structures of Collectins
(from Holmskov et al., 2003)
26
Introduction 1
1.5.1 Structural aspects of MBL
MBL consists of multimers of a single polypeptide chain of 25KDa, which on post- 
translational modification (including hydroxylation and glycosylation) attains a 
molecular weight of ~32KDa (Jensen et al., 2007a). Each chain comprises four distinct 
regions encoded by different exons of the MBL-2 gene as illustrated in Figure 1.4 and 
discussed in 1.5.3.
Each chain has a C-terminal calcium dependent carbohydrate recognition domain 
(CRD), a short a-helical hydrophobic neck region (coiled-coil configuration), a 
collagenous region containing 19 Gly-Xaa-Xaa triplets and a cysteine rich N-terminal 
region (Figure 1.4). Three polypeptide chains form a triple helix within the collagenous 
region, further stabilised by non covalent hydrophobic interactions (Sastry et al., 1989) 
and inter-chain disulphide bonds (Drickamer et al., 1986; Colley and Baenziger, 1987) 
within the N terminal cysteine rich region. The triple helix is the basic building block of 
circulating MBL. MBL oligomers ranging from dimers to hexamers (and higher) are 
found in serum (Dahl et al., 2001). X-ray crystallography and electron microscopy 
suggest a sertiform or bouquet like structure for MBL (similar to Clq) most likely due 
to an interruption in the collagenous region giving rise to a kink/hinge (Lu et al., 1990; 
Holmskov et al., 2003; Jensen et al., 2005;). The ability of MBL to bind 
microorganisms and activate complement depends on the presence of higher order 
oligomer structure (tetramers and above) (Larsen et al., 2004). Importantly, trimer and 
tetramers are the most abundant oligomer forms in serum (Teillet et al., 2005).
Each CRD binds a calcium ion enabling it to form coordination bonds with the 3- and 4- 
hydroxyl groups of specific sugars; mannose, glucose, L-fucose, N-acetyl-mannosamine 
(ManNAc) and N-acetyl-D-glucosamine (GlcNAc) (Weis et al., 1991; Weis and 
Drickamer, 1994). The three CRDs in each structural subunit are separated by a 
constant 45 A distance (Sheriff et al., 1994). Clustering of the structural subunits
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Figure 1.4 Structure of the human MBL-2 gene and the encoded protein product.
Positions of the exonl and promoter polymorphisms are shown. Three identical 32KDa 
MBL polypeptides form a collagenous triple helix.
provides a flat platform, which permits binding of MBL to the arrays of repeating sugar 
groups on microbial surfaces. Although the binding affinity of each individual CRD- 
sugar interaction is relatively low at 10‘3M (Iobst et al., 1994) the formation of higher 
order oligomers provides multiple CRDs which are able to bind simultaneously with 
high avidity.
MBL is a major pattern recognition molecule of the innate immune system. It primarily 
recognises specific sugar groups (as above) on the surface of microorganisms (enabling 
it to distinguish self from non-self). It has been shown to bind to a wide range of 
bacteria, viruses, fungi and protozoa (Table 1.2) but can also bind phospholipids, 
nucleic acids (Palaniyar et al., 2004) and non-glycosylated proteins.
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Microbes References
Fungi
Aspergillus fumigatus (Neth et al., 2000)
Candida albicans (Tabona et al., 1995; Neth et al., 2000)
Cryptococcus neoformans (Schelenz et al., 1995)
Bacteria
Actinomyces israelii (Townsend et al., 2001)
Bifidobacterium bifidum (Townsend et al., 2001)
Burkholderia cepacia (Davies et al., 2000)
Chlamydia pneumoniae (Swanson et al., 1998)
Escherichia coli (van Emmerik et al., 1994)
Fusobacterium (several species) (Townsend et al., 2001)
Haemophilus influenzae (van Emmerik et al., 1994; Neth et al., 2000)
Klebsiella aerogenes (Neth et al., 2000)
Leptotrichia buccalis (Townsend et al., 2001)
Listeria monocytogenes (van Emmerik et al., 1994)
Mycobacterium avium (Polotsky et al., 1997)
Neisseria meningitidis (van Emmerik et al., 1994; Neth et al., 2000)
Proprionibacterium acnes (Townsend et al., 2001)
Pseudomonas aeruginosa (Davies et al., 2000)
Salmonella montevideo (Kuhlman et al., 1989)
Staphylococcus aureus (Neth et al., 2000)
Streptococcus pneumoniae (Neth et al., 2000)
Veillonella dispar (Townsend et al., 2001)
Protozoa
Cryptosporidium parvum (Kelly et al., 2000)
Plasmodium falciparum (Klabunde et al., 2002)
Trypanosoma cruzi (Kahn et al., 1996)
Viruses
Influenza A (Kase et al., 1999; Saifuddin et al., 2000; Hart et al., 2002; Ji et al., 2005)
HIV (Saifuddin et al., 2000; Hart et al., 2002; Ji et al., 2005)
Herpes simplex 2 (Fischer et al., 1994; Gadjeva et al., 2004)
SARS-CoV (Ip et al., 2005)
Table 1.2 MBL binds to a range of microbial surfaces
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Using flow cytometry Neth et al demonstrated MBL binding to clinically relevant 
bacterial isolates from immunocompromised children and noted differences in binding 
within some species (Neth et al., 2000). The role of specific structures on 
microorganisms (e.g. the capsule) which permit or prevent binding to MBL has been 
explored (Krarup et al., 2005). Early studies suggested lipopolysaccharide (LPS) may 
play a crucial role in MBL binding and function (Kawakami et al., 1982). Other 
mechanisms which enable microorganisms to avoid recognition include 
lipooligosaccharide (LOS) sialyation (Jack et al., 1998; Devyatyarova-Johnson et al., 
2000).
1.5.2 Functional aspects of MBL
MBL is implicated in diverse processes including complement activation, complement- 
independent opsonophagocytosis, inflammation, recognition of altered self-structures 
and apoptotic cell clearance.
1.5.2.1 MBL and complement activation
Complement was first described in the 1890s by Jules Bordet as a heat labile protein in 
serum that ‘complemented’ heat stable antibodies in the killing of bacteria. It is now 
known to be a highly developed host-defence system involved both in innate and 
antibody-mediated immunity (Walport, 2001a; Walport, 2001b; Gros et al 2008). It 
consists of over 30 protein components involved in a cascade of reactions which 
ultimately result in opsonization of pathogens, chemotaxis and activation of leucocytes 
and direct killing of pathogens via the membrane-attack complex (MAC). There are 
three activation pathways, namely the classical (Cooper, 1985), alternative (Pillemer et 
al., 1954) and lectin (Fujita et al., 2004) which converge into one common final lytic 
pathway (Figure 1.5).
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Figure 1.5 Activation of the classical, alternative and lectin pathways.
Alternative pathway inhibitors are not illustrated (Fujita, 2002).
A role for MBL in host defence was first proposed in 1987 when Ikeda et al observed 
that the protein was able to activate the classical pathway of complement (Ikeda et al., 
1987). However, it is now clear that MBL activates the novel third pathway of 
complement, often termed the MBL Lectin pathway, in an antibody and Cl-independent 
fashion. This pathway is also activated by Ficolins which are discussed in detail in 
Section 1.6.
MBL circulates in association with a group of MASPs (Sorensen et al., 2005). In 1992 a 
novel complement enzyme thought to generate C3 convertase (C4bC2a), associated 
with classical pathway activation was identified (Matsushita and Fujita, 1992).
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However, this activity was later found to be mediated by MASP2 (Thiel et al., 1997) 
and the original enzyme is now known as MASP1. Subsequently a small fragment of 
MASP2 termed sMAP or Mapl9 was reported (Stover et al., 1999; Takahashi et al., 
1999). A third MASP (MASP3) has also been identified (Dahl et al., 2001). The 
MASPs are described in more detail in Section 1.7.
MBL (or Ficolins) binding to microorganisms leads to auto-activation of MASP2. 
MBL/MASP2 complexes initially cleave C4 to produce C4b and C4a. C4b remains 
attached near to the MBL/MASP complex and recruits C2 which is also cleaved by 
MASP2 (Wallis et al., 2007). This results in formation of C2b and C2a, the latter of 
which remains attached to C4b to form C3 convertase (C4b2a). The C3 convertase is 
indistinguishable in specificity to that found in the other two activation pathways of 
complement (Feinberg et al., 2003). Recent studies suggest that both MASP1 and 
MASP2 are required for the generation of C3 convertase with MASP3 acting as a 
competitive inhibitor (Dahl et al., 2001; Moller-Kristensen et al., 2007).
Interaction between MBL and the alternative pathway has been proposed (Brouwer et 
al., 2006) and one report suggests an MBL dependent C2 bypass mechanism for 
alternative pathway- mediated C3 activation (Selander et al., 2006).
1.5.2.2 Opsonophagocytosis
In 1968, Miller et al reported a plasma associated defect of phagocytosis in a child with 
severe recurrent infections, failure to thrive and diarrhoea (Miller et al., 1968). In-vitro 
work revealed a failure of the child’s plasma to opsonise heat killed bakers yeast 
{Saccharomyces cerevisiae). This defect was later detected in the sera of children with 
recurrent, unexplained infections (Soothill and Harvey, 1976) and chronic diarrhoea of 
infancy (Candy et al., 1980). Interestingly, studies revealed a relatively high frequency 
of this defect in the general population (-5%). This defect was subsequently shown to 
be due to decreased deposition of C3b on yeast surfaces, linking it to the complement
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system (Turner et al., 1981). Finally, the opsonic defect was found to be associated with 
low levels of MBL (Super et al., 1989).
1.5.2.3 Cell receptors for MBL
MBL interacts directly with cell surface receptors and promotes opsonophagocytosis 
(Kuhlman et al., 1989). MBL has been shown to neutralize influenza A virus (Kase et 
al., 1999). A number of putative MBL-binding proteins/receptors have been proposed 
including cClqR/calreticulin (Malhotra et al., 1990), ClqRp (Tenner et al., 1995), CR1 
(Klickstein et al., 1997; Ghiran et al., 2000) and a2pi Integrin (Edelson et al., 2006). 
MBL may share a common receptor with Clq (Oroszlan et al., 2007). Down stream 
signalling pathways also remain elusive. The TLR/NF-kB pathway has been implicated 
in downregulation of the pro-inflammatory cytokine response to LPS by SP-A and Clq 
but not MBL (Alcorn and Wright, 2004; Yamada et al., 2004). At present, it is unclear 
whether MBL acts as a direct opsonin or acts as a modulator of other complement 
pathways and/or antibody mediated phagocytosis.
1.5.2.4 MBL in inflammation
The role of MBL as a modulator of inflammation appears to be complex and, 
accordingly, its mechanism(s) of action remains unclear. Early work suggested that 
MBL could inhibit TNFa output by monocytes in response to streptococcal rhamnose 
glucose polymers (a molecule related to LPS) and cryptococcal membrane glycoprotein 
(Soell et al., 1995; Chaka et al., 1997). However increased TNFa release was 
demonstrated in response to other organisms including Candida, Leishmania chagasi 
and HIV-1 gpl20 protein (Ghezzi et al., 1998; Santos et al., 2001; Heggelund et al.,
2005). Further work suggests that the effect of MBL on cytokine production may be 
concentration dependent. This concept was addressed in studies by Jack et al using 
Neisseria meningitidis incubated with increasing concentrations of MBL before being 
added to MBL deficient whole blood. Release of TNF-a, IL-lp and IL-6 from
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monocytes was enhanced at MBL concentrations below 4jig/ml but suppressed at higher 
concentrations (Jack et al., 2001). Further studies have supported the finding that MBL 
can modulate the pro-inflammatory cytokine response (Nadesalingam et al., 2005; 
Fraser et al., 2006). MBL also appears to promote production of the anti-inflammatory 
cytokine IL-10 (Sprong et al., 2004; Fraser et al., 2006).
Clinical studies of critically ill patients requiring intensive care management have 
shown that individuals who are MBL deficient are more likely to develop Systemic 
Inflammatory Response Syndrome (SIRS) and progress to septic shock and death 
(Garred et al., 2003a; Fidler et al., 2004), findings which may well relate to the 
proinflammatory cytokine response. It should also be noted that chronic inflammation is 
now increasingly accepted to be a risk factor for myocardial infarction (MI) and a recent 
study by Saevarsdottir et al has found that patients with high MBL levels have a 
decreased likelihood of suffering a myocardial infarction - again suggesting a potential 
role for MBL in modulating the inflammatory response (Saevarsdottir et al., 2005).
1.5.2.5 The role o f MBL in the recognition of altered self and apoptosis 
A role for MBL in the clearance of apoptotic cells has been proposed (Ogden et al., 
2001; Palaniyar et al., 2003; Palaniyar et al., 2004). Defects in the clearance of 
apoptotic cells have been implicated in the pathogenesis of certain autoimmune 
conditions although the precise role of MBL, if any, remains elusive. For example, 
MBL deficient mice display defective apoptotic cell clearance, and yet do not develop 
autoimmune diseases (Stuart et al., 2005).
In animal studies MBL has been implicated in the pathophysiology of ischemia 
reperfusion injury due to its ability to recognize altered self-structures. Studies by Stahl 
et al have proposed the lectin pathway as a mediator of this process in certain organs 
and the absence of MBL/MASP pathway activation appears to afford protection in these 
disease models (Hart et al., 2005; Walsh et al., 2005). Different roles for the MBL and
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classical pathways in skeletal muscle ischaemia reperfusion injury have been 
demonstrated with the MBL pathway mediating the cytotoxic effects of reperfusion 
injury and the classical pathway mediating vascular injury (Chan et al., 2006). 
However, the relevance of these findings to human health needs to be established. 
Changes in cell surface structures during oncogenic transformation appear to promote 
binding of MBL to cancer cells (Hakomori, 2001) where the protein can mediate 
cytotoxic effects including MBL-dependent cell mediated cytotoxicity (MDCC) (Ma et 
al., 1999; Nakagawa et al., 2003). The relative importance of such mechanisms in 
tumour immunology is, at present, unknown.
1.5.3 Genetics of human MBL
Although there are two human MBL genes, MBL1 is a pseudogene and only MBL2 
encodes a protein product. The functional MBL2 gene is located on chromosome 
10qll.2-q21 (Sastry et al., 1989; Taylor et al., 1989) in a cluster encoding SP-A and 
SP-D (Kolble et al., 1993). MBL comprises four exons as illustrated in Figure 1.4. Exon 
1 encodes the signal peptide, the N-terminal cysteine-rich region and part of the glycine 
rich collagenous region. Exon 2 encodes the remainder of the collagenous region and 
exon 3 encodes the a-helical ‘neck’ region. The fourth exon encodes the carbohydrate 
recognition domain. The promoter region contains a number of regulatory elements 
which are known to affect transcription (Naito et al., 1999).
The complete nucleotide sequence of the MBL2 gene was established in two British 
children with recurrent infections and low MBL protein levels (Sumiya et al., 1991). In 
both individuals a point mutation was observed in codon 54 (GGC —*• GAC, glycine to 
aspartic acid). Familial studies confirmed the defect was inherited in an autosomal 
dominant fashion. Since then further mutations in exon 1 have been identified. The
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codon 57 mutation (GGA —> GAA, glycine to glutamic acid) was identified in a sub- 
Saharan African population (Lipscombe et al., 1992) followed by the mutation in codon 
52 (GCG —► GTG, arginine to cysteine) originally identified in both Caucasian and 
Kenyan populations (Madsen et al., 1994). These point mutations are commonly 
referred to as variants B, C and D with A indicating the wildtype (WT). The B variant 
occurs at a gene frequency of -25% in Eurasian populations. In contrast, the C variant is 
rare in Eurasians but common in sub-Saharan African populations with frequencies of 
50-60%. Population studies suggest that the B variant mutation may have arisen 20,000- 
50,000 years ago (Turner et al., 2000).
The effect of exon 1 mutations on protein function is an active area of research. 
Impairment of oligomer structure and MASP binding/activation results in functional 
deficiency. B and C mutations result in replacement of critical axial glycines in the 
triple helix by dicarboxylic acids which result in distortion and destabilisation of helix 
formation (Sumiya et al., 1991; Persikov et al., 2004). In contrast the D mutation results 
in replacement of an arginine with a cysteine. An extra cysteine is likely to cause 
adventitious disulphide bond formation affecting higher oligomer formation (Wallis and 
Drickamer, 1999).
Three polymorphisms, H/L, X/Y and P/Q at positions -550, -221 and +4 in the promoter 
region of the MBL2 gene have also been reported (Madsen et al., 1995; Madsen et al., 
1998). Subsequently, four common haplotypes LXP, LYP, LYQ and HYP are known to 
occur. Of these, HYP, associated with medium to high levels of MBL and LXP, 
associated with low levels of the protein, appear to have the most profound effect. These 
promoter haplotypes are in strong linkage disequilibrium with the exon 1 mutations 
resulting in seven common extended haplotypes, namely, HYP A, LYP A, LYQA, 
LXPA, HYPD, LYPB and LYQC. Figure 1.6 illustrates the frequency of these various 
haplotypes in selected populations and highlights the degree of ethnic variation. Other
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Figure 1.6 MBL haplotype frequencies in different populations.
Haplotype frequency data are taken from published population studies. 
l=Chiriguanos, Argentina (Madsen et al., 1998), 2=Mapuche, Argentina (Madsen et al.,
1998), 3=Eskimos, Greenland (Madsen et al., 1998), 4= Caucasians, Spain (Lozano et 
al., 2005), 5=Caucasians, Denmark (Madsen et al., 1998), 6=Mozambique (Madsen et 
al., 1998), 7=Kenya (Madsen et al., 1998), 8=Korea (Lee et al., 2005a), 9=Japan 
(Matsushita et al., 1998), 10=Warlpiri, Australia (Turner et al., 2000).
rare haplotypes have also been described (Boldt and Petzl-Erler, 2002) and additional 
polymorphisms in other areas of the gene are also under investigation (Bemig et al., 
2004; Bemig et al., 2005).
Combined structural gene and promoter polymorphisms result in dramatic variation in 
MBL concentration even in apparently healthy individuals (Caucasian range <20-10000 
ng/ml) (Figure 1.7). Such variation in MBL concentration is observed when levels are 
measured using antibody capture techniques utilising antibodies that preferentially 
detect higher (functional) MBL oligomers. Recent work using alternative capture
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Figure 1.7 Correlation between MBL levels and genotype
Genotypes are shown in a simplified form using just the exonl and XY promoter 
genotypes. The O allele represents any of the exonl variant alleles, B,C or D (adapted 
from Christiansen et al., 1999).
antibodies which detect both large and small oligomers now suggests that levels may 
not vary so dramatically in individuals in possession of variant MBL but just that their 
MBL has reduced complement activating ability (Garred et al., 2003b).
MBL may also act an acute phase reactant (Ezekowitz et al., 1988). Studies have shown 
MBL levels can increase up to 3 fold during the acute phase, the response being variable 
between individuals (Thiel et al., 1992; Dean et al., 2005; Van Till et al., 2006). It 
should be noted that during an acute phase response individuals heterozygous or 
homozygous for MBL mutations appear unable to achieve the protein levels o f those 
possessing a WT genotype. More recently it has been suggested that MBL synthesis 
may be subject to hormonal regulation (Sorensen et al., 2006).
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Approximately one third of the Caucasian population possess genotypes conferring low 
levels of ‘functional’ MBL with approximately 5% having very low levels i.e 
homozygotes or compound heterozygotes. No absolute level of MBL deficiency has 
been defined. Genotype and phenotype show a relatively strong correlation and studies 
often use just one measure to infer deficiency.
1.5.4 MBL gene evolution
Although two MBL genes are present in the human genome only MBL2 encodes the 
protein. This is in contrast to rodents and rhesus monkeys where MBL occurs in two 
distinct forms (Mogues et al., 1996; Hansen et al., 2000). The two human MBL genes 
are most likely due to a gene duplication event (Sastry et al., 1995) and the potential 
mechanisms responsible for silencing the MBL1 gene are under debate. An intron 1 
splicing defect leading to two stop codons in exons 3 and 4 of the MBL1 gene may be 
one such mechanism (Guo et al., 1998). More recently, Seyfarth et al identified glycine 
substitutions in codon 53 of the MBL1 gene which bear a close resemblance to those 
found in codon 54 of MBL2 (Seyfarth et al., 2005). Such substitutions were also found 
in other higher primates including chimpanzees and gorillas but not in more distant 
primates such as the rhesus monkey. It has been proposed that both the MBL1 and 
MBL2 genes have been selectively silenced by the same molecular mechanisms, but 
skewed in time resulting in overall downregulation of MBL levels in the present human 
population.
1.5.5 The MBL Paradox
The high frequency of variant alleles observed in certain populations suggests that 
functional MBL deficiency may well be advantageous. Certain intracellular parasites
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use C3 opsonization and C3 receptors on monocytes/macrophages to enter their host. 
Therefore any reduction in complement-activating function of the host may reduce the 
probability of parasitization. Studies of visceral leishmaniasis revealed that patients are 
more likely to have high MBL levels than uninfected controls (Santos et al., 2001; 
Alonso et al., 2007). Presence of MBL deficiency has also been shown to confer 
protection against lepromatous or borderline lepromatous leprosy (Garred et al., 1994; 
Domelles et al 2006; de Messias et al., 2007). An alternative explanation of the 
unexpectedly high frequency of low MBL phenotype individuals found in many tropical 
regions is that excessive complement activation can result in immunopathologically 
mediated host damage and therefore any mechanism that reduces complement activation 
may be beneficial (Lipscombe et al., 1992).
1.S.6 MBL polymorphisms and disease
The clinical significance of MBL deficiency was initially studied in young children with 
recurrent infections, where it was suggested that MBL may provide protection during 
the ‘window of vulnerability’(approximately during 6-24 months of age), i.e. the period 
when maternal IgG antibody levels have waned and the infant’s own adaptive immune 
response is still immature (Super et al., 1989; Summerfield et al., 1997; Koch et al., 
2001). However numerous studies have shown that MBL plays a role throughout life, as 
an ante-antibody, a critical component of first line host defence (Ezekowitz, 1991; 
Summerfield et al., 1995). MBL deficiency has been implicated in both disease 
susceptibility and as a modulator of severity although it is often difficult to make such a 
distinction. Table 1.3 highlights a selection of studies to illustrate the diverse evidence 
that has been accrued.
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CONDITION OUTCOME REFERENCE
Meningococcal infection Increased susceptibility in patients who were homozygous for 
MBL variant alleles- Hospital study 7.7% cf. 1.5% in controls, 
Community study- 8.3% cf. 2.7% in controls
Hibberd et al., 
1999
Faber et al., 
2007
Increased frequency of MBL variant genotypes in patients 
compared to controls (32% Vs 8%)
Mycoplasma infection Increased frequency of MBL deficiency in patients with primary 
antibody deficiencies and Mycoplasma compared to controls
Hamvas et al., 
2005
Invasive Pneumococcal 
infection
12% patients were homozygous for MBL variants cf. 5% controls Roy et al., 
2002; Moens et 
al., 2006
Small but significantly increased risk of infection in individuals 
with variant genotypes
SARS Increased frequency of MBL deficient genotypes in patients 
compared to controls
Ip et al., 2005; 
Zhang et al., 
2005
HIV- susceptibility Susceptibility was 8% in HIV infected homozygous patients, vs. 
0.8% in healthy controls and 0% among high-risk controls
Garred et al., 
1997
HIV- disease progression Duration o f survival for patients with variant alleles and those 
with WT alleles, 11 vs. 18 mths
Chronic hepatitis B D variant allele in 27% of white patients with hepatitis B and in 
4% of healthy uninfected controls
Thomas et al., 
1996
Yuen et al., 
1999; Chong et 
al., 2005
B variant allele in 44% of Chinese patients with cirrhosis and in 
23% of healthy uninfected controls
Increased occurrence of cirrhosis and hepatocellular carcinoma in 
individuals in possession of MBL variant alleles
Chronic hepatitis C -IFN 
responsiveness
LX promoter or B variant allele was present in 60.7% of 
unresponsive patients vs. 38.5% of responsive patients.
Matsushita et 
al., 1998
Plasmodium falciparum B and C variant alleles were more common in patients from 
Gabon with severe malaria
Luty et al., 
1998
Susceptibility to 
Crytosporidium parvum
MBL variant alleles were more common among HIV infected 
patients
Kelly et al., 
2000
Chronic necrotising 
pulmonary aspergillosis
MBL variant alleles were present in 70% of patients Vs. 26% of 
control subjects
Crosdale et al., 
2001
Cystic fibrosis Lung function significantly impaired in patients with variant 
MBL alleles. Association between MBL variant alleles and 
Burkholderia cepacia and Pseudomonas aeruginosa infection. 
MBL deficiency associated with earlier onset o f infection and 
faster decline of pulmonary function
Garred et al., 
1999b;
Dorfman et al., 
2008
Severity of liver disease in CF patients is more severe in patients 
with variant MBL alleles
Gabolde et al., 
2001
Homozygosity for MBL variant alleles is associated with reduced 
lung function and more frequent hospital admissions in adults
Davies et al., 
2004
Rheumatoid arthritis MBL variant alleles are associated with increased severity and 
early onset of disease
Graudal et al., 
1998; Ip et al., 
2000
SLE Increased frequency of variant alleles in patients. Over­
representation of Homozygotes for MBL variant alleles in Danish 
SLE patients, who had more significant renal involvement and 
infections
Garred et al., 
1999a, 2001; 
Lee et al., 
2005b
Homozygosity for MBL variant alleles is associated with an 
increased risk o f arterial thrombosis
Ohlenschlaeger 
et al., 2004
Systemic Inflammatory 
response syndrome 
(SIRS) -Adults
MBL variant alleles were associated with an increased risk of 
developing sepsis, severe sepsis, septic shock and death.
Garred et al., 
2003a
SIRS- Children MBL variant alleles were associated with an increased risk of 
developing SIRS and of progression to sepsis and septic shock.
Fidler et al., 
2004
Myocardial infarction Individuals with high MBL levels had a decreased likelihood of 
suffering a myocardial infarction.
Saevarsdottir et 
al., 2005
Table 1.3 Clinical associations between MBL and disease
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The impact of such a common immunodeficiency on the wellbeing of the general 
population has been questioned. Dahl et al studied 9245 Danish Caucasian adults as part 
of the Copenhagen Heart Study. Morbidity (any hospitalisation and infection) and 
mortality were recorded for 24 and 8 years, respectively. After adjustment for potential 
confounders, neither the relative risk for hospitalisation per se, nor hospitalisations for 
infection or death was significantly different between MBL deficient and MBL 
sufficient individuals (Dahl et al., 2004). Similar findings in unselected adults admitted 
to hospital with infections have been reported (Tacx et al., 2003). Studies by Roos et al 
offered one potential explanation for these observations. They found that antibody- 
mediated activation of the classical pathway of complement compensated for impaired 
target opsonization via the MBL pathway in MBL deficient individuals (Roos et al., 
2004). The high prevalence of MBL variant alleles without a major effect on population 
fitness suggests that MBL may be relatively redundant in the healthy host (Verdu et al., 
2006). However MBL deficiency appears to assume greatest clinical importance when it 
occurs in combination with defects in other arms of the immune system (Aittoniemi et 
al., 1998). One such population are patients on treatment for malignancy discussed in 
detail in Section 1.8.
1.6 Ficolins
The lectin pathway of complement is also activated by Ficolins. Ficolins are a group of 
proteins that consist of lectin domains linked to collagen and fibrinogen-like domains 
(Lu and Le, 1998). They were originally identified as transforming growth factor-pl 
(TGF-pl) binding proteins on porcine uterus membranes (Ichijo et al., 1991; Ichijo et 
al., 1993). Ficolins have now been identified in several species including rodents 
(Fujimori et al., 1998), hedgehogs (Omori-Satoh et al., 2000) and invertebrates (Kenjo 
et al., 2001).
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In human serum, two ficolins have been isolated: L-ficolin/P35 (Matsushita et al., 1996; 
Lu et al., 1996) and H-ficolin or Hakata antigen, (Fujimori et al., 1998; Akaiwa et al.,
1999) encoded by the FCN2 and FCN3 genes respectively. They bind to MASPs and 
activate the lectin pathway (Matsushita et al., 2000a). L- and H-ficolins are synthesised 
by hepatocytes, although H-ficolin has also been detected in bronchial/alveolar fluid and 
in bile (Matsushita et al., 1996; Akaiwa et al., 1999). A third human ficolin, M-ficolin is 
found on peripheral blood mononuclear cells (PBMCs), polymorphonuclear cells and 
type II lung epithelial cells and is encoded by the FCN1 gene. It can also bind MASPs 
and activate the lectin pathway (Lu et al., 1996; Teh et al., 2000; Frederiksen et al., 
2005; Liu et al., 2005).
1.6.1 Ficolin structure and function
Ficolins are structurally similar to MBL, as illustrated in Figure 1.8 and consist of three 
identical polypeptide subunits which form functional oligomers. Their fibrinogen-like 
domains enable specific binding to N-acetyl-glucosamine (GlcNAc) residues on 
microbial surfaces (Matsushita et al., 1996; Sugimoto et al., 1998; Fujimori et al., 1998; 
Ohashi and Erickson, 1997; Garlatti et al., 2007) and a number of non sugars (Krarup et 
al., 2004).
L-ficolin can bind lipoteichoic acid (LTA) from the cell wall of gram-positive bacteria 
(Lynch et al., 2004) and binding to a number of gram-positive and gram-negative 
organisms has now been demonstrated (Krarup et al., 2005; Aoyagi et al., 2005) . H- 
ficolin does not bind to Staphylococcus aureus or Streptococcus pneumoniae but can 
bind and inhibit growth of Aerococcus viridans (Tsujimura et al., 2002) and M-ficolin 
has been shown to bind specifically to Staphylococcus aureus (Liu et al., 2005). In 
addition to complement activating function there is also evidence to suggest that L- and
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Figure 1.8 Domain and oligomeric structure of mannose-binding lectin and 
ficolins. (from Fujita, 2002).
H-ficolin participate in the clearance of dying cells by binding to DNA on apoptotic and 
necrotic cells (Jensen et al., 2007b; Honore et al., 2007).
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1.6.2 Ficolins and disease
At present the impact of Ficolin deficiency on clinical disease is largely unknown. L- 
ficolin and H-ficolin are present in the serum at mean concentrations of -lOpg/ml and 
15pg/ml, respectively, which vary up to 10 fold in healthy blood donors (Kilpatrick et 
al., 2003a) and there is no accepted level indicating deficiency to date. H-ficolin has 
been reported to be elevated in systemic lupus erythematosus (SLE) (Yoshizawa et al., 
1997) and acute hepatitis and decreased in hepatic cirrhosis (Fukutomi et al., 1996). A 
study investigating L-ficolin levels in 313 Polish children with respiratory infections 
found levels below the lower limit of control values in 6% of patients (p=0.03) and were 
most strongly associated with children having atopic disorders (11%; p=0.002). The 
authors concluded that L-ficolin may have a role in protection from microorganisms 
complicating allergic diseases (Atkinson et al., 2004). Polymorphisms have been 
identified in the L-ficolin/FCN2 gene which correlate with low serum levels and altered 
function (Hummelshoj et al., 2005; Herpers et al., 2006; Munthe-Fog et al., 2007). A 
limited number of studies have investigated ficolin polymorphisms and susceptibility to 
disease. FCN1 single nucleotide polymorphisms (SNPs) have been implicated in the 
development of Rheumatoid arthritis and FCN2 SNPs have been linked with Behcets 
disease (Vander Cruysson et al., 2007; Chen et al 2007).
1.7 MBL associated serine proteases (MASPs)
As discussed previously, MASPs are a family of serine proteases found in serum in 
complex with both MBL and Ficolins. They are primarily synthesised in the liver but 
mRNA has recently been detected at other sites; MASP1 and MASP2 mRNA in the 
small intestine and testis tissue and MASP3 mRNA in brain, spleen, lung and thymus 
(Schwaeble et al., 2002; Seyfarth et al., 2006).
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The three MASPs and Map 19 are generated from two genes by alternative splicing 
(Figure 1.9). The MASP1 gene is located on chromosome 3q27-28 (Sato et al., 1994) 
and consists of 17 exons of which 16 encode MASP1 mRNA. Exons 1-10 encode 5 N- 
terminal domains and exons 12-17 encode the serine protease domain. Two splice 
variants of the gene generate MASP1 and MASP3. They share exons 1-10, with exon 
11 encoding the serine protease domain of MASP3 (Dahl et al., 2001). MASP2 and 
MApl9 (or sMAP) are generated by alternative splicing of the MASP2/MAp 19 gene 
located on chromosome lp36.2-3 (Stover et al., 1999; Stover et al., 2001). M Apl9 and 
MASP2 share exons 1-4 with the C terminal of MApl9 encoded by a unique exon 
encoding four amino acids, EQSL, followed by a stop codon.
Figure 1.9 Genomic organisation and protein structure of MASPs and MApl9
The exon-intron structure of the MASP and M Apl9 genes. The asterisks identify 
potential glycosylation sites and the arrows show the Arg-Ile bond for activation, 
(adapted from Schwaeble et al., 2002).
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MASPs share structural homology with Clr and Cls (Sato et al., 1994; Endo et al., 
1996; Arlaud et al., 1998). The N terminal structure is composed of two CUB (Uegf, a 
member of the epidermal growth factor family and bone morphogenic protein I) 
domains (Clr/Cls like domains), separated by an epidermal growth factor (EGF) like 
domain. In combination these domains are responsible for calcium dependent 
interaction with MBL or ficolins (Chen and Wallis, 2001; Cseh et al., 2002; Feinberg et 
al., 2003).
Two complement control protein (CCP) domains complete the non catalytic component, 
or A chain. A small linker region covalently bonds the A chain to the B chain or serine 
protease domain.
MASPs are synthesised as inactive presursors, which circulate as zymogens activated 
when MBL and ficolins bind to carbohydrates. On binding, MASPs are cleaved at the 
peptide bond (arginine-isoleucine) in the N terminal part of the serine protease domain. 
The active protease domain remains covalently attached to the MASP molecule by a 
disulphide bond.
The crystal structures of rat and human MASP2 have been elucidated (Feinberg et al.,
2003). The rat CUB1-EGF-CUB2 fragment exhibits an elongated structure responsible 
for binding to MBL and Ficolin and the CCP and serine protease domains determine the 
substrate specificity and recognition (Ambrus et al., 2003; Rossi et al., 2005; Girija et 
al., 2007). The recombinant human MASP2 CCP2/SP joint was found to be flexible 
most likely allowing for auto-activation (Harmat et al., 2004). Human MASP 1-3 and 
MApl9 form homodimers which independently associate with MBL in a calcium 
dependent complex (Thielens et al., 2001). Figure 1.10 illustrates a model of MASP2 
activation by MBL. On binding, changes in MBL structure enable conformational 
change at the flexible regions of the MASP resulting in activation.
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Figure 1.10 Model of MASP2 activation by MBL (from Wallis, 2007).
Studies to date suggest MASP complexes may not interact with the same MBL or 
Ficolin molecule even though there is similarity in their binding sites, with lys55 
playing a critical role in function (Mayilyan et al., 2005; Teillet et al., 2007). MBL 
oligomers differentially activate complement (Wallis and Drickamer, 1999) and appear 
to associate with different MASPs suggesting diversity in function is likely (Dahl et al., 
2001). MASP1 and MApl9 have been shown to associate with trimers possessing C3 
cleavage activity. In contrast, MASP2 associates with tetramers responsible for C4 
cleavage and MASP3 forms complexes with higher (tetramer and above) MBL 
oligomers. Importantly, MBL2 exon 1 polymorphisms affect MASP binding by 
destabilizing oligomer formation and also prevent conformational changes occurring in 
the bound MBL/MASP complex inhibiting MASP activation (Wallis and Dodd, 2000, 
Wallis 2007).
1.7.2 MASP activity
Autoactivation of MASP2 on MBL or Ficolins binding to a target ligand leads to 
activation of the lectin pathway o f complement (Gal et al., 2005) (Section 1.5.2.1.). The
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role of MApl9 or sMAP is not clearly understood but recent work suggests that it 
competes with MASP2 to bind MBL and attenuates lectin pathway activation in mouse 
models (Iwaki et al., 2006).
The role of MASP 1 in the activation of the lectin pathway of complement is somewhat 
controversial. MASP1 has been shown to cleave both C2 and C3 (Matsushita and Fujita, 
1992; Matsushita and Fujita, 1995; Matsushita et al., 2000b; Chen and Wallis, 2004) but 
has no activity towards C4. Studies using purified and recombinant MASP1 have 
resulted in contrasting results (Wong et al., 1999; Rossi et al., 2001; Ambrus et al., 
2003;) questioning the biological significance of MASP1 mediated C3 cleavage. 
However, recent data suggest that despite different modes of action both MASP1 and 
MASP2 are required for the generation of efficient C3 convertase (Moller-Kristensen et 
al., 2007). Studies investigating the physiological substrate for MASP1 have shown that 
it can cleave Factor XIII and fibrinogen, catalysing the formation of crosslinked fibrin 
(Hajela et al., 2002). It has been suggested that MASP1 may provide a link between the 
complement system and the coagulation system, thus playing a role in limiting spread of 
infection (Hajela et al., 2002; Gal et al., 2007).
Understanding of MASP3 function remains limited. MASP3 forms complexes with 
MBL oligomers and can act as a competitive inhibitor of both MASP1 and MASP2 
activity but does not auto-activate (Dahl et al., 2001; Moller-Kristensen et al., 2007). 
Recombinant MASP3 does not cleave C2, C3 or C4 and on activation does not complex 
with Cl inhibitor (Zundel et al., 2004). MASP3 has been shown to cleave insulin-like 
growth factor binding protein (IGFBP) 5 and a synthetic substrate for plasmin and 
kallikreins but the biological significance of these effects is unknown (Cortesio and 
Jiang, 2006).
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1.7.3 MASP genetics and deficiency
To date MASP2 is the only family member investigated in human disease. In 2003, the 
first case of MASP2 deficiency resulting in non-functional lectin-mediated complement 
activation was reported (Stengaard-Pedersen et al., 2003). Despite normal levels of 
MBL, the patient suffered from recurrent infections and chronic inflammatory disease. 
Sequence analysis of the MASP2/MAp 19 gene revealed that the patient was 
homozygous for a mutation in exon 3 which resulted in the substitution of an aspartic 
acid for a glycine at position 105 in mature MASP2 (D105G) preventing formation of 
functional MBL-MASP2 complexes. Approximately 0.3% of the population are 
expected to be homozygous for the D105G mutation and gene frequencies have been 
shown to vary between diseased and healthy populations (Carlsson et al., 2005). Other 
MASP SNPs have been reported which also show ethnic diversity (Lozano et al., 2005; 
Thiel et al., 2007). MASP2 may be a disease modifier in Cystic fibrosis (Olesen et al.,
2006).
1.8 The lectin pathway of complement in patients with cancer.
As discussed previously, MBL may be relatively redundant in the healthy host, 
assuming greatest clinical importance when it occurs in combination with defects in 
other arms of the immune system such as those experienced by patients on treatment for 
cancer. To date, the majority of studies involving patients with cancer have investigated 
associations between MBL polymorphisms and infectious complications (Table 1.4). 
Ficolin levels have been analysed in only one study to date (Kilpatrick et al., 2003b) and 
four studies have explored MASPs (Ytting et al., 2004; Ytting et al., 2005a; Ytting et 
al., 2005b; Granell et al., 2006).
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There have also been reports that MBL polymorphisms may be a risk factor for the 
development of malignancy. In children, there has been one study that suggests that 
MBL polymorphisms are a risk factor for development of childhood acute 
lymphoblastic leukaemia (ALL), particularly with early age of onset (Schmiegelow et 
al., 2002). There have also been studies conducted in adults with solid tumours 
implicating an increased risk in MBL variants (Baccarelli et al., 2006; Bemig et al.,
2007).
1.8.1 The lectin pathway and infectious complications in cancer patients
In 2001, two studies were published which implicated low MBL as a risk factor for 
increased infectious complications in patients on chemotherapy. Neth et al reported that 
MBL deficiency has an important adverse influence on the duration of FN episodes in 
100 children receiving chemotherapy for malignancies. Children with variant MBL 
alleles suffered twice as many days of FN over a six month period when compared to 
those with a WT genotype (20.5 days vs. 10 days, p=0.014) (Neth et al., 2001). The 
median duration of each FN episode was also significantly higher in patients who were 
MBL deficient. This study suggested that determination of the MBL status of all 
children receiving chemotherapy for malignancies would be beneficial to identify those 
at higher risk of infections. Another simultaneous study investigated 54 adult patients 
who were on chemotherapy for various haematological malignancies. They found a 
significant association between low concentrations of MBL and serious infections, 
defined as pneumonia, bacteraemia or both, contracted within three weeks of starting 
chemotherapy. Patients with an MBL concentration of 0.5|ig/ml or less were at highest 
risk of severe infection. They suggested that MBL replacement in patients having 
chemotherapy could reduce susceptibility to infection (Peterslund et al., 2001).
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Study Patient population (n) Design MBL Assay Follow up Outcome measures Conclusions
PAEDIATRIC
Neth et al 
2001
100 (55-ALL, 12-AML) Prospective Genotype
Level
6 months Frequency and duration of 
infection
Episodes in patients with MBL mutations were 
twice as long as wildtype
Lausett et 
al 2006
136 ALL Retrospective Genotype 50d Frequency o f infections MBL deficiency had no effect on frequency of 
infections during ALL induction therapy
Frakking 
et al 2006
110 total, 66 with FN. 38% 
Haem, 45% Solid 17% 
Lymphoma
Prospective Genotype 2-46 months 
median 13
Infection parameters, 
duration, type. ICU 
admission
Infectious parameters did not differ between MBL- 
deficient and MBL-sufficient neutropenic children
Schlapbach 
et al 2007
94 total, 63 with 177 FN 
episodes. 34% ALL
Retrospective Level Cumulative 
81.7 years
Frequency of FN, type of 
infection
Very low MBL levels associated with more 
frequent FN episodes, mainly due to severe 
bacterial infections
ADULT
Peterslund 
etal 2001
54 Haem (13%-AML) Retrospective Level 3 weeks Clinically significant 
infection
Significant association between low MBL and 
serious infections related to chemotherapy
Mullighan 
etal 2002
97 Donor-Recipient pairs 
allogeneic SCT
Retrospective Genotype 16 months Risk of major infection pre 
and post neutrophil recovery
MBL genotype influences the risk o f infection 
following allogeneic SCT
Rocha et al 
2002
107 Donor-Recipient pairs 
HLA-identical sibling BMT
Prospective Genotype 6 months Severe infection, Neutrophil 
recovery, Mortality
No effect o f MBL genotype observed
Bergmann 
etal 2003
80 AML Prospective Level
Function
1 month Fever, severe infection and 
mortality
MBL levels had no influence on the occurrence or 
course of infections in AML patients
Kilpatrick 
etal 2003
128 Haem (23% AML) (67% 
BMT conditioning )
Prospective Level 1 -4 months Severity of infection, 
Duration of FN
MBL did not have a major influence on 
susceptibility to infection
Horiuchi et 
al2005
113 Haem, treated with high 
dose chemo and Auto SCT
Retrospective Genotype 100 days post 
SCT
Major bacterial infection Low MBL producing genotypes, B/B and B/LXA, 
were associated with major bacterial infection
Molle et al 
2006
113 Multiple myeloma, high 
dose chemo and Auto SCT
Retrospective Genotype 180 days post 
SCT
Severe infections MBL wild-type patients had a significantly 
reduced risk of septicaemia during the AutoSCT
Molle et al 
2006
133 Multiple myeloma, 390 
chemotherapy cycles
Retrospective Genotype 28 days Septicaemia Indications o f a reduced septicaemia in wild-type 
compared with variant MBL2 patients
Vekemans 
etal 2007
255 Haem, 569 chemotherapy 
cycles. FN in 200 patients
Prospective Genotype
Level
1 chemo 
cycle, max 
45days
Ratio of duration o f FN to 
duration of neutropenia 
Severe infection
MBL deficient patients had more severe infections 
and first severe infection was earlier than in MBL 
wild-type patients
Table 1.4 Summary of studies investigating the influence of MBL on infectious complications in patients on chemotherapy
ALL, Acute Lymphoblastic Leukaemia. AML, Acute Myeloid Leukaemia. BMT, Bone marrow transplant. Auto SCT, Autologous stem cell transplant. ICU, Intensive care unit.
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induction phase of treatment. During this 50 day period they found no association 
between frequency of infection and MBL genotype (Lausen et al., 2006). The other two 
studies have investigated more heterogenous groups of paediatric oncology patients. 
Frakking and colleagues were unable to demonstrate a difference between the infectious 
parameters in their MBL deficient and sufficient patients but they did not dismiss the 
potential use of MBL replacement in such patients in the future as their patient numbers 
may have been too small to demonstrate an effect (Frakking et al., 2006). In contrast 
Schlapbach et al did observe that very low MBL levels were associated with more 
frequent FN episodes which were more likely to be due to severe bacterial infections 
(Schlapbach et al., 2007).
Three studies to date have investigated the role of MASPs in adults with colorectal 
cancer. Using a MBL/MASP2 assay measuring C4 cleavage, patients were found to 
have increased complement activation function compared to healthy controls (Ytting et 
al., 2004) but this MBL/MASP2 activity was not predictive of post-operative infections 
or long term prognosis (Ytting et al., 2005a). However MASP2 concentration prior to 
surgery was an independent prognostic marker with high levels predicting recurrence 
and poor survival. No association between MASP2 concentration and postoperative 
infection was found (Ytting et al., 2005b). A further study of adults undergoing 
allogeneic stem cell transplantation has demonstrated that patients heterozygous for the 
MASP2 D105G allele had an increased risk of invasive fungal infection (Granell et al.,
2006).
The role of MBL and the lectin pathway of complement in this heterogenous patient 
group remains unclear as all the studies discussed have asked different questions and 
compared a number of different outcome measures. Supporting evidence for a role for 
MBL in the context of chemotherapy induced neutropenia has been investigated using a
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mouse model. MBL double knockout mice (MBLAVMBLC) infected with 
Staphylococcus aureus IV showed an increased death rate when compared to WT 
littermates; 48h post-inoculation all MBL null-mice had died compared to 55% survival 
of WT mice. Interestingly, when mice were inoculated via the intraperitoneal route this 
difference was not observed until the mice were rendered neutropenic following 
administration of cyclophosphamide. The neutropenic MBL-null mice displayed 
enhanced bacterial accumulation in organs compared to the neutropenic MBL WT mice. 
By day 8 post inoculation the neutropenic MBL WT mice had sterilized their blood but 
there was persistent bacteraemia in the neutropenic MBL-null mice despite a recovery 
of circulating neutrophils. Treatment with recombinant MBL restored activation of the 
lectin pathway of complement and correlated with decreased bacterial accumulation in 
the tissues (Shi et al., 2004).
1.9 MBL replacement therapy
MBL replacement therapy is now available and is being tested in patients. MBL 
replacement was first attempted when plasma infusions were given to a patient and 
found to correct the ‘common opsonic defect’ (Miller 1968). Since then affinity- 
purified MBL has been safely given to patients, resulting in normalization of ELISA 
detectable MBL and complement mediated opsonic activity (Valdimarsson et al., 1998). 
A phase one study showed half life to vary between 18 and 115h (Valdimarsson et al.,
2004). Recombinant MBL (rMBL) has been developed and has undergone phase 1 
tolerability and pharmacokinetic studies with promising results (Petersen et al., 2006). It 
has advantages over the purified form in terms of production/availability and the risks 
associated with the use of blood products. The product is licensed and the results of 
phase 2/3 trials are awaited. Its use in animal studies has been encouraging, 
demonstrating positive effects of reconstitution (Shi et al., 2004; Gadjeva et al., 2004;
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Moller-Kristensen et al., 2006). It has been proposed as a potential therapeutic agent 
against control of infection in immunocompromised patients but further work is 
required to define exactly who could benefit and whether MBL could be used as a 
prophylactic or ‘rescue’ treatment.
1.10 Aims of the thesis
The work described in this thesis explores several aspects of the MBL lectin pathway of 
complement in a population of paediatric oncology patients.
We hypothesise that innate ‘host defence factors’, specifically MBL and components of 
the lectin pathway of complement, influence infection risk and severity in children 
treated with chemotherapy for cancer.
The specific aims of this thesis were:
1) To explore the influence of MBL gene polymorphisms on the susceptibility and 
severity of infection in children treated for cancer.
2) To study the effects of chemotherapy and/or infection on MBL structure and lectin 
pathway function.
3) To investigate the transcriptional regulation of MBL gene expression.
The following schematic briefly outlines the results chapters of this thesis.
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Clinical outcome data collected for the 
PINE project on all FN episodes in SE 
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the impact of MBL2 genotype on FN 
outcome utilising clinical data from the 
PINE project 
(n=261)
Chapter 6
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2.0 Materials and Methods
2.1 Study populations
Specialist management o f children with cancer in the South East of England is provided 
by four Paediatric Oncology Centres (POCs). These consist of the Royal London 
Hospital (RLH) and the Royal Marsden Hospital (RMH) which care for children of all 
ages in the south and east of the region. In the north and west o f the region Great 
Ormond Street Hospital for Sick Children (GOSH) cares for children under 13 years of 
age and University College Hospital (UCLH) cares for children over 13 years and 
adolescents. In partnership with the POCs, over forty Paediatric Oncology Shared Care 
Units (POSCUs) provide supportive care (including FN management) for patients close 
to their home. Figure 2.1 shows a simplified schematic of this system illustrating that 
different POSCUs link with different Thames POCs.
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Figure 2.1 Illustration of POC and POSCU structure.
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It should be noted that not all POSCUs are represented in Figure 2.1 and that some 
POSCUs link with more than one POC due to patient age or for geographical reasons. 
Patients recruited into the studies presented in this thesis were managed in these four 
POCs. Chapter 3 describes the PINE (Paediatric Infections during Neutropenic 
Episodes) project, a multicentre audit of FN episodes occurring in both the POCs and 
POSCUs. Clinical data obtained from this project was used in the analysis of the 
MBL/lectin pathway studies presented. Chapter 4 introduces the patient population 
investigated. Different subsets of this total population are described in Chapters 5-7. All 
patients had blood samples taken for MBL genetic analysis and those involved in the 
lectin pathway studies also had blood taken for protein analyses. The specific 
populations will be introduced in the relevant chapters.
2.2 DNA extraction from whole blood
Genomic DNA was extracted from whole blood using a commercial kit (QIAamp DNA 
blood mini kit, Qiagen, Crawley, UK) according to the manufacturer’s instructions. 
Whole blood samples in potassium ethenediamine tetra-acetic acid (EDTA) were 
equilibrated to room temperature (RT) and mixed by vortexing (Vortex Genie-2, 
Scientific Industries, NY, USA). 200pl whole blood was mixed with 20pl Qiagen 
Protease before the addition of 200pl buffer AL followed by vortexing for 15sec. The 
mixture was incubated at 56°C for lOmin. At the end of the incubation 200pl absolute 
ethanol was added and the sample was vortexed for 15sec. The resulting solution was 
loaded onto a QIAamp Spin Column held in a 2ml collection tube. Centrifugation 
(8000rpm, lmin (Eppendorf 5415R microfuge, Eppendorf, Germany)) was performed 
which allowed genomic DNA to bind to the column. Filtrate in the collection tube was 
discarded and a fresh collection tube attached to the column. 500pl buffer AW1 was 
added to the column prior to centrifugation (8000rpm, lmin). The wash step was
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repeated with 500pl buffer AW2 and the sample was centrifuged (13000rpm for 3min). 
The filtrate was discarded and the spin column was placed in a new tube and re-spun 
(13000rpm, lmin) to ensure complete removal of wash buffer AW2. Genomic DNA 
was eluted by the addition of 200pl buffer AE with 5min equilibration at RT before 
centrifugation (8000rpm, lmin). Eluted DNA was appropriately aliquoted and stored at 
-20°C until further use. The concentration of resuspended DNA was determined by 
measuring absorbance (U-1800 Spectrophotometer, Digilab Hitachi, Tokyo, Japan) at 
260nm and 280nm. The amount of DNA (pg/pl) was calculated as follows:
[(absorbance at 260nm) x (dilution factor) x 50] /1000.
Purity of DNA was calculated using the ratio, A26o/A280- Pure DNA gives a ratio of 1.8. 
Routinely, 5-10pg DNA was obtained from 200pl of whole blood.
2.3 MBL genotyping
In the present study two methods of genotyping have been utilised to detect mutations 
in Exonl and the promoter region of the MBL-2 gene.
2.3.1 Heteroduplexing
Briefly, this method involved the use of a universal heteroduplex generator (UHG), a 
synthetic DNA molecule based on the target genomic sequence, containing insertions 
and deletions (Wood and Bidwell, 1996). Genomic DNA polymerase chain reaction 
(PCR) product was combined with UHG PCR product, and the two were allowed to 
anneal to produce characteristic heteroduplexes for different alleles. These 
heteroduplexes display different electrophoretic mobility on a polyacrylamide gel, thus 
enabling identification of a subject’s genotype (Jack et al., 1997). A general outline of 
the steps involved and the characteristic band patterns obtained by this technique are 
shown schematically in Figure 2.2 and each step is described in detail below.
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Figure 2.2 Schematic representation of the Heteroduplexing technique.
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Commercially synthesised UHGs (MWG- Biotech, Milton Keynes, UK) specifically 
designed to detect the exon 1 and X/Y promoter polymorphisms were used as templates 
and their sequences are shown in Table 2.1. Specific primers used for amplification of 
the exon 1 and promoter regions are shown in bold in Table 2.1. Two separate PCR 
reactions were performed on genomic and UHG DNA to amplify exon 1 and X/Y 
promoter regions respectively i.e. four PCR reactions in total.
UHG Sequence 5*-3*
Exon 1 
133bp
‘"CTG TGA CCT GTG AGG ATG CCC AAA AGA CCT GCC CTG 
CAG TGA TTG CCT GTA GCT CTC CAG GCA TCA ACG GCT TCC 
CAG GCA AAG ATG GGC GTG ATG TTG CAC CAG_AGA AAA 
GGG GGA ACC AGG TAC GTG TTG G“ 7
Promoter
lllb p
™AGG CAT AAG CCA GCT GGC AAT GCA CGG TCC CAT TTG 
TTC TCA CTG CCA CCC ATG TTT ATA GTC TTC CAG CAG CAA 
CGC CAG GTG TCT AGG CAC AGA TGA ACC CCT CCT T A G 155
Table 2.1 Exon 1 and X/Y promoter UHG sequences.
Primer sequences are shown in bold and the positions of the polymorphisms are 
underlined.
The PCR reaction volumes were 20pl and both reaction mixes (genomic and UHG) 
consisted of 2pl lOx PCR buffer (Roche Applied Sciences, Welwyn Garden City, UK), 
1.2pl 25mM MgCh (Roche Applied Sciences, Welwyn Garden City, UK) and 0.5pl 
lOmM deoxynucleotide triphosphates (dNTP) mix (Promega, Southampton, UK). The 
genomic DNA PCR mix also contained 1.2pl (0.6pl of each) 50pM primers (Sigma, 
Gillingham, UK), 0.2pl Amplitaq Gold DNA polymerase (5U/ pi; Roche Applied 
Science, Welwyn Garden City, UK) and 5pl genomic DNA (~0.1-0.5pg). The UHG 
PCR mix contained 0.6pl 50pM primers (0.3pi of each), 0.12pl Amplitaq Gold DNA 
polymerase (5U/ pi) and 20pg UHG per reaction. The remaining volume was made up 
with sterile water (Sigma, Gillingham, UK). Mastermixes were prepared for multiple 
reactions to minimize inter-sample variation.
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PCR amplification was carried out in a thermal cycler (Peltier Thermal Cycler, MJ 
Research, BioRad, Hemel Hempstead, UK) as follows:
a) 95°C for 15min -1 cycle
b) 95°C denaturation for 45sec
56°C annealing for 45sec - 35 cycles
72°C extension for 45sec
c) 72°C for lOmin -1 cycle
The PCR products were analysed using 2% agarose (Invitrogen Life Technologies, 
Paisley, UK) gels prepared in 1 x Tris-borate-EDTA (TBE) buffer (Sigma, Gillingham, 
UK). Ethidium bromide (1 jig/100ml; Sigma, Gillingham, UK) was added to the cooled 
gel mix, before pouring onto a casting tray. PCR samples were run at 100V for lh and 
visualized using the Alphalmager system (Alpha Imager, Multimage Light Cabinet, 
Alpha Innotech Corporation, Essex, UK). Gel electrophoresis allowed visual 
quantification of PCR products.
b) Heteroduplex generation and analysis
Approximately equal amounts of the relevant genomic and UHG PCR products were 
combined and heated to 95 °C for 5min on a thermal cycler. The mix was then allowed 
to cool to RT over 2h to enable greater specific annealing prior to analysis by 
polyacrylamide gel electrophoresis (PAGE). Routinely 20% non-denaturing 
polyacrylamide gels were prepared (Table 2.2).
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30% Acrylamide /Bis acrylamide mix (National Diagnostics, UK) 10ml
lOx TBE Buffer 3 ml
Sterile water 2.5ml
10% Ammonium Persulfate solution (National Diagnostics, UK) 150pl
TEMED (N,N,N’,N’- tetramethylethylenediamine) (Sigma, 
Gillingham, UK)
15(0.1
Table 2.2 20% polyacrylamide gel composition of a 16x16 cm gel
10pl of heteroduplexing product was loaded into each well. The promoter 
heteroduplexing products were analysed on 16x16cm gels (150V, 15h, 16°C). The 
exonl products were analysed using the Protean II system (BioRad Laboratories, Hemel 
Hempstead, UK) for optimal separation (200V, 5h, 4°C). Better resolution was obtained 
when gels were run in 2x TBE buffer. Gels were stained in lxTBE containing ethidium 
bromide for 10-15min on an orbital shaker (Rotatest, Denley, UK) and visualized and 
photographed using an Alphalmager.
2.3.2 Innogenetics line probe assay- INNO-LiPA MBL-2
This method relies on genomic DNA: probe DNA hybridization technology that enables 
detection of exon 1 and all 3 promoter polymorphisms using a commercial kit (INNO- 
LiPA MBL2 Amplification and INNOLiPA MBL2, INNOGENETICS N.V., Belgium). 
Amplified biotinylated genomic DNA was chemically denatured and the separated 
DNA strands hybridized with specific oligonucleotide probes immobilized on 
membrane-based strips. A stringent wash step allowed removal of any mismatched 
hybridization. Addition of streptavidin (conjugated with alkaline phosphatase) allowed 
avid binding to the biotin moiety of the hybrid DNA. Finally, incubation with an 
alkaline phosphatase substrate solution containing chromogen resulted in a 
purple/brown precipitate. The resulting probe pattern could then be translated into its 
appropriate genotype. Figure 2.3 represents a brief outline of the technique and each 
step is described in detail below.
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Figure 2.3 Schematic representation of the INNO-LiPA method
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a) Amplification of the promoter and exon 1 regions of the MBL2 gene
A multiplex PCR reaction mix was prepared containing lOpl amplification buffer, lOjil 
MBL2 amplification primer solution, 0.3 pi HotStar Taq DNA polymerase (Qiagen, 
Crawley UK) and 24.7pl sterile water. The reaction mix was vortexed and added to 5pi 
genomic DNA giving a total volume of 50pl. PCR amplification was carried out in a 
thermal cycler as follows:
a) 95°C for 15min -1 cycle
b) 95°C denaturation for 30sec
56°C annealing for 30sec 
72°C extension for 60sec
c) 72°C for 7min 
lOpl PCR product was analysed on a 2%
379bp were observed as shown in Figure 
-20°C until required.
b) Hybridisation
In a trough, lOpl PCR product was combined with lOpl of denaturing solution for 5min 
at RT. At the end of the incubation period, a single probe strip was introduced and 2ml 
of prewarmed (37-56°C) hybridization solution was added, submerging the strip. 
Troughs were incubated in a shaking waterbath (Grant OLS 200, Grant Instruments, 
Cambridge, UK) (80 rpm, 30min 56°C +/- 0.5°C). Hybridization solution was aspirated 
using a vacuum (Vaccubrand GmbH, Wertheim, Germany) and 2ml pre-warmed 
stringent wash solution (37-56°C) was added and placed on a shaking platform 
(Rotatest, Denley, UK) (60 +/- 30sec, RT). This wash step was repeated once more and
- 35 cycles 
-1 cycle
agarose gel. Two amplicons of size 478bp and 
2.3. The remaining PCR product was stored at
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was followed by a final lOmin wash step involving re-incubation in the shaking water 
bath at 56°C.
c) Colour development
The remaining steps were carried out at RT on a shaking platform. After the lOmin 
stringent wash, liquid was aspirated and each strip was washed twice for lmin in 2ml 
rinse working solution. Finally, 2ml conjugate working solution was added and the 
strips were incubated for a further 30min. The substrate working solution was prepared 
lOmin prior to requirement by addition of substrate buffer to substrate BCIP/NBT (lOOx 
solution). Each strip was washed twice for lmin in 2ml rinse working solution and 
once in 2ml substrate buffer. 2ml substrate working solution was added to each strip and 
incubated for 30min, allowing colour development to take place. The reaction was 
stopped by washing the strips twice in 2ml sterile water for at least 3min/wash. Strips 
were removed and blotted dry prior to interpretation. To validate each strip the 
conjugate control must be positive. The strips contain 6 mutant type probes (M- types) 
and 6 wild type probes (W). The presence of a visible line at a particular probe position 
indicates that the corresponding sequence is present in one or both alleles (Figure 2.4).
r\>»-*Ovooo>sJo^ui^u)POi-»
Figure 2.4 Schematic of INNO-LiPA MBL2 assay strip showing presence of all 
probe sequences
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As discussed previously, linkage disequilibrium between polymorphisms in the 
promoter and exon 1 region give rise to seven common haplotypes, which give rise to 
28 possible haplotype combinations. Table 2.3 highlights the haplotype combinations 
corresponding to each positive probe pattern.
Haplotype combinations PiDsitive prc►be numibers
LXPA/LYQC 1 2 3 6 8 9 1 0 1 1 1 2
LXPA/LYQA 1 2 3 8 9 1 0 1 1 1 2
LXPA/HYPD 1 2 4 7 8 9 1 0 1 1 1 2
LXPA/LYPB 1 2 5 8 9 1 0 1 1 1 2
LXPA/HYPA 1 2 7 8 9 1 0 1 1 1 2
LXPA/LYPA 1 2 8 9 1 0 1 1 1 2
LXPA/LXPA 1 2 9 1 0 1 1 1 2
LYQC/HYPD 1 3 4 6 7 8 9 1 0 1 1 1 2
LYQA/HYPD 1 3 4 7 8 9 1 0 1 1 1 2
LYPB/LYQC 1 3 5 6 8 9 1 0 1 1 1 2
LYQA/LYPB 1 3 5 8 9 1 0 1 1 1 2
LYQC/HYPA 1 3 6 7 8 9 1 0 1 1 1 2
LYPA/LYQC 1 3 6 8 9 1 0 1 1 1 2
LYQC/LYQC 1 3 6 8 1 0 1 1
LYQA/LYQC 1 3 6 8 1 0 1 1 1 2
LYQA/HYPA 1 3 7 8 9 1 0 1 1 1 2
LYQA/LYPA 1 3 8 9 1 0 1 1 1 2
LYQA/LYQA 1 3 8 1 0 1 1 1 2
LYPB/HYPD 1 4 5 7 8 9 1 0 1 1 1 2
LYPA/HYPD 1 4 7 8 9 1 0 1 1 1 2
LYPB/HYPA 1 5 7 8 9 1 0 1 1 1 2
LYPA/LYPB 1 5 8 9 1 0 1 1 1 2
LYPB/LYPB 1 5 8 9 1 0 1 2
LYPA/HYPA 1 7 8 9 1 0 1 1 1 2
LYPA/LYPA 1 8 9 1 0 1 1 1 2
HYPD/HYPD 4 7 8 9 1 1 1 2
HYPD/HYPA 4 7 8 9 1 0 1 1 1 2
HYPA/HYPA 7 8 9 1 0 1 1 1 2
Table 2.3 Haplotype combinations and probe patterns
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2.4 Analysis of MBL and the Lectin pathway
2.4.1 Buffers and solutions used in protein/functional assays and Western blotting.
General Buffers
Phosphate buffered saline (PBS) One PBS tablet (Oxoid, UK) to 100ml MilliQ water (Millipore, 
Watford, UK)
Tris buffered saline (TBS) lOmM TrisHCL, 140mM NaCl, 15mM NaN3, pH 7.4
PBS/Tween (PBS/T) PBS with 0.05% Tween 20 (polyoxyethylene (20) sorbitan 
monolaurate) (BDH, Poole,UK)
TBS/Tween (TBS/T) TBS with 0.05% Tween 20
MASP/C4/C3 assay buffers
Blocking solution TBS, 1 mg/ml Human Serum Albumin (HSA) (Serum Statens 
Institute, Denmark)
Coating buffer 15mM Na2C 03> 35mM NaHC03, 0.02% NaN3. pH 9.6
MASP2 sample buffer TBS/T, lOmM EDTA, 0.86mM NaCl, lOOpg/ml heat aggregated 
normal human IgG (Serum Statens Institute, Denmark)
MASP2 secondary buffer TBS/T, 5 mM CaCl2, 1% bovine serum, 1% heat aggregated normal 
human IgG
Rosa buffer 20mM TrisHCl, 1M NaCl, 0.05% Triton X-100, lOmM CaCl2, 
1 mg/ml HSA. pH 7.4
MASP3 secondary buffer TBS/T, 5 mM CaCl2, 1% bovine serum
B1 buffer 4mM Barbital, 145mM NaCl, 2mM CaCl2, ImM MgCl2 pH 7.4
B2 buffer As for B1 buffer with addition of 0.05% Tween 20
Enhancement buffer 0.57%(v/v) acetic acid, 0.1%(v/v) Triton X-100, 1% (w/v) 6000 
polyethylene glycol
Immediately prior to use 15pM 2-naphtoylfluoroacetone (2-NTA)(P- 
NTA) and 50pM Tri-n-octylphosphine oxide (TOPO) was added
TBS/T/Ca2+ Wash buffer TBS/T, 5 mM CaCl2
TBS/T/EDTA TBS/T, 25mM EDTA
Western blotting buffers
Blocking buffer PBS, 4 % non fat milk (Marvel, UK)
Electrode buffer (lOx) 30g Tris, 144g Glycine, lOg SDS, 1L MilliQ water
Sample buffer (4x) 3.8ml MilliQ water, 1ml 05.M Tris (pH6.8), 0.8ml Glycerol, 1.6ml 
SDS, 0.2% Bromophenol blue
Transfer buffer 3.03g 25mM Tris, 14.4g 0.2M Glycine, 20% Methanol. 4°C (1L)
Table 2.4 Buffers and solutions used in protein/functional assays and Western 
blotting. Reagents are from Sigma, Gillingham, UK unless stated otherwise.
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2.4.2 Antibodies used in protein/functional assays and Western blotting
Name Company Product code
anti-human C3c, rabbit polyclonal Dako, Ely, UK A0062
anti-human C4, mouse monoclonal 
IgG clone 162-2
The Antibody Shop, 
Copenhagen, Denmark
HYB 162-02
anti-human C4, mouse monoclonal 
IgG clone 162-4
The Antibody Shop, 
Copenhagen, Denmark
HYB 162-04
anti-human MASP 1/3, mouse 
monoclonal IgG clone IE2
Hycult biotechnology, 
Netherlands
HM 2092
anti MASP2, rat monoclonal IgG 
clone 8B5
Hycult biotechnology, 
Netherlands
HM 2190
anti MASP2/MApl9, rat 
monoclonal IgG 6G12
Hycult biotechnology, 
Netherlands
HM 2191
anti MASP3 38:12-3 Gift of J.C.Jensenius, University of Aarhus, 
Denmark
anti human MBL, mouse 
monoclonal IgG clone 131-1
The Antibody Shop, 
Copenhagen, Denmark
HYB 131-01
anti mouse Ig/HRP, goat polyclonal Dako, Ely, UK P0447
Table 2.5 Antibodies used in protein/functional assays and Western blotting
2.4.3 Protein assays
2.4.3.1 Determination of MBL protein concentration by ELISA
MBL protein levels were determined by symmetrical sandwich enzyme-linked 
immunosorbent assay (ELISA) using a commercial kit (MBL Oligomer ELISA kit, 
Antibody Shop, Copenhagen, Denmark) according to manufacturer’s instructions.
The kit provides a 96 well plate pre-coated with a monoclonal antibody against MBL. 
Bound MBL is detected with the same antibody labelled with Biotin, followed by 
development with horse-radish peroxidase (HRP) - conjugated streptavidin and a 
chromogenic substrate.
Serum samples were diluted, dependent on known genotype (wild-type-1 in 200, variant 
alleles 1 in 20), using sample diluent. Cell culture supernatant samples were left 
undiluted. MBL standards (0-40ng/ml) and test samples (lOOpl) were applied to wells in
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duplicate and incubated on a shaking platform (200 rpm, lh, RT). Unbound material 
was removed by washing with 300pl wash solution (x3) and blotted dry. This procedure 
was followed in all wash steps. Biotinylated monoclonal antibody (lOOpl) was added to 
each well, incubated on a shaking platform (200 rpm, lh, RT) followed by washing of 
unbound antibody. Addition of HRP-Streptavidin and incubation on a shaking platform 
(200rpm, lh, RT) allowed complex formation with the biotinylated antibody. Any 
unbound material was removed by washing. Chromogenic peroxidase substrate, 
tetramethylbenzidine (TMB; lOOpl) was added and incubated for 15min at RT in the 
dark followed by addition of 50pl stop solution. Colour intensity was measured at 
450nm using an ELISA reader (MRX, Dynatech Laboratories Ltd, Sussex UK) within 
30min of termination of the reaction. Optical density readings for the standard samples 
were used to construct a calibration curve from which concentrations of MBL in the test 
samples were determined. The interassay coefficient of variation (CV%) for the high 
and low internal controls was 7% and 10.5% respectively.
2.4.3.2 Determination of MASP2 protein concentration by TRIFMA
Microtiter wells (FluoroNunc plate, NUNC, Roskilde, Denmark) were coated with 
0.7pg anti-MASP2 antibody (clone 8B5, which captured the CCP 1/2-SP fragment [or 
C-terminal part] of MASP2) in lOOpl coating buffer and incubated overnight at 4°C. 
Coating buffer was removed and the wells incubated (lh, RT) with 200pl blocking 
solution to block non-specific binding sites. Each subsequent step was followed by a 
wash step which involved three washes using TBS/T. Test serum samples and 4 internal 
controls were diluted 1 in 25 with MASP2 sample buffer. A pool of plasma for use as 
standard (608 ng/ml) was serially diluted. Negative control wells received buffer only. 
Wells were washed and incubated with lOOpl of diluted test and standard samples (in 
duplicate) overnight at 4°C. MASP2 was detected using a biotinylated anti-MASP
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2/MApl9 antibody (clone 6G12, specific to the N-terminal end of MASP2 and also 
MApl9, 1:2000 in MASP2 secondary buffer, 100pl/well) incubated for 2h at RT. The 
assay was developed using time resolved immunofluorometry described in section
2.4.4.3. The interassay coefficient of variation (CV %) for the high, medium and low 
internal controls was 1.3, 8.14 and 4.23% respectively.
2.4.3.3 Determination of MASP3 protein concentration by TRIFMA
Microtiter wells were coated with anti-MASPl/3 antibody (clone IE2, which recognises 
the heavy/A chain common to both MASP1 and MASP3, 2pg/ml in PBS, lOOpl/well) 
and incubated overnight at RT. The coating solution was removed prior to addition of 
200pl blocking solution for lh at RT. Test serum and 3 internal controls were diluted 
100 fold in Rosa buffer. Negative control wells received buffer only. Pooled plasma as 
standard (533 ng/ml) was serially diluted. Wells were washed three times with TBS/T 
prior to addition of lOOpl of sample (in duplicate) incubated overnight at 4°C. Each 
subsequent step from this point on was followed by a wash step which involved three 
washes using TBS/T/Ca . Bound MASP3 was detected using lOOpl biotinylated anti- 
MASP3 antibody (38:12-3, specific to MASP3, 0.5 jig/ml in MASP3 secondary buffer) 
incubated for 2h at RT. Following a wash step the assay was developed as described in 
section 2.4.4.3. The interassay coefficient of variation (CV%) for the high, medium and 
low internal controls was 1.1,10.5 and 13.25% respectively.
2.4.4 Functional assays
2.4.4.1 MBL/MASP2 complex activity/C4b deposition assay
This assay assesses the ability of an individual’s MBL/MASP2 complex to cleave C4 by 
detection of C4b deposition (solid phase C4 activation product) (Petersen et al., 2001).
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The addition of exogenous C4 overrrides any contribution of the C4 present in the test 
serum sample.
Microtiter wells were coated with lpg of mannan in lOOpl coating buffer overnight at 
4°C, prior to blocking as described above. Test serum samples were diluted in Rosa 
buffer (high ionic strength to prevent classical pathway activity), according to known 
MBL concentration as measured by ELISA (section 2.4.3.1), i.e. 1 in 200 if MBL serum 
concentration <4pg/ml and 1 in 400 if >4pg/ml. Four plasma samples were used as 
internal controls and diluted accordingly. Pooled standard plasma (assigned the value 
lOOOmunits/ml) was serially diluted. Wells were washed with TBS/T and incubated 
with lOOpl of test and control samples (in duplicate) overnight at 4°C. Each subsequent 
step was followed by a wash step (three washes with TBS/T/Ca ). After sample 
removal and washes, human C4 (0.98 mg/ml, Natlmmune, Denmark, in lOOpl B1 
buffer) was added for 1.5h at 37°C. After washing, bound C4b was detected by 
incubating with a biotinylated anti-C4b antibody (clone 162-2, 25ng/100pl TBS/T/Ca2+)
for 1.5h at RT. Following a wash step the assay was developed as described in section
2.4.4.3. The interassay coefficient of variation (CV%) for the high and medium internal 
controls was 15.8 and 9% respectively.
2.4.4.2 C3 cleavage assay/C3b deposition
This assay assesses both MASP1 and MASP2 mediated activation of C3 via the MBL 
lectin pathway by detection of the C3 cleavage product C3c.
Mannan coated wells were prepared and blocked as described above. Test serum 
samples and internal controls (x4) were diluted (1 in 100 in B2 buffer). Pooled plasma 
(lOOOmunits/ml) was used as standard and was serially diluted. Wells were washed with 
TBS/T and then incubated with lOOpl of dilute sample (in duplicate) for lh at 37°C in a 
humidified box to allow C3 cleavage. Each subsequent step was followed by wash steps
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(x3) using TBS/T/Ca2+. C3 cleavage was detected using a biotinylated anti C3c 
antibody (200ng/ml, diluted 1:1000 in TBS/T/Ca2+, 100pl/well) incubated overnight at 
4°C. Following a wash step the assay was developed as described in section 2.4.4.3. The 
interassay coefficient of variation (CV %) for the high and medium internal controls 
was 2.6 and 15.3% respectively.
2.4.4.3 Time Resolved ImmunoFhioroMetric Assay (TRIFMA)
Time resolved fluorometry is more sensitive than enzyme based immunoassays for 
measuring compounds present at low concentrations. It utilises the fluorescent label 
Europium which has a long decay time, whose emissions can be detected at a given 
wavelength following pulsed light excitation (Hemmila et al., 1984).
Following a final wash step, wells were incubated with lOng Europium (Eu3+) - labelled 
streptavidin in lOOpl TBS/T/EDTA for 1.5h at RT. 200jil enhancement buffer was 
added to each well and incubated for 5min on a shaking platform. The low pH of the 
enhancement buffer allows dissociation of Eu3+ from streptavidin. Triton X-100, 2-NTA 
and TOPO micelles capture Eu ions free in solution. Excitation of this complex was 
detected using a fluorometer (1420 Multilabel counter Victor 3, Perkin Elmer, USA). 
Standard sample readings were used to construct a calibration curve from which 
concentrations in the test samples were determined.
2.4.4.4 Wieslab total complement screen
This semi-quantitative assay is designed to screen all three pathways of complement 
activation (classical, MBL and alternative) simultaneously using an ELISA based 
detection method which is commercially available (Wieslab, Lund, Sweden). 
Instructions and reagents were provided. Briefly, all reagents (unless stated otherwise) 
were equilibrated to RT prior to use. Serum was thawed on ice and mixed by vortexing.
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The positive control (lyophilised pooled human sera) was reconstituted by adding 200pl 
distilled water, incubated on ice for 5min, vortexed until all material had dissolved and 
kept on ice prior to use. Positive and negative controls were diluted in the same way as 
the serum samples of interest. Serum was diluted in pathway specific diluent and 
incubated accordingly as shown in Table 2.6.
Pathway Dilution Incubation at RT Plate coating
Classical 1 in 1 0 1 < lh IgM
MBL 1 in 1 0 1 > 15min Mannan
Alternative 1 in 18 < lh LPS
Table 2.6 Pathway specific dilution factors, incubation times and plate coatings
Samples were added to the appropriate pre-coated wells (lOOpl/well) in duplicate and 
incubated for 60-70min at 37°C. Diluent alone was used to calculate background 
activity. This step was followed by three washes using diluted wash solution. Alkaline 
phosphatase-labelled antibody to human C5b-9 was then added to each well (lOOpl) for 
30min, RT. After further washes (x3), lOOpl substrate was added for 30min, RT and 
absorbance read at 405nm (within 30min) using an ELISA plate reader.
Results were calculated by subtracting diluent alone value from all the other pathway 
results and using the following equation to calculate specific activity;
Pathway activity =
100% x (mean A405 (Sample) -  mean A405 (negative control))
(mean A405 (positive control) -  mean A405 (negative control))
The interassay coefficient of variation (CV%) for the internal control samples is shown 
in Table 2.7.
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Sample mean SD CV%
Classical SI 96 5.2 5
S2 98 4.2 4
MBL SI 49 6.8 13
S2 0 - -
Alternative SI 83 5.8 7
S2 92 4.5 5
Table 2.7 Wieslab Total Complement Screen interassay variation
2.4.5 Western blotting of MBL
This technique was used to explore inter and intra-individual differences in higher order MBL 
oligomers present in serum. Samples were thawed on ice and diluted in sample buffer 
according to the desired dilution. Dilution factors differed between individuals according to 
their known MBL serum concentrations (as calculated by ELISA, section 2.4.3.1) and the 
same dilution factor was applied to all sequential samples from an individual. In general 
serum was diluted to ensure lng MBL protein (~ 5pi) was loaded onto the gel. Purified MBL 
(230ng/ml, a gift from M.Johnson, Institute of Child Health, London) was used as an internal 
control. Samples were subjected to non-reducing SDS PAGE (4% stacking and 6% resolving, 
Table 2.8) in a Mini-Protean 3 cell unit (BioRad Laboratories, Hemel Hempstead, UK).
6%  Resolving Gel (10 ml) Volume (ml)
Water 5.3
30% Acrylamide mix (Protogel, National Diagnostics, UK) 2.0
1.5 M Tris (pH 8.8) 2.5
10% SDS 0.1
10% Ammonium persulfate 0.1
TEMED 0.008
4% Stacking Gel (10 ml) Volume (ml)
Water 7.2
30% Acrylamide mix 1.33
1.0 M Tris (pH 6.8) 1.25
10% SDS 0.1
10% Ammonium persulfate 0.1
TEMED 0.01
Table 2.8 Composition of Tris SDS gels
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5|li1 of rainbow molecular weight (MW) marker (Amersham Biosciences, Little Chalfont, 
UK) was always included for MW determination and as a visual check for transfer efficiency. 
Gels were electrophoresed at 110V (BioRad PowerPac 3000, BioRad Laboratories, Hemel 
Hempstead, UK) for 5h at 4°C. Prior to transfer, blotting paper (VWR, Lutterworth, UK), 
nitrocellulose membrane (Hybond C extra, Amersham Biosciences, Little Chalfont, UK) and 
the gel were allowed to equilibrate in chilled transfer buffer for at least lOmin. Proteins were 
transferred using a wet transfer cell system (BioRad Laboratories, Hemel Hempstead, UK) at 
400mA for 90min at 4°C. Post transfer, non-specific binding was blocked by incubating the 
membrane in blocking buffer overnight at RT with gentle shaking. This was followed by 2h 
incubation with primary anti human MBL antibody (clone 131-01, 1:5000), in blocking 
buffer on a rotary shaker at RT.
After 3-4 washes in PBS/T for lOmin each, the blot was exposed to secondary antibody (goat 
anti-mouse Ig/HRP, 1:2000), for 2h on a rotary shaker at RT. Blots were washed as described 
before detection using an enhanced chemiluminescence (ECL) reaction for 5min (ECL plus, 
Amersham Biosciences, Little Chalfont, UK) followed by autoradiography (MXB film, 
Kodak, UK). The membranes were developed from 5sec to 5min as required (XD2 developer 
and XF2 fixer solutions, Photosol, Essex, UK).
2.5 Transcriptional regulation of MBL and Promoter analysis
2.5.1 Cell culture
2.5.1.1 Human hepatocellular carcinoma cell-lines
The human hepatocellular carcinoma cell-lines Huh7 and HepG2 (gift from M. Jacobs, 
Royal Free Hospital, London) were used to investigate transcriptional regulation of 
MBL. These cell-lines were maintained in Dulbeccos modified Eagles medium (with 
4500mg/L Glucose and GlutaMAX™) (Gibco, Paisley, UK) supplemented with 10%
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fetal calf serum (FCS) (Insight technologies, London, UK), 100 units/ml penicillin and 
100pg/ml streptomycin (PAA laboratories, Yeovil, UK) (complete media). Cells were 
maintained at 37°C in 5% CO2 in a humidified incubator (Galaxy R, Wolf laboratories, 
York, UK).
2.5.1.2 Cell Passage of adherent cell-lines
Confluent Huh7 and HepG2 monolayers were routinely passaged every 3-4 days. Cells 
were washed with sterile PBS before adding lx  Trypsin-EDTA (Gibco, Paisley, UK) to 
cover the cell surface for l-2.5min at 37°C which allowed the adherent cells to detach. 
Trypsin activity was immediately inhibited by addition of complete media. The 
resultant cell suspension was spun (lOOOrpm, lOmin, 4°C) and cell pellet resuspended 
in complete media. The cell suspension was passed through a 23 gauge needle (Terumo, 
Leuven, Belgium) to ensure no cell clumps remained. Cells were seeded and maintained 
in 75cm2 culture flasks, 6 or 96 well plates at a concentration as required.
2.5.1.3 Counting viable cells
lOpl of cell suspension was removed and added to lOjul of 0.4% trypan blue (Sigma, 
Gillingham, UK) for lmin. lOpl of this mixture was placed onto a haemocytometer 
counting chamber (Neubauer, Weber, Sussex, UK), and observed under a microscope 
(Zeiss, Germany) at a magnification of x40. The unstained viable cell count was:
The number of cells (within a 25 box field) x dilution factor = Total number of cells x 
104 per ml.
2.5.1.4 Freezing cells
For long term storage, confluent adherent cell-lines were washed with sterile PBS and 
trypsinised as described above. Cells were centrifuged (lOOOrpm, 5min, 4°C) and
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resuspended in freezing media (80% FCS, 10% complete media and 10% sterile 
dimethyl sulphoxide [DMSO, Sigma, Gillingham, UK]). 1ml cell suspension aliquots 
were transferred into cryovials (Nunc, Roskilde, Denmark) and slowly chilled and 
stored at -80°C.
2.5.1.5 Thawing cells from -80°C storage
Cryovials were removed from storage and placed into a water bath at 37°C to permit 
rapid thawing. Thawed cells were added to complete media previously warmed to 37°C 
followed by centrifugation (lOOOrpm, 5min, 4°C) to remove DMSO/ glycerol. The cell 
pellet was resuspended in complete media, before proceeding with culturing in 25cm 
tissue culture flasks.
2.5.2 Cytokine stimulation studies
This series of experiments were undertaken in media supplemented with 0.5% FCS, in 
the presence of antibiotics. Cells were maintained in this media overnight prior to and 
during the experimental timeframe. All recombinant cytokines (Peprotech, London, 
UK) and E.coli LPS (Sigma, Gillingham, UK) were reconstituted according to the 
manufacturer’s instructions.
2.5.3 Total RNA isolation
Supernatant was aspirated from adherent cells for protein analysis and stored at -80°C 
until required. Total RNA isolation was carried out using a monophasic solution of 
phenol and guanidine thiocyanate (TRIZOL® (Invitrogen, Paisley, UK)), of which 1ml 
was added directly to 1 well of a 6 well plate. The cell suspension was gently shaken for 
lOmin at RT to allow homogenization of cellular contents. Further homogenisation was 
achieved by repeated dispersion of the solution through a syringe and needle (25 gauge).
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The resultant Trizol solution was allowed to stand at RT for 5min to permit greater 
dissociation between nucleic acid-protein complexes. 200pi chloroform (Sigma, 
Gillingham, UK) was added for every 1ml Trizol used and the mixture was vortexed 
thoroughly for 15sec before centrifugation (13000rpm, 25min, 4°C). This procedure 
allowed organic extraction of the total RNA from the remaining cellular debris. The 
resultant top aqueous layer (comprising RNA) was aspirated (approximately 400pl) and 
transferred into a fresh microcentrifuge tube. RNA was precipitated by the addition of 
an equal volume of isopropanol (Sigma, Gillingham, UK). Extracted RNA was stored at 
-20°C. Total RNA was pelleted by centrifugation (13000rpm, 20min, 4°C) and washed 
with ice-cold 70% ethanol (BDH Laboratories, Poole, UK). The RNA pellet was air- 
dried to remove traces of ethanol prior to the addition of RNase- free water.
2.S.3.1 Spectrophotometric quantification of total RNA
Appropriate amounts of resuspended RNA solution were diluted in water and the 
concentration determined by absorbance (U-1800 Spectrophotometer, Digilab Hitachi, 
Tokyo, Japan) at 260nm and 280nm. The amount of RNA (pg/pl) was calculated as 
follows:
[(absorbance at 260nm, A260) x (dilution factor) x 40] /1000
The ratio of the readings at 260nm and 280nm (A260/A280) was used to estimate the 
purity of the RNA, with a ratio of 2.0 signifying a pure sample.
2.5.4 Reverse transcription
Reagents used in sections 2.5.4 and 2.5.5 were from Invitrogen, Paisley, UK, unless 
stated otherwise.
l-5pg of total cellular RNA was transcribed to complementary DNA (cDNA) using 
Moloney murine leukaemia virus reverse transcriptase (MMV-RT). In a typical MMV-
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RT reaction, lpl (0.5pg) oligo-dT was added to 5pg RNA and heated to 70°C for lOmin 
followed by immediate chilling to permit specific annealing between the oligo-dT and 
poly-A tail of mRNA molecules. The remaining components of the reaction comprised: 
4pi 5x first strand buffer, 2pl 0.1M dithiothreitol (DTT), lpl lOmM dNTP mix, 0.5pl 
sterile water and 0.5pl 100U enzyme (Superscript II reverse transcriptase). The reaction 
was allowed to proceed at 42°C for lh and was terminated by heat inactivation at 70°C 
for lOmin.
2.5.5 Polymerase Chain Reaction (PCR)
cDNA obtained was used in subsequent PCR reactions. Reaction volumes were 30pl, 
comprising: 3pl 10 x PCR Buffer [200mMTris-HCl (pH8.4), 500mM KCL], 0.9pl 
50mM MgCl2 , 0.6pl lOmM dNTP mix, 1.2pl of 20pmol of each oligonucleotide primer 
and 0.2pl 0.1 units Taq polymerase. Primer sequences are listed in Table 2.9. The 
remainder consisted of RNase free water to a total volume of 30pl.
Sense Antisense Product size 
(bp)
MBL ‘"ACT GTG ACC TGT 
GAG GAT GCC CA151
4uuc t t  t c t  g a g  g c a
GCC AGG CTA CTA 
TCA CC372
271
GAPDH W0CTA CTG GCG CTG 
GCAAGGCTGT652
WUGCC ATG AGG TCC 
ACC ACC CTG CTG966
360
Table 2.9 Sequences of synthetic oligonucleotide primers utilised in the study
Mastermixes were prepared for multiple reactions to minimize inter-sample variation. 
The contents of the PCR reactions were mixed by brief centrifugation. PCR 
amplification was carried out in a thermal cycler as follows:
a) 95°C for 5min -1 cycle
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b) 95°C denaturation for lmin 30sec
58°C annealing for lmin 30sec - 34-36 cycles
72°C extension for lmin 30sec
c) 72°C for 5min -1 cycle
Subsequently, PCR products were visualized on 2% agarose gels. Semi-quantitative 
analyses were conducted by densitometric measurements of bands via normalization to 
the house-keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), using 
the Alpha Imager system.
2.5.6 Cloning of the MBL promoter
All reagents used were from Promega, Southampton, UK or Invitrogen, Paisley, UK 
unless stated otherwise. Data shown in Section 8.2.2.
The initial step for cloning the MBL promoter sequence was specific amplification of a 
2933bp fragment 5’ of the ATG codon. Primers were designed with restriction enzyme 
sites tagged at the 5’ end of both sense and antisense primers as listed below and 
highlighted in bold type.
Sense (5’-3’)
GCGCAAGCTTCTGATGGCTTTAGGCATGTGGCTCTG Hind III
Antisense (5’-3’)
GTCCCATGGTCCTCACCTTGGTGTGAGAAAACTC Nco 1
The full sequence was analysed for potential restriction enzyme sites using the 
NEBcutter program, http://tools.neb.com/NEBcutter2/index.php.
Genomic DNA from an individual of MBL genotype LYPA/HYPA, was used as a 
template (lOpl/reaction). PCR reaction volumes were 50jil and comprised: 5jxl lOx
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PCR buffer, 4pl 25mM MgCh, ljil lOmM dNTPs, lpl 50pM primers (0.5pl of each), 
lpl Amplitaq Gold DNA polymerase (5U/ pi) and lOpl genomic DNA. The remainder 
consisted of sterile water. 3x 50pl reactions were prepared and amplification was 
carried out in a thermal cycler as follows:
a) 95°C for 5min -1 cycle
b) 95°C denaturation for lmin 30sec
60°C annealing for lmin 30sec - 36 cycles
72°C extension for 3min
c) 72°C for 5min -1 cycle
Amplified DNA fragments (1% agarose gel in Tris-acetate EDTA buffer (TAE)) were 
cut under a UV illuminator (UVP, Hannover, Germany) and subjected to purification 
using the Qiagen QIAquick Gel Extraction Kit (Qiagen, Crawley, UK). Briefly, three 
volumes of Buffer QG were added to one volume of gel (100mg~ lOOpl) before 
incubating them together for lOmin at 50°C to dissolve the gel. The resulting mixture 
was added to a QIAquick column and spun (13000rpm, lmin). To ensure removal of all 
traces of agarose a further 500pl Buffer QG was added to the column, spun for lmin as 
before and then followed by a wash step using 750pl Buffer PE and one further spin. 
The column was transferred to a clean 1.5ml polypropylene tube and DNA elution was 
achieved by addition of 50pl Buffer EB (lOmM Tris-Cl, pH8.5) followed by incubation 
for lmin at RT prior to a final lmin spin.
2.5.6.1 Enzyme digest and ligation of the MBL promoter sequence into the pGL3 
basic vector
Both DNA and vector were subjected to sequential enzyme digestion to release sticky 
ends. Hind III digest was followed by Ncol due to differing salt buffer concentrations.
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Both digests were performed for 2h at 37°C in a thermal cycler. A 50pl reaction volume 
was used for Hind III digestion of the genomic DNA PCR product and comprised 5pi 
lOx REACT 2 buffer, lpl Hind III enzyme, 25pi DNA (~250ng) and 19pl water. Hind 
III digestion of the vector was performed in a 25pi reaction comprising; 2.5pl lOx 
REACT 2 buffer, lpl Hind III enzyme, 0.5pl DNA (~500ng) and 21 pi water. Both 
digested DNA and vector were purified using a Qiagen PCR Purification Kit (Qiagen, 
Crawley, UK) prior to the second digestion and before ligation.
Digestion of the purified genomic DNA PCR product with Ncol was performed in a 
50pl reaction volume comprising: 5pi lOx REACT 3 buffer, lpl Ncol enzyme, 28pl 
DNA and 16pl water. Ncol digestion of the vector was performed in a 40pl reaction 
comprising; 4pl lOx REACT 3 buffer, lpl Ncol enzyme, 28pl DNA and 7pl water. 
Ligation is an enzymatic reaction that allows joining of a target DNA fragment with a 
second DNA (i.e. vector). T4 DNA ligase repairs breaks in the dsDNA backbone and 
can covalently rejoin annealed cohesive ends in the reverse of a restriction enzyme 
reaction, to create new DNA molecules. The reaction was performed utilising different 
amounts of MBL promoter and vector to obtain optimum product. Reactions were 
vector alone (control) or PCR product + vector (1:3) carried out at 14°C overnight in a 
thermal cycler. In a total volume of 20pl the PCR + vector reaction comprised: 1.5pl 
~12.5ng Hindlll/Ncol digested vector, 12pl~60ng Hindlll/Ncol digested PCR product, 
4pl 5x DNA ligase reaction buffer, 1 pl~0.limits T4 DNA Ligase and 1.5pl Water. The 
vector only reaction comprised: 1.5pi ~12.5ng cut vector, 4pl 5x DNA ligase reaction 
buffer, 1 pl~0.1 units T4 DNA Ligase and 13.5pl Water. Ligated DNA was observed by 
the presence of higher molecular weight product on agarose gel.
The pGL3 basic vector, a promoterless luciferase reporter vector was utilised. It 
contains a multiple cloning site and an ampicillin resistance gene. Luciferase is an 
enzyme which catalyzes a light producing reaction. The luciferase gene is downstream
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of the promoter sequence of interest and the regulatory potential of this sequence is 
measured by subsequent luciferase expression as described in section 2.5.7.
2.5.6.2 Transformation
Transformation is a process by which bacteria can uptake foreign DNA. In the 
laboratory E.coli (Recombinase negative) cells are routinely used and can be made 
‘competent’ by specific pre treatment e.g. with calcium which destabilises the bacterial 
membrane allowing for uptake of exogenous DNA.
Ampicillin (100pg/ml) containing (Luria Bertani) agar/broth was prepared according to 
standard microbiological techniques. Plates were stored (for a maximum of 2 weeks) at 
4°C until required. Competent JM109 E.coli cells were removed from -80°C and 
thawed on ice. Ligated DNA (l-10ng) was added to 75pi of competent cells 
respectively and incubated on ice for lOmin. A gentle flicking action was performed to 
encourage DNA binding to JM109 cell membranes. Cells were heat-shocked at 42°C for 
50sec and immediately chilled on ice for 2min. This step allows entry of exogenous 
DNA into cells. 900pl LB broth with lOmM Mg and D-glucose was added to each 
transformation reaction and the mixture was incubated for lh at 37°C (to allow cells to 
recover) on a shaking platform at low speed. Ampicillin (lOOpg/ml) containing LB agar 
plates were brought to RT and lOOpl of the undiluted transformation mix was plated out 
and incubated overnight at 37°C.
Plates were checked for colonies the following morning and numbers per plate were 
compared to assess transformation efficiency. Selected colonies were screened for 
presence of MBL promoter insert in vector. A single colony was picked using a 
bacterial loop and added to LB broth in small culture volumes. After 4h, lOOpl of broth 
was pelleted and resuspended in lOOpl water (to lyse the bacteria). 10pl of the resulting
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solution was used in a 25 pi PCR reaction to confirm presence of MBL promoter 
sequence inserts.
Positive plasmid broths were utilised for long term storage. 70% Broth and 30% 
Glycerol (autoclaved) stocks were transferred to Nunc cryovials (Nunc, Roskilde, 
Denmark) and slowly chilled before freezing at -80°C.
2.5.6.3 Sequence analysis of MBL promoter construct
Plasmid DNA was prepared for sequencing using a Qiagen Mini-prep kit (Qiagen, 
Crawley, UK) which is based on a modified alkaline lysis procedure. An aliquot of the 
resulting plasmid DNA was run on a 1% agarose gel to determine yield and purity and 
quantity by spectrophotometry. Multiple DNA samples were digested with Hind III and 
Ncol enzymes to confirm the presence of the insert in the cloned vector.
Sequencing of plasmid DNA using commercial primers spanning the vector was 
performed at the UCL core facility.
Sense 5’-3’ GGACTCGTTCCAAACTGGG 
Antisense 5’-3’ CCAGGGCGTATCTCTTCATAGC
Analysis of over 600bp confirmed complete homology with the published sequence 
and, specifically, all three MBL promoter polymorphism sites were present. Large scale 
preparation and purification of plasmid DNA was performed using the Qiagen Maxi 
prep kit (Qiagen, Crawley, UK).
2.5.7 Transient transfection studies
In order to study transcriptional regulation of MBL, it’s promoter construct was 
transiently transfected into liver cell-lines. Transfection is a method used to introduce 
DNA into eukaryotic cells.
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HepG2 and Huh7 cell-lines were set up in 96 well plates at a density of 3 and 1.5 x 104 
cells/well respectively in lOOpl complete media without antibiotics. Transfections were 
conducted the following day when cells were 70-80% confluent using Lipofectamine 
2000™ (Invitrogen, Paisley, UK). Plasmid DNA was stored in aliquots at a 
concentration of 0.5pg/pl. Each transfection comprised a total DNA content of 230ng. 
This included:
a) Firefly luciferase construct under investigation i.e MBL or IL-8 promoter 
(positive control for cell line, kindly provided by Dr A Bowie, Trinity College, 
Dublin, 60 ng/well)
b) HSV TK Renilla luciferase construct (kindly provided by Dr A Bowie, Trinity 
College, Dublin), to correct for transfection efficiency (20 ng/well)
c) Empty vector (pcDNA3.1; Stratagene, Cambridge, UK) to ensure a total of 
230ng DNA was added (150ng/well)
Each experimental condition was performed in triplicate. Mastermixes were prepared of 
different promoter constructs under investigation. The protocol used was adapted from 
the Invitrogen Lipofectamine 2000™ manual. For each well, DNA to be transfected was 
prepared as follows: 230ng of DNA was added to 25pl OptiMEM® media (Gibco, 
Paisley, UK), in a separate tube lpl Lipofectamine 2000 was added to 25pl OptiMEM. 
The Lipofectamine/OptiMEM mix was incubated for 5min at RT before combining it 
with the DNA/OptiMEM mix. The mixture of DNA, Lipofectamine and Optimem (50pl 
total) was incubated for 20min at RT to allow DNA-Lipofectamine complexes to form 
prior to addition to resident media. The transfection reaction was left to proceed for 22- 
24h, media was subsequently removed and replaced with 200pl media (DMEM, 0.05% 
serum) containing relevant stimulants (e.g. cytokines and LPS). Control wells received 
media alone. Experiments were terminated by removal of media followed by addition of
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50(0.1 reporter lysis buffer. The plate was incubated for 10-15min on a shaking platform 
before freezing at -80°C until analysis.
Prior to analysis, plates were thawed on ice and 20pl cell lysate was transferred to two 
white luciferase assay plates (Labtech International, East Sussex, UK). One plate was 
used for analysing Renilla luciferase activity, where 40pl of its substrate Coelentrazine 
(Insight technologies, London, UK) was added. The second plate was used to assess 
luciferase activity to which lOOpl firefly luciferase substrate was added. A 96-well plate 
luminometer (LUCY1 luminometer, Anthos Labtech Instruments, Austria) was utilised 
for measuring luciferase activity. Ratio of Luciferase to Renilla activity was calculated 
for each condition in triplicate. Mean values were compared to control and expressed as 
relative fold induction.
2.6 Statistical analysis
The clinical data, MBL genotypes and protein assay data were entered onto an SPSS 
database and analysed using SPPS v.12 statistical software. Comparisons between 
groups were analysed using Mann Whitney U, Kruskal Wallis and Chi square tests 
where appropriate. Paired t-tests were used to assess change in MBL and MASP levels 
and function pre- and post-chemotherapy. The mean and standard error of the mean of 
experimental data (n=3) was calculated and plotted on graphs accordingly.
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Chapter 3
Design and implementation of a febrile neutropenia 
management strategy incorporating risk stratification
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3.0 Introduction
This thesis explores the role of MBL and the lectin pathway of complement in children 
with cancer who are immunosuppressed by their treatment and are at risk of infection. 
In this chapter the clinical management of infection/FN is discussed. Outcome data 
collected as part of the large scale PINE audit conducted in the South East of England 
was utilised in the disease association studies presented in this thesis. This audit project 
was run in collaboration with the NHS Audit, Information and Analysis Unit (London 
Specialised Commissioning Group) who coordinated data collection and entry. The 
candidate was specifically involved in the development of the new infection/FN 
management protocol and the analysis of audit data, jointly with Mrs J Geary (PINE 
project co-ordinator), under the supervision of Dr J Chisholm (Clinical lead).
A patient who is febrile (i.e. temperature > 38.0°C for more than 4 hours or > 38.5°C on 
one occasion) and neutropenic (ie. absolute neutrophil count < 1.0 x 109/L or < 0.5 
xl09/L) is presumed to have an infection until proven otherwise and requires medical 
assessment and broad spectrum antibiotics. The routine use of empirical intravenous 
antibiotics is the gold standard of treatment and has lead to a dramatic reduction in 
mortality from infection (Schimpff et al., 1971). However, FN still remains a major 
cause of morbidity and is the second most common reason for inpatient (IP) admission 
after chemotherapy (Chisholm and Dommett, 2006). In comparison to adults, children 
with FN have been reported to have a lower mortality rate (4% and 1%, respectively) 
and fewer documented infections (28% and 19%, respectively). Overall incidence of 
bacteraemia is similar (24% and 22%) but fever of unknown origin is more common 
(35% and 49%, respectively) (Hann et al., 1997). This means that in approximately half 
of all paediatric FN episodes there is no documented clinical or microbiological site of 
infection. These patients may be at low risk of life threatening complications and the 
episodes may be suitable for outpatient management.
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Improvements in the identification of FN episodes in which there is a low risk of 
adverse outcome has enabled the development of ‘low risk’ management protocols 
which safely reduce the need for prolonged hospital admission (Ammann et al., 2005). 
The implications of reduced hospital stay are advantageous for the patient, their family 
and also the hospital, in terms of quality of life and cost savings (Ahmed et al., 2007). 
Early work on risk assessment focused on identifying adult cancer patients at lower risk 
of infection. Talcott and colleagues reviewed 261 medical records of patients with FN. 
They identified four subgroups of patients, three of which were considered to be at 
higher risk of infection (patients already hospitalised when fever developed, outpatients 
with comorbidity and outpatients with cancer ‘not in remission’) and one group of Tow 
risk’ patients (Talcott et al., 1988). Their risk prediction model utilized clinical 
information available on the first day of FN and they went on to validate it in a 
prospective trial. Of 444 patients with FN, 34% of patients in one of the high risk 
groups were found to suffer from serious medical complications compared to only 5% 
in the low risk group (Talcott et al., 1992). However the criteria, although effective at 
predicting adverse outcome, were not sufficient to discriminate between bacterial 
infections and other causes of fever. More recently, the Multinational Association for 
Supportive Care in Cancer (MASCC) developed a new clinical risk index, which 
identifies adult patients at low risk of medical complications during resolution of fever 
(Klastersky et al., 2000).
The criteria used to identify low risk adult episodes cannot be directly translated into 
paediatric practice but several studies have been conducted in paediatric populations 
addressing the same issues (Aquino et al., 1997; Klaassen et al., 2000; Santolaya et al., 
2004; Rondinelli et al., 2006) To date there is no universally agreed, validated, set of 
parameters for identifying low risk paediatric episodes. The most important adverse 
outcomes in children are intensive care admission and death but the majority of
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paediatric studies to date have focussed on prediction of bacteraemia and identified 
absolute monocyte count, temperature, high CRP, hypotension, relapsed leukaemia, low 
platelet count and chemotherapy within the previous 7 days, as independent risk factors 
(Rackoff et al., 1996; Klaassen et al., 2000; Santolaya et al., 2001). Clinical variables 
including; predicted degree and duration of neutropenia, type and status of underlying 
disease, associated systemic symptoms indicative of severe infection, proven 
bacteraemia, and fever and neutrophil count at the time of presentation have all been 
used to select episodes which are suitable for management on low risk strategies.
The successful identification of low risk episodes has subsequently lead to the 
development of a number of different management strategies for use in such episodes 
which have either been piloted or validated against standard IP treatment;
a) Ambulatory/Outpatient intravenous therapy following a period of 
hospitalisation. This has been reported to be safe and enabled discharge from hospital 
within 24-36h with continued IV treatment in the outpatient setting (Wiemikowski et 
al., 1991; Santolaya et al., 2004). Santolaya et al were able to demonstrate that there 
was no significant difference in outcome between patients managed on either 
ambulatory or continued IP therapy (Santolaya et al., 2004).
b) Ambulatory intravenous therapy from onset of FN episode. A number of small 
single centre studies have demonstrated that once daily IV Ceftriaxone was effective in 
stable children without significant comorbidity (Preis et al., 1993; Kaplinsky et al., 
1994; Mustafa et al., 1996). IP admission was required in up to 19% of episodes which 
all resolved without significant morbidity or mortality. These strategies have not yet 
been proved equivalent to standard management.
c) Step-down strategies. These involve a period of IP care (either a single dose of IV 
antibiotics or admission for a period of IV antibiotics) followed by a change to oral 
antibiotics. High rates of success without modification have been reported in two
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studies where patients were randomised to either continued IV treatment or oral 
Cefixime after 48-72h (Paganini et al., 2000; Shenep et al., 2001). Studies utilising 
shorter observation periods have reported relatively low re-hospitalisation rates but 
higher rates of treatment modification (Mullen et al., 1999a; Aquino et al., 2000; 
Paganini et al., 2003).
d) Oral therapy from the outset. Two small studies have reported the use of oral 
antibiotics from the outset in groups of very carefully selected patients with low 
hospitalisation rates (6-9%) and no significant difference in outcome when compared 
with IV treatment (Petrilli et al., 2000; Malik, 1997). The majority of these studies have 
been conducted in single centres with a maximum of six centres involved in the 
minority. There have been no reports of the safe implementation of such strategies in a 
large multicentre setting, to date.
As mentioned above (Chapter 2), the specialist care of children with cancer in the South 
East of England is provided by four tertiary Paediatric Oncology Centres (POCs) in 
London working in collaboration with over forty Paediatric Oncology Shared Care 
Units (POSCUs) based at district general hospitals (Figure 2.1). Importantly, the POCs 
and POSCUs use unified supportive care guidelines ensuring that all children are 
managed in the same way. This is in contrast to other parts of the United Kingdom 
where management practice is diverse (Phillips et al., 2007). There has been an ongoing 
interest in the management of infection in the shared care setting in the South East of 
England. An audit of FN episodes in POSCUs conducted in 2001/2002 showed that the 
recommended empirical antibiotic regimen was safe, levels of antibiotic resistance were 
low and median inpatient stay was 5 days (Duncan et al., 2007).
Following on from this a new FN management protocol incorporating RS was designed 
and a step-down strategy was deemed most suitable for this multicentre healthcare
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setting. This chapter describes the design of the new protocol and the results from the 
PINE project relating to RS and low risk management.
3.1 Methods
3.1.1 Risk Stratification Criteria
A literature review was conducted of all relevant adult and paediatric studies and RS 
criteria, excluding patients from low risk management, were identified (Figure 3.1). The 
categories included; age, medical conditions requiring IP treatment independent of FN, 
high risk diagnosis or treatment regime, previous admission to PICU during FN and 
social concerns which could be patient or carer related. The specific criteria were 
discussed with the PINE working party, a group of POC and POSCU clinicians and 
microbiologists, before a unified decision was reached.
3.1.2 Patient assessment
All patients were admitted to hospital for a minimum of 48h. On admission a full 
history was taken, clinical examination performed and risk assessment (low or standard) 
made using the RS checklist (Figure 3.1). Blood cultures were taken prior to 
commencing empirical antibiotics and other relevant investigations were carried out 
according to the clinician’s assessment. At 48h, a full blood count was taken and repeat 
risk assessment performed. This assessment also incorporated the RS checklist, absolute 
neutrophil count (ANC) and blood culture results. A 48h ANC of <0.1xl09/L and/or 
positive blood cultures excluded the patient from low risk management irrespective of 
the RS checklist. Presence of any of the RS criteria on admission or at 48h also 
excluded them from low risk management.
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Febrile Neutropenia- Risk Stratification Checklist
Hospital Date of Admission
Criteria excluding patients from Low Risk protocol
/ /
T all relevant 
exclusion criteria 
On At 
Admission 48h
Age
< 1 year
Associated medical conditions requiring hospitalization
Shock or compensated shock
Haemorrhage
Dehydration
Metabolic instability
Altered mental status
Pneumonitis
Mucositis(unable to tolerate oral fluids or requiring IV analgesia)
Respiratory distress/compromise
Perirectal or other soft tissue abscess
Rigors
Irritability/Meningism
Organ failure
Cancer associated comorbidities
ALL at diagnosis/relapse <28 days
ALL not in remission >28 days
AML
Infant ALL
Intensive B-NHL protocols
Allogenic BMT or Autologous PBSC transplant
Sequential high dose chemotherapy with PBSC rescue
History
PICU admission during last FN episode
Non adherence- Social concerns
Patient
Inability to tolerate oral antibiotics
If one or more exclusion criteria are present follow Standard Febrile Neutropenia 
Protocol
Figure 3.1 Risk Stratification criteria
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The final decision regarding low risk management lay with the attending clinician as 
patients had to be considered ‘clinically well’ but this did not mean they had to be 
apyrexial (Figure 3.2). Patients with a temperature >38°C could still be discharged on 
the low risk protocol. Episodes excluded from low risk management continued on the 
standard risk protocol (Figure 3.3).
3.1.3 Low risk management
In low risk episodes, patients stopped IV antibiotics, were discharged and continued 
oral Co-Amoxiclav (Augmentin) at home until they had been afebrile for 48h (Figure 
3.4). If, at any time after discharge, the patient’s condition deteriorated or there was 
parental concern, the patient was reviewed in hospital. A phone call was made at 72h to 
monitor progress and a clinical review was performed at 96h, either at home or in 
hospital depending on local arrangements. At the 96h review an ANC was repeated, 
vital signs were checked and any late cultures were chased. A patient remaining febrile 
(>38°C) at 96h was readmitted to hospital to recommence IV antibiotics, including an 
antifungal agent, as per the standard risk protocol. If the temperature was settling and 
the patient remained clinically well they returned home and discontinued antibiotics as 
planned.
The new protocol was implemented in all POCs and POSCUs in April 2004 and audited 
from the outset. Following liason with the local ethics committee, consent for data 
collection was not required. The clinical outcome data was recorded using audit 
proformas (Figures 3.5 and 3.6).
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Management of Febrile Neutropenia according to 
risk stratification*
Risk assessment 
on admission*
Tazocin + Gentamicin
Local Empirical Regimen
Risk assessm ent 
at 48 hrs No exclusion criteria* Exclusion criteria 
present*
Standard
Febrile
Neutropenia
Management
Protocol
NO
Temp > 38°C Reculture
Add Teicoplanin or 
Vancomycin for 
tunnel infection or 
if child has 
endoprosthesis
Low Risk Protocol
Complete Febrile Neutropenia Risk Stratification checklist
Blood Culture NEGATIVE
Total ANC 20.1 x 109/L
Clinically well
and
and
Figure 3.2 Protocol for selection of patients eligible for low risk management
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10 Hours 1
148 Hours!
Empirical antibiotic regimen
REASSESS
Add teicoplanin or 
vancomycin for tunnel 
infection or if child has 
endoprosthesis
(See p52 for more 
information on management 
of tunnel infection)
Persistent Fever
i
R e c u l t u r e
Fever Settling
Negative Blood 
Cultures
Discontinue 
vancomycin/teicoplanin 
if used, except in 
tunnel infection
Positive Blood 
Cultures
Review sensitivities 
Add vancomycin or teicoplanin 
if staphylococcus
Negative Blood 
Cultures
See Flow Chart 
For Stopping 
Antibiotics p21
96 Hoursl REASSESS
Fever Settling
I
Fever Persists
Positive Blood Cultures
Review Antibiotics 
Consider Line Removal"
Persistent Fever 
Reculture
Negative Blood Cultures
i
Amphotericin B
R E A S S E S S
Figure 3.3 Management protocol for Standard risk patients
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48 hrs Commence Augmentin 
Confirm 72 and 96 hr Contact/Review
HOME
Monitor temperature twice daily and keep record
Clinically well Clinical deterioration
Parental concern
Unable to tolerate Augmentin
72 hrs PHONE CALL
Hospital
Review
Concerns
If admission is 
necessary follow 
Standard Febrile 
Neutropenia 
Management 
Protocol
at relevant time point
Child remains well
96 hrs
CLINICAL REVIEW
Vital signs —
FBC
Check Blood Culture results
Temp £ 38°C or __
+ve blood culture 
requiring inpatient care or 
Clinical deterioration
ADMIT
Temp < 38°C 
and
Clinically well
HOME
Discontinue antibiotics 
when
Temp < 38°C for 48 hrs
If temp > 38°C at 
any time beyond 96 
hrs
ADMIT
Figure 3.4 Outpatient management protocol for low risk patients
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No in Series
A udit, In fo rm atio n  and  A nalys is  U n it (Lo nd on , K ent, S urrey  &  S u ssex )
PAEDIATRIC INFECTIONS IN FEBRILE NEUTROPENIC EPISODES (PINE) 
PRESENTING TO SHARED CARE UNITS WORKING WITH THE TPOC’s
TO BE COMPLETED AT 48 HOURS
Please complete a separate form for each admission during the period 1st April 2004 - 31st March 2005
Name of Hospital
Patient's Date of Birth
& sex (please circle)
Oncology Diagnosis
Symptoms reported 
on admission
(please 7)
Clinical/Radiological 
evidence of infection
(please 7)
Admission Antibiotics 
used (please 7)
Admission results 
Positive culture results
I I M
Tertiary Centre for this 
patient (please circle)
Date of Admission
Risk Stratification 
Checklist completed
GOS I RMH I RLH I Middx
I I
Yes Nc
Fever only Line related
Respiratory Skin
Gastrointestinal Urine
Central nervous system  (CNS) Other
Fever only Line related
Respiratory Skin
Gastrointestinal Urine
Central nervous system  (CNS) Septic shock
Cardiac signs Other
Gentamicin □ Amikacin □ Ceftriaxone □
Piptazobactam □ Ciprofloxacin □ Ceftazadim e □
Teicoplanin □ Vancomycin □
Other
Fluid Bolus 
Required
(please circle)
Yes No
ANC 48 hour results ANC
D a te S i t e  (please 7) O r g a n i s m S e n s i t i v i t i e s R e s i s t a n c e s
Blood
Urine
Skin
Other
PLEASE FAX RISK STRATIFICATION CHECKLIST
Risk a sse ssm en t
(please circle)
On admission LOW STANDARD At 48 hours LOW STANDARD
LOW RISK PATIENTS ONLY
Managed on Low Risk 
protocol
(please circle)
Discharge Antibiotics
(please 7)
Yes No * Total inpatient nights nights
Augmentin □
Ciprofloxacin □
Clarithromicin □
Other
* If m anaged on 
Standard risk 
protocol
* Reason
Figure 3.5 Clinical outcome data collection sheet 1
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No in Series
A udit, In fo rm ation  &  A n alys is  U n it (London , Kent, S urrey  & S u ssex ;
PAEDIATRIC INFECTIONS IN FEBRILE NEUTROPENIC EPISODES (PINE) 
PRESENTING TO SHARED CARE UNITS WORKING WITH THE TPOC’s
TO BE COMPLETED AT END OF EPISODE
Please complete a separate form for each admission during the period 1st April 2004 - 31st March 2005
Name of Hospital
Patient's Date of Birth
& sex (please circle)
Tertiary Centre for this 
patient (please circle)
GOS /  RMH / RLH / Middx
/  / M F Date of Discharge /  /
Patients assessed and managed as LOW RISK at 48 hours
Outpatient Management
Hospital review required
Other than planned at 96 hours 
(please circle)
Yes* No Outcome
(please circle)
Returned Home Admitted
If Yes *, No. of days Clinical Deterioration
Post Discharge Indication Persistent Fever
days (please T) Unable to tolerate oral antibiotics
Date /  / Parental Concern
96 hour review
Total No of days on 
oral antibiotics
ANC
days
Date Site (please T) Organism Sens Resist
Blood
Urine
Skin
Other
If Readmission required at any time
No of days post Clinical Deterioration
Discharge Indication Persistent Fever
days (please T) Unable to tolerate oral antibiotics
Date /  / Parental Concern
Change/addition of 
antibiotic required
(please circle)
Total Antibiotic Days
Yes No
days
* Details
Final Discharge 
Date I I Total inpatient nights
Original + readmission
nights
Patients assessed and/or managed as STANDARD RISK AT 48 hours
Additional Positive Blood 
Culture results
(please circle)
Change/addition of 
antibiotic required
(please circle)
Total inpatient nights
Positive culture results
Date Site (please 7) Organism Sens Resist
Blood
Urine
Skin
Other
Yes No
nights
* Details
All Patients
Transferred to POSCU
(please circle) Yes No
PICU admission 
required (please circle) Yes No
Death
(please circle) Yes No
Figure 3.6 Clinical outcome data collection sheet 2
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3.2 Results
3.2.1 Patient and episode characteristics
PINE data was returned from 44 out of 47 eligible hospitals between April 2004 and 
March 2005. Of these, 40 were POSCUs and 4 were POCs. 762 FN episodes were 
eligible for analysis from 368 patients, of which 213 (28%) episodes were initiated in 
POCs and 549 (72%) were initiated in POSCUs. The median patient age at first 
admission for FN was 5 years 7 months (range 1 month to 17 years 6 months). Patient 
numbers stratified by diagnosis, mean number of FN episodes and their distribution 
between POC and POSCU are detailed in Table 3.1. Acute Lymphoblastic Leukaemia 
(ALL) is the commonest cause of childhood cancer and ALL patients represented 51% 
of the total patient population and accounted for 50% of the total FN episodes captured. 
The majority of ALL episodes (82.3%) were initiated in POSCUs. In contrast, the 
second largest group of patients captured in the audit were those with Acute Myeloid
Leukaemia (AML) (9%) and the majority of their episodes (89%) initiated in POCs.
Diagnosis Patients 
n (%*)
Mean no.
of
episodes
Episodes 
initiated in a 
POC
n (%*)
Episodes 
initiated in a 
POSCU 
n (%*)
Total 
episodes 
N (%*)
ALL 188 (51) 2 68 (32) 316(58) 384 (50)
AML 33 (9) 3 89 (42) 11 100(13)
Non-Hodgkins Lymphoma 28 (8) 2 21 (10) 35 (6) 56(7)
Hodgkins Lymphoma 8 1 3 6 9
PTLDt 1 2 0 2 2
Brain tumour 18 2 3 28 31
Bone tumour 20 2 3 36(7) 39(5)
Neuroblastoma 20 2 15(7) 19 34
Wilms tumour 14 3 4 31 35
Soft Tissue Sarcoma 12 2 2 25 27
Germ Cell tumour 2 1 1 1 2
Other 24(7) 2 4 39(7) 43
Total 368 2 213 549 762
Table 3.1 Patient diagnosis, mean number of FN episodes and their distribution 
between POC and POSCU. *Percentages are quoted for the 4 largest groups in each 
category+PTLD, Post Transplant Lymphoproliferative Disease
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3.2.2 Risk stratification and management
The differences in the patient populations treated for FN in POCs and POSCUs were 
clearly demonstrated when analysing the RS checklists detailing the criteria excluding 
patients from low risk management (Table 3.2). Overall the POC FN patient population 
consists of those treated on high risk protocols e.g. AML, B cell Non Hodgkins 
Lymphoma (NHL) and Stage IV Neuroblastoma (requiring PBSC) and ALL patients at
the time of diagnosis or relapse, all excluded from low risk management.
Exclusion criteria On admission At 48h
POC
(%)
POSCU
(%)
Total
(%)
POC
(%)
POSCU
(%)
Total
(%)
Age < 1 yr only 1 7 8 2 8 10
(0.5) (1.3) (1.0) (0.9) (1.5) (1.3)
Age < 1 yr 17 3 20 16 2 18
in combination (8.0) (0.55) (2.6) (7.5) (0.36) (2.4)
Diagnosis only 147 38 185 147 41 188
(69) (6.9) (24.3) (69) (7.5) (24.7)
Diagnosis 37 12 33 35 10 45
in combination (17.4) (2.2) (4.3) (16.4) (1.8) (5.9)
Medical conditions only 9 46 55 7 47 54
(4.2) (8.4) (7.2) (3.3) (8.6) (7.1)
Medical conditions 25 16 41 18 13 31
in combination (11.7) (2.9) (5.4) (8.5) (2.4) (4.0)
Patient history only 3 14 17 4 15 19
(1.4) (2.6) (2.2) (1.9) (2.7) (2.5)
Patient history 4 12 16 3 10 13
in combination (1.9) (2.2) (2.1) (1.4) (1.8) (1.7)
Other 5 6 11 5 9 14
(2.3) (1.1) (1.4) (2.3) (1.6) (1.8)
No exclusion criteria 9 401 410 12 376 388
(4.2) (73) (53.8) (5.6) (68.5) (50.9)
No documentation 0 16
(2.9)
16
(2.1)
1
(0.5)
37
(6.7)
38
(5.0)
Table 3.2 Exclusion criteria recorded on the RS checklist at 0 and 48h in both POC 
and POSCUs.
For criteria shown in bold, actual percentages are detailed but for criteria in non bold 
percentages are cumulative and not exclusive i.e. total ^ 100%
Diagnosis was the most common reason, both independently or in combination with 
other criteria, for exclusion from low risk management in the POCs. In contrast, the 
most common reason for exclusion from low risk in POSCU episodes was medical
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conditions that required IP treatment independently of FN. These included respiratory 
compromise and shock i.e. reflecting a patient who was clinically unwell. However, the 
majority of POSCU episodes had no exclusion criteria both on admission (73%) and at 
48h (68.5%) compared to the minority of POC episodes (4.2 and 5.6%, respectively). 
Overall 388 episodes (50.9%) had no exclusion criteria on the RS checklist at 48h. 
Clinicians recorded any clinical or radiological evidence of infection and this was 
documented in 628 episodes (data was missing from 134 forms). Overall, evidence of 
infection was reported in 258 episodes (41%) and fever only was reported in 370 (59%). 
Evidence of respiratory and GI infection was most common, reported in 13 and 11% of 
episodes, respectively.
Positive blood cultures were present in 223 (29%) episodes at 48h and positive cultures 
from any source were present in 254 (33%) episodes. Approximately two thirds of 
blood culture isolates were gram-positive bacteria of which 70.5% were Staphylococcus 
epidermidis and other coagulase-negative Staphylococci. Gram-negative bacteria 
accounted for 28.3% of isolates and fungal organisms accounted for just 2.2%. The 
mean ANC in POSCU episodes rose between admission and 48h from 0.26 to 0.42 
x109/L in comparison to POC episodes where it fell slightly from 0.13 to 0.12 x l09/L, 
reflecting the relative degree of immunosuppression in the different populations and 
their capacity for count recovery.
On admission 403 (53%) episodes were identified as eligible for low risk management 
and at the 48h assessment 212 (28%) remained eligible. Of the 191 episodes which 
changed from low to standard risk, positive blood cultures and ANC <0.1 x l09/L were 
solely responsible in 69 and 50 episodes, respectively. Positive blood cultures and/or 
low ANC were responsible for the change of risk assignment in 74% (142/191) of these 
episodes. Other reasons for a change in risk assessment are detailed in Table 3.3.
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Reason for change Episodes, n (%)
Positive blood culture only 69 (36)
ANC <0.1 50 (26)
Other clinical reasons 7(4)
Positive blood cultures and ANC <0.1 23 (12)
Exclusion criteria at 48h (not present at admission) 25 (13)
Inappropriate risk assignment 15(8)
No reason given 2(1)
Total 191
Table 3.3 Reasons for change from low to standard risk at 48h
Of the remaining 212 episodes eligible for low risk management, 143 episodes were 
actually managed as low risk. This left 69 patients who were managed as standard risk 
and the reasons given for this decision are shown in Table 3.4. The only reason given in 
6 episodes was that the patient had a persistent fever but this should not have excluded 
the child from low risk management. A number of the reasons given were unclear or not
given at all.
Reason for standard management Episode 
n (%)
Clinical decision 35 (51)
Persistent fever only 6(9)
Confusion over ANC threshold 4(6)
No reason/unclear 24 (35)
Total 69
Table 3.4 Reasons given for decision to manage patients eligible for low risk on the 
standard risk protocol
Overall, 19% (143/762) of the total episodes were managed appropriately on the low 
risk protocol. A further 18 patients who should have been managed as standard risk 
were managed as low risk, giving a total of 161 episodes of which 160 were initiated in 
POSCUs. The recommended oral antibiotic, Co-Amoxiclav, was prescribed in 71% of 
these episodes. Of the remaining episodes; other antibiotics were used in 9%, no 
antibiotics were prescribed on discharge in 15% and there was no documentation in 5%. 
The median number of oral antibiotic days was 5 and total antibiotic days was 7.
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Hospital review was required in 17 patients before the planned 96h assessment. At the 
96h assessment, the ANC was recorded in 110 (68.3%) episodes and of these only 8 had 
an ANC <0.1 x l09/L.
Readmission was required in a total of 11 of the episodes managed as low risk. The 
readmission rate in patients who had been treated appropriately on the low risk protocol 
was 5.6% (8/143) compared to 16.6% (3/18) in those who had been managed 
inappropriately. For six episodes the number of days post discharge was not recorded. 
For the remaining episodes, the mean number of days between discharge and 
readmission was 1.4 (median 1, range 1-2). The most common reason for readmission 
was clinical deterioration which was recorded in 6 episodes. Other reasons included; 
persistent fever, parental concern, inability to tolerate oral antibiotics and development 
of herpes zoster. Eight of the readmission episodes required a change in antibiotics 
although none had any new positive blood culture results. All patients requiring 
readmission made a satisfactory recovery and spent on average 4 extra nights in 
hospital. The total number of IP nights and antibiotic days for all patients managed on 
the low risk protocol are summarised in Table 3.5.
Episode Type Median Mean Range No data
Total
inpatient
nights
All Low Risk Patients 2 2.5 1 -4 0
Non-readmitted patients 2 2.5 1 -4 0
Re-admitted patients 6 6.8 3 - 1 4 0
Total
antibiotic
days
All Low Risk Patients 7 6.0 2 - 2 0 5
Non-readmitted patients 7 5.8 2-11 4
Re-admitted patients 8.5 9.8 6 - 2 0 1
Table 3.5 IP nights and antibiotic days for patients managed on the low risk 
protocol
The median number of IP nights for all low risk patients was 2 in comparison to 
standard risk patients who spent 7 nights in hospital (data not shown). The median stay 
in POSCU standard risk patients was 5 nights, identical to that reported in the previous 
audit (Duncan et al., 2006) and significantly shorter than the median IP stay in POC 
standard risk episodes which was 11 nights. It should also be noted that no patients
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managed on the low risk protocol required transfer to their POC because of FN and 
there were no PICU admissions or deaths in any low risk patients.
3.3 Discussion
This chapter describes the safe implementation of a new low risk FN management 
strategy in over 40 hospitals across the South East of England. It is the first report of the 
use of RS and its applicability in such a large paediatric multicentre setting, made 
possible by the established partnership between our POCs and POSCUs and the use of 
shared management protocols.
A number of previous studies have been conducted in relatively selective single centre 
populations. An advantage of our study is that we have captured a patient population 
that represents the full spectrum of paediatric haemato-oncology diagnoses, from ALL 
to the less common e.g. Germ cell tumours and Anaplastic Large Cell Lymphoma 
(ALCL), by utilising data collected in both POCs and POSCUs. The location of 
supportive care of such patients is largely governed by the intensity of their treatment 
protocol; for example AML patients receive 6 months of intensive chemotherapy and 
spend most of this time as an IP in their POC whereas ALL patients receive less 
immunosuppressive treatment over 2-3 years, generally as an outpatient with much of 
the supportive care delivered at the POSCU. This was demonstrated by the distribution 
of FN episodes initiated in POCs or POSCUs (Table 3.1). The majority of solid tumour 
patient episodes were also managed in POSCUs which also reflects the nature of their 
treatment and the fact that they have normally been discharged from their POC after 
chemotherapy before their ANC falls and they become febrile and neutropenic.
It has been proposed that between one-third and one-half of children with FN at are low 
risk of serious infection (Orudjev and Lange, 2002) but the proportion suitable for 
treatment on low risk strategies is dependent on the specific selection criteria. Our
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protocol enabled early discharge in 19% of total episodes after 2 IP nights and if the 
POSCU episodes are considered separately, 29% (160/549) were managed on the low 
risk protocol. A recent study by Quezada et al, reported that 26% of their patient 
population were eligible for management on a step-down strategy similar to ours but 
that only 56% of these actually received any outpatient care (Quezada et al., 2007). It is 
important to note that their patients were all managed in a large American oncology 
centre and did not include many low risk diagnoses e.g.4 good risk’ ALL or low stage 
Wilm’s tumour. Patients were required to have a declining fever to qualify for 
outpatient management, which is in contrast to our protocol and meant that their 
patients spent on average 3.5 days as an IP and 3.5 days as an outpatient. Interpretation 
of results from other similar studies must include the eligibility/exclusion criteria used 
and patients studied. Some very encouraging results have been reported in studies which 
have been highly selective of their patient population (Malik, 1997; Petrilli et al., 2000) 
and may not be comparable to our practice.
A step-down strategy was chosen because it enabled a period of IP admission and an 
informed discharge decision utilising both blood culture results and ANC in order to 
optimise both patient safety and experience. The 48h observation period ensured the 
identification of patients with significant gram negative sepsis who most commonly 
deteriorate within the first 24h of admission; there were no late gram negative infections 
in any episodes identified as low risk in our study. Positive blood cultures alone were 
responsible for the change to standard management in 36% of episodes but it could be 
debated whether all patients with gram positive infections should have been excluded 
from management on a low risk management strategy as they may have been 
adequately treated with once daily IV or even oral antibiotics at home. Knowledge of 
blood culture results at the time of discharge should prevent the need for readmission of 
patients who require prolonged IV antibiotics to treat a microbiologically defined
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infection although in some studies positive blood cultures are not considered an 
absolute indication for IP management (Mullen et al., 1999a). Reassuringly none of the 
re-admitted low risk patients had any new positive cultures. The 48h ANC was used to 
assess evidence of impending bone marrow recovery which is important for predicting 
uneventful recovery of FN (Jones et al., 1994; Lucas et al., 1996). ANC alone was 
responsible for the change to standard management in 25% of episodes. Interestingly, of 
those patients discharged on the low risk protocol with an ANC >0.1 at 48h, 7% had an 
ANC <0.1 at 96h but continued to make an uneventful recovery which may indicate 
that clinical wellness may be more relevant in predicting outcome in this low risk group. 
Most importantly none of the episodes managed on the low risk protocol required PICU 
admission and there were no deaths.
Timing of risk assessment or step-down is very important and has repercussions for 
both the patient and healthcare system. The accuracy of risk assignment needs to be 
high if low risk patients are to be discharged after a short IP stay or a single dose of 
antibiotics, in order to prevent the need for re-admission. For some parents, the 
uncertainty of outpatient management may be more problematic or inconvenient than 
prolonged IP admission especially if co-ordinating the care of other children. 
Readmission rates were low (6%) in our patients discharged appropriately on the low 
risk protocol. Some patients were readmitted because of parental concern which may in 
part relate to the change in protocol because using the old protocol patients were only 
discharged when afebrile. Parental confidence is paramount to the success of these 
strategies and it remains unclear whether more radical protocols encompassing oral 
antibiotics from the onset of FN would be widely accepted (Sung et al., 2004).
Any patient with FN in the outpatient setting requires rigorous follow up, whether that 
is ambulatory or at home. Our patients were contacted at home, 24h after discharge and 
reviewed at 48h to ensure that the episode was resolving. Most of the patients requiring
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readmission presented within 48h of discharge therefore the 96h review served more to 
reassure parents than to detect actual deterioration. The ability to follow up these 
episodes was dependent on relevant personnel e.g. paediatric community nurses; these 
services were not universally available and may have limited or prevented the use of the 
low risk protocol in some centres. Reduction in treatment costs for care delivered in the 
outpatient (Mustafa et al., 1996b; Ahmed et al., 2007) or home setting (Raisch et al., 
2003) has been demonstrated and early step-down to oral antibiotics after a single dose 
of IV has been shown to be less costly than outpatient IV therapy in a randomised study 
(Mullen et al., 1999b). A full cost-benefit analysis has not been performed for the 
current study but such information will inform future practice.
Overall, adherence to the new management strategy was good with the majority of 
hospitals utilising the low risk protocol appropriately. ‘Health care system competence’ 
has been identified as a significant risk factor in the treatment of low risk FN (Mullen, 
2001). This competence relates to the ability to identify patients correctly in the first 
instance and the ability to adequately follow up patients as discussed. We conducted a 
review of all the audit proformas in order to assess the accuracy of both risk assignment 
and subsequent management. We identified 18 patients who were managed 
inappropriately on the low risk protocol predominantly due to incorrect risk assignment, 
3 of whom required readmission. This could have been due to poor understanding of the 
protocol or over confidence in low risk management. It is also possible that there may 
have been some parental pressure for early discharge in some cases. Fortunately none of 
these episodes had an adverse outcome and all resolved promptly after re-admission. 
When introducing any new protocol one cannot underestimate the importance of 
educating the personnel who will be interpreting and using it.
Further refinement of the RS process should improve our ability to identify episodes 
suitable for management on low risk protocols which may ultimately prevent admission
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altogether. Acute phase proteins such as procalcitonin and proinflammatory cytokines 
such as IL-8 and IL-6 have been investigated for their ability to identify individuals 
with FN who have significant infection, or as markers of clinical deterioration, with 
differing results (de Bont et al., 1999; Lehmbecher et al., 2004; Lilienfeld-Toal et al., 
2004; Persson et al., 2005; Hodge et al., 2006; Secmeer et al., 2007). In 2005, Oude 
Nijhuis et al reported their ability to identify a subpopulation of FN patients using both 
clinical parameters and plasma IL-8 levels in whom they were able to withhold 
antibiotic treatment safely (Oude Nijhuis et al., 2005). As discussed in Chapter 1 we 
may also be able to utilise genetic information about a patient’s infection susceptibility 
profile in the RS process (Oude Nijhuis et al., 2002) and MBL may be a potential 
candidate gene.
In summary we have designed and implemented a new management strategy for FN in 
over 40 hospitals utilising RS based on clinical criteria. This has enabled early 
discharge from hospital and ongoing management with oral antibiotics in 19% of all FN 
episodes and 29% of those initiated in POSCUs. The protocol was safe and resulted in a 
low re-admission rate in those treated correctly. Approximately 66% of the patients 
captured in the PINE project were recruited into the MBL/lectin pathway studies with 
consent to access PINE data. These patients are described in the subsequent chapters 
and the PINE data was specifically used in the analysis of the studies reported in 
Chapters 5 and 7.
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Chapter 4
MBL genotyping in children with cancer
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4.0 Introduction
Our knowledge of an association between MBL deficiency and disease has improved 
significantly since 1989 when Super et al observed that low levels of mannan-binding 
protein (now known as MBL) were associated with 4a common defect of opsonisation’ 
(Super et al., 1989). The identification of three mutations in exon 1 of the MBL2 gene 
over the following 5 years, and the later discovery of polymorphisms within the 
promoter region are now known to account for the majority of inter-individual variation 
in MBL protein levels (Sumiya et al., 1991; Lipscombe et al., 1992; Madsen et al., 
1994; Madsen et al., 1995). When analysing for disease association, genotype offers 
more information than serum protein level alone and both measures should ideally be 
utilised (Garred et al., 2003b). Genotype is also a constant measure, unlike serum levels 
which can change depending on the current health of the individual.
An ideal method for genotyping large cohorts of patients requires it to be accurate, fast 
and cost effective. A number of methods for genotyping the MBL2 gene have been 
described, some of which are listed in Table 4.1. All the methods listed rely on PCR but 
vary in the number of reactions and subsequent steps required which influence their 
applicability. In the present study two different methods, heteroduplexing, a technique 
developed and established in our laboratory and the INNO-LiPA MBL2 assay, a 
commercial kit, were utilised to genotype the patient cohort. The INNO-LiPA method 
had previously been validated against other genotyping methods including PCR with 
sequence specific primers (PCR-SSP) (Steffensen et al., 2000) and real time PCR 
(Steffensen et al., 2003). However this study is the first to validate the INNO-LiPA 
assay against heteroduplexing.
The focus of this study is the influence of MBL on infection related morbidity in 
children with cancer. Studies to date have reported conflicting findings (Section 1.8)
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Genotyping method Reference
Amplification refractory mutations system (ARMS) (Davies et al., 1995)
PCR and restriction fragment length polymorphism 
(RFLP)
(Lipscombe et al., 1992; 
Madsen et al., 1994)
PCR and restriction fragment length polymorphism 
(RFLP) and site directed mutagenesis
(Madsen et al., 1998)
Heteroduplexing (Jack et al., 1997)
Denaturing gradient gel electrophoresis (DDGE) (Gabolde et al., 1999)
PCR using sequence specific primers (SSP) (Steffensen et al., 2000)
PCR-SSP and sequence specific oligonucleotide probes 
(SSOP)
(Boldt and Petzl-Erler, 
2002)
Oligonucleotide ligation assay (Roos et al., 2003)
Real-time PCR with fluorescent hybridization probes (Steffensen et al., 2003)
TaqMan® assay using minor groove binder probes (Van Hoeyveld et al., 
2004)
Multiplex PCR (Skalnikova et al., 2004)
PCR + Pyrosequencing (Roos et al., 2006)
INNO-LiPA reverse hybridization (Nuytinck and Shapiro, 
2004)
DNA Microarray-based on-chip PCR (Mitterer et al., 2005)
Table 4.1 MBL2 genotyping methods
but sample sizes have been relatively small (~ 100 patients/study) which may explain 
the differing results. The present study was designed to investigate MBL and the lectin 
pathway in a larger patient population. This chapter describes two different MBL2 
genotyping methods and compares the practicalities of their use. The genotyping for the 
study population was investigated and the potential interaction between MBL genotype 
and diagnosis highlighted.
4.1 Methods
4.1.1 Patient population
A cross sectional observational study was performed during a one year period (April 
2004- March 2005). It was designed to capture all children on active treatment for 
cancer treated at the 4 London POCs.
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Inclusion criteria
1. Age 0-16 years inclusive.
2. Currently receiving chemotherapy/on active treatment for any solid tumour or a 
haematological malignancy in remission.
Exclusion criteria
1. Patients who had received an allogenic bone marrow transplant (BMT) or autologous 
peripheral blood stem cell (PBSC) transplant.
2. Leukaemia at first diagnosis (< 28 days) or relapse, not in remission.
4.1.1.1 Sample and data collection
Blood samples were collected from children when they were clinically well and 
attending their POC for a routine outpatient clinic or at the time of admission for routine 
treatment. Informed, written consent from the parent/guardian (or the child where 
applicable) with verbal assent from the child was obtained for blood sampling and 
access to data from the PINE audit project.
lml of whole blood was collected and stored at -20°C until required for DNA 
extraction. Blood was collected through a central venous line, where available, at a time 
when blood was being collected for other reasons. Clinical information (age, sex, 
diagnosis and ethnic status) was obtained on all patients.
The MBL and Lectin pathway studies were approved by the Research Ethics 
committees of the 4 London POCs, Section 2.1.
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4.1.2 MBL2 Genotyping 
4.1.2.1 Heteroduplexing
The heteroduplexing method is described in detail in Section 2.3.1. Briefly, a universal 
heteroduplex generator (UHG), a synthetic DNA molecule based on the MBL genomic 
sequence, containing appropriate insertions and deletions is used as a template (Wood 
and Bidwell, 1996). Patient genomic DNA PCR product was combined with UHG PCR 
product, and the two were allowed to anneal to produce characteristic heteroduplexes 
for different alleles. These heteroduplexes display different electrophoretic mobility on 
PAGE, thus enabling identification of a subject’s genotype (Jack et al., 1997).
4.1.2.2 INNO- LiPA assay
The methodology is described in detail in Section 2.3.2. Briefly, the method relies on 
genomic DNA: probe DNA hybridization technology that enables detection of exon 1 
and all 3 promoter polymorphisms using a commercial kit (INNO-LiPA MBL2 
Amplification and INNOLiPA MBL2, INNOGENETICS N.V., Belgium). Amplified 
biotinylated genomic DNA was chemically denatured and the separated DNA strands 
were hybridized with specific oligonucleotide probes immobilized on membrane-based 
strips. Addition of streptavidin (conjugated with alkaline phosphatase) allowed avid 
binding to the biotin moiety of the hybrid DNA. Finally, incubation with an alkaline 
phosphatase substrate solution containing chromogen resulted in a purple/brown 
precipitate. The resulting probe pattern could then be translated into its appropriate 
genotype.
4.1.2.3 Terminology
MBL2 genotyping data can be expressed in a number ways encompassing the different 
exon 1 and promoter polymorphisms. To ease interpretation exon 1 variant alleles (B,C 
& D) are often referred to collectively as the ‘O’ allele and heterozygotes for variant
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alleles (A/O) are often grouped with homozygotes or compound heterozygotes (ie. two 
different variant alleles) (O/O). The INNO-LiPA assay provides a full haplotype 
combination encompassing the exon 1 alleles, A,B,C and D and the three promoter 
polymorphisms X/Y, H/L and P/Q for more detailed characterisation (Nuytinck and 
Shapiro, 2004).
4.2 Results
4.2.1 Heteroduplexing
Initial experiments revealed problems with the existing heterpduplexing methodology 
which hindered interpretation of the results. A number of experiments were undertaken 
to optimise the technique prior to patient sample analyses. Genomic DNA from 
laboratory staff volunteers was used for these studies. The quality and amount of 
Universal Heteroduplex Generator (UHG) required was optimised as variability in 
heteroduplex clarity with different UHGs (1 & 2) was observed as illustrated in Figure 
4.1. Degradation of UHG was eliminated and the optimal concentration required 
established. Variation in band pattern (i.e. additional non-specific bands) was observed 
with different UHG preparations and this effect was also concentration dependant. 
Optimum band resolution was achieved using 20pg UHG/PCR reaction (Figure 4.2, 
lanes la, 2a and 3a).
MBL Genotyping was undertaken using the optimum concentration of UHG 1 
(20pg/reaction). Examples of representative heteroduplexing are shown in Figure 4.3 
and 4.4.
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U HG 2UH G  1
Figure 4.1 Exon 1 heteroduplex band patterns using different UHG preparations 
(1&2) on 9 DNA samples.
Arrows highlight an example of the variation in band pattern seen with the same DNA 
sample combined with different UHG preparations. Multiple non-specific bands prevent 
accurate interpretation of the genotype.
la 1b 1 c 2a 2b 2c 3a 3b 3c
Figure 4.2 Promoter samples heteroduplexed with different UHG preparations of 
varying concentration, a) UHG 1- 20pg/reaction (optimal concentration 
highlighted with arrows) b) UHG 1- 200pg/reaction c) UHG 2-100 pg/reaction
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Figure 4.3 XY promoter polymorphism heteroduplexing results for patients 37-50. 
Specific genotype results are detailed with corresponding band patterns.
BC AA AB AB AA AB AA AA
45 46 47 48 49 50
AD AB AC AA AA AA
Figure 4.4 Exon 1 polymorphism heteroduplexing results for patients 37-50. 
Specific genotype results are detailed with corresponding band patterns.
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4.2.2 INNO-LiPA MBL2 assay
All patient samples were amplified at the first attempt but two samples failed to 
adequately hybridize generating an uninterpretable result on the nitrocellulose strip. 
Increasing DNA concentration in the initial PCR reaction did not improve the results 
and at present the reason for this failure is unknown. The results for samples 37-50 are 
illustrated in Figure 4.5 (heteroduplexing shown previously, Figures 4.3 and 4.4).
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Figure 4.5 INNO-LiPA strip probe patterns and corresponding haplotype 
combination for patients 37-50
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4.2.3 Comparison of Genotyping methods
Both methods revealed the same genotype result for each sample analysed making the 
new INNO-LiPA method as reliable as the heteroduplexing method. It should be noted 
that heteroduplexing of the H/L and P/Q promoter polymorphisms was not performed 
and therefore only data obtained for the exonl and XY polymorphisms can be 
compared. This is the first time the INNO-LiPA method has been validated against 
heteroduplexing. Table 4.2 details a comparison of the two methods highlighting the 
differences in timing and cost.
Heteroduplexing INNO-LiPA
Polymorphism analysis Exon 1 
XY promoter
Exon 1
XY, HL, PQ promoters
Procedure 4 PCRs 1 multiplex PCR
Duration 2h Heteroduplex formation 
5-15h Gel analysis
3h Amplification step
Results 283/283 281/283
Cost/sample <£5 ~ £30
Table 4.2 Comparison of heteroduplexing and INNO-LiPA genotyping methods
4.2.4 MBL2 gene and haplotype frequencies
MBL2 genotyping data was available on 283 children with cancer recruited in the 
London POCs between April 2004 and March 2005.
4.2.4.1MBL2 exonl allele and genotype frequencies
Exon 1 allele frequencies in the study population were as follows; wild-type (A) 0.76, 
codon 54 (B) 0.11, codon 52 (D) 0.08 and codon 57 (C) 0.04. Figure 4.6 illustrates the 
exon 1 allele frequencies for the total group and specific ethnic groups within the study 
population (data for the mixed race group and “other” group is not shown).
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Figure 4.6 Exon 1 allele frequencies for the total group and specific ethnic groups.
The A or WT allele was predominant and present in similar frequencies throughout the 
different ethnic groups. The D allele was observed in white, asian and mixed race 
patients. The C allele was the only variant allele observed in black patients and the B 
allele was the only variant allele observed in Chinese patients. The patient cohort was 
ethnically diverse (26.5% non-white) and representative o f South East England.
Exon 1 genotype frequencies were; AA, 0.576; AB, 0.184; AD, 0.12; AC, 0.071; DB, 
0.025; BC, 0.007; CD, 0.004; BB, 0.007; DD, 0.007, (Figure 4.7). The exonl genotype 
frequencies obeyed the Hardy-Weinberg expectations i.e. there was no significant 
difference between observed and expected populations, chi square= 1.679 (non 
significant) (Table 4.3).
Total White
(73.5%) Black(6.4%)
Exon
Asian
(12.4%) Chinese(1.4%)
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0.6
AA AB AD AC BD BC CD BB DD
Figure 4.7 Exon 1 genotype frequencies
Genotype Observed Expected
Number Frequency Number Frequency
AA 163 0.576 165 0.582
AB 52 0.184 50 0.175
AD 34 0.120 35 0.124
AC 20 0.071 18 0.063
BD 7 0.025 6 0.020
BC 2 0.007 3 0.009
BB 2 0.007 3 0.012
CD 1 0.004 2 0.006
CC 0 0.000 0 0.001
DD 2 0.007 2 0.007
Total 283 283
Table 4.3 Observed and expected MBL exonl genotypes in the study population
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4.2.4.2 MBL2 promoter allele and genotype frequencies.
The X/Y promoter has the most profound effect on MBL levels and allele frequencies 
were Y, 0.756 and X, 0.244 in the study population. The YY genotype associated with 
high levels was most common in our study population with a frequency of 0.562. Least 
common was the low producing XX genotype, present at a frequency of 0.049 followed 
by the intermediate XY genotype present at a frequency of 0.389 (Figure 4.8). The H/L 
and P/Q allele frequencies were H 0.366/L 0.633 and P 0.777/Q 0.223, respectively. 
The H/L genotype frequencies were HH, 0.121; HL, 0.491 and LL, 0.388. The P/Q 
genotype frequencies were similar to the X/Y genotype frequencies. The QQ genotype 
was least frequent at 0.057, with PQ, 0.331 and the PP, 0.612. The population obeyed 
Hardy-Weinberg expectations with respect to the three promoter genotypes (data not 
shown).
0.7
>»
g  0.6 
0)
3  0.5
CT
2  0.4
I 0.3
f  0.2
S  0.1
Figure 4.8
4.2.4.3 MBL2 haplotype frequencies
Due to linkage disequilibrium between the polymorphisms in the promoter and exon 1 
regions, only seven common haplotypes are described leading to 28 possible haplotype
il .Ii i
XX XY YY HH HL LL QQ PQ PP
Promoter genotype frequencies
125
MBL genotyping 4
combinations. Using the INNO-LiPA method we were able investigate the haplotype 
frequencies in the population (table 4.4).
HYPA LYPA LYQA LXPA HYPD LYPB LYQC
Frequency of 
homozygous- 
variant 
alleles
Total
population 0.28 0.06 0.18 0.24 0.08 0.11 0.04 0.05
White
(73.5%) 0.29 0.05 0.17 0.25 0.10 0.12 0.03 0.06
Black
(6.4%) 0.17 0.17 0.31 0.14 0.00 0.00 0.22 0.00
Asian
(12.4%) 0.30 0.04 0.19 0.21 0.07 0.14 0.04 0.03
Chinese
(1.4%) 0.38 0.25 0.13 0.00 0.00 0.25 0.00 0.20
Mixed
(4.6%) 0.31 0.08 0.15 0.35 0.04 0.04 0.04 0.00
Other
(4.6%) 0.30 0.00 0.20 0.30 0.00 0.20 0.00 0.00
Table 4.4 MBL haplotype and homozygote frequencies for the total population and 
stratified by ethnicity. Dominating haplotypes are indicated in bold.
Differences in haplotype frequencies are noted within the different ethnic groups 
although some groups were small (e.g. Chinese) and such differences did not reach 
statistical significance. The population is predominantly white with the HYPA and 
LXPA haplotypes most common. As discussed previously the only variant exon 1 allele 
observed in the black patients was the C allele hence the LYQC haplotype was observed 
in this group with the LYQA haplotype being most common. The asian population is 
predominantly Indian or Bangladeshi and bears similarities to the white population in 
terms of haplotype frequencies. The Chinese population is very small but of note the 
only variant haplotype present is LYPB. 26 of the possible haplotype combinations 
were present in the study population and the relative frequencies are shown in Figure 
4.9. Of the exon 1 WT genotypes the LXPA/HYPA haplotype combination was most 
frequently observed in the cohort. The most common exonl heterozygote combination
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was the LYPB/HYPA and the most common homozygote or compound heterozygote 
combination was LYPB/HYPD.
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Figure 4.9 Haplotype combination frequencies.
4.2.5 Genotype and Disease
To explore any potential association between MBL genotype and oncological diagnosis, 
genotype frequencies within the different diagnostic groups were analysed (Table 4.5). 
Due to small numbers within some diagnostic categories, haematological diagnoses 
other than ALL were combined as were all solid tumour patients. Exon 1 variant alleles 
collectively are represented by the O allele (Figure 4.10). ALL patients and the ‘other 
haematological’ diagnoses group did not differ significantly from the total patient 
population. Of note within the AML group there was a higher frequency of wildtype 
individuals (11/15, 0.73) compared to other groups. Marked variation within the solid 
tumour patients was observed and overall there was a higher frequency of heterozygotes
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compared to the other groups. There was no evidence of a higher proportion of 
homozygotes in any of the diagnostic groups.
Diagnosis AA AO OO Total
ALL 105 65 10 180
AML 11 4 0 15
Infant ALL 4 2 0 6
T cell Non Hodgkins Lymphoma 5 4 2 11
Hodgkins Lymphoma 2 0 0 2
B cell Non Hodgkins Lymphoma 1 3 0 4
Anaplastic Large Cell Lymphoma 0 1 0 1
Neuroblastoma 6 3 0 9
Brain tumours 9 7 0 16
Wilms tumour 6 7 0 13
Rhabdomyosarcoma/Rhabdoid 3 2 0 5
Hepatoblastoma 1 0 0 1
Sarcomas 3 2 2 7
PNET 1 1 0 2
Retinoblastoma 0 1 0 1
Other solid tumours 6 4 0 10
283
Table 4.5 Exon 1 genotype frequencies and diagnosis
0.7
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o 0.4
£ 0.3
0.2
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u
Total ALL Other Haem Solid tumours
■ AA 0.576 0.583 0.589 0.546
□AO 0.375 0.361 0.359 0.422
■ OO 0.049 0.055 _____ 0.051 0.031______
Figure 4.10 Exon 1 genotype frequencies in different diagnostic groups
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More detailed investigation of the specific haplotype frequencies revealed differences 
between the different diagnostic groups but these did not reach significance (Table 4.6). 
The solid tumour group had the highest frequency of LYPB and LYQC haplotypes and 
the lowest frequency of homozygotes but was also the most ethnically diverse with a 
non-white population of 34%.
%
non­
white HYPA LYPA LYQA LXPA HYPD LYPB LYQC
Frequency of 
homozygous- 
variant 
alleles
Total
population
26.5
0.28 0.06 0.18 0.24 0.08 0.11 0.04 0.05
ALL 25 0.27 0.06 0.18 0.24 0.08 0.11 0.04 0.05
Other
Haem
21
0.38 0.03 0.18 0.18 0.10 0.09 0.04 0.05
Solid
tumours
34
0.25 0.06 0.16 0.28 0.06 0.13 0.05 0.03
Table 4.6 MBL haplotype and homozygote frequencies for the total population and 
stratified by diagnostic group.
4.3 Discussion
The work described in this chapter represents the largest oncology population on whom 
MBL2 genotyping has been performed to date. We used two different genotyping 
methods in order to compare their accuracy and the practicalities of their use when 
genotyping large patient cohorts. The heteroduplexing method was developed in-house 
and required further modification prior to routine use. A number of modifications were 
introduced and reproducibility of results was optimized. The INNO-LiPA assay was a 
new method established during the course of the present study. Overall there was 
excellent concordance between the results from the two assays but they each had 
advantages and disadvantages to consider. The INNO-LiPA technique was fast and 
provided a clear, unambiguous result for both the exonl and all three promoter
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polymorphisms. Of the 283 samples genotyped, only two samples failed to produce an 
interpretable pattern, the reasons for which remain unclear. The heteroduplexing method 
gave less information and required more bench time. The interpretation of results was 
potentially more prone to error due to the close proximity of the band patterns but the 
clear advantage of the method was the lower reagent cost which may therefore make it a 
more suitable technique for use in resource poor settings. It should be noted that the cost 
of personnel may also dictate preferred method of choice.
The 283 paediatric cancer patients represent an ethnically diverse population from the 
South East of England undergoing treatment for a wide range of diseases. In order to 
answer questions as to whether MBL2 variant alleles are over or under represented in 
our study population we would have needed to recruit a matched control group. 
Defining an appropriate control group is itself a difficult task and then matching them 
for both disease and ethnicity is even harder. This is an ongoing issue in paediatric 
studies and particularly when studying relatively uncommon diseases. Many studies 
utilize adult blood donor populations which are not an equivalent population. Due to the 
lack of detailed genotyping information in previously published studies, comparisons 
between similar patient populations have not been made.
The best control group available to us for comparison is from the Avon Longitudinal 
Study of Pregnancy and Childhood (ALSPAC). This cohort is part of a European-wide 
World Health Organisation prospective study designed to determine factors influencing 
health and development of children in Europe. Approximately 14,000 expectant British 
mothers and their subsequent children were recruited. MBL2 exon 1 genotype 
frequencies have been published on a subgroup of these patients (n=302) (Mead et al., 
1997). Differences observed between our population and this ‘healthy UK paediatric 
population’ are predominantly explained by the ethnic diversity within the two samples.
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The proportion of non-white subjects was 26.5% in our study group representative of 
populations in London and the South East of England compared to < 5% in ALSPAC 
where patients were recruited from Bristol and the South West of England. The most 
marked difference is seen in the C allele frequency commonly associated with black 
Africans which is 0.008 in ALSPAC and 0.04 in the study group. Overall the AA, AO 
and OO frequencies from Mead’s data were 0.596, 0.357 and 0.046 respectively which 
are very similar to our study group, 0.576, 0.375 and 0.049.
The full haplotype frequencies we observed were in keeping with a predominantly 
Caucasian population (Crosdale et al., 2000; Dahl et al., 2004) with high frequencies of 
both HYPA and LXPA haplotypes. Despite studying small groups clear differences 
were seen in variant allele distribution between specific populations. In our black 
patients the C allele (LYQC haplotype) was dominant and in our Chinese population the 
B allele was the only variant allele observed. These findings reflect similar homogenous 
ethnic groups e.g. African and Korean populations where the LYQC and LYPB 
haplotypes have been reported to be disproportionately high, respectively (Madsen et 
al., 1998, Lee et al., 2005a). Our asian population was predominantly Indian or 
Bangladeshi and gene frequencies were similar to those observed in white patients. To 
date there is very little data available from Indian populations with whom we can make 
comparison. The INNO-LiPA assay enabled us to generate a full haplotype combination 
and 26 of the possible 28 combinations were present in our patients albeit some in small 
numbers. The use of such detailed genetic information in disease association studies is 
limited by patient numbers. The majority of studies use exon 1 genotype with or without 
the X/Y promoter to enable meaningful statistical analysis.
The potential influence of MBL genotype on disease predisposition was addressed using 
this data set (Tables 4.5 and 4.6, Figures 4.10). In the patient cohort presented the
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frequency of MBL homozygosity in the ALL patients was 5.5% compared to 4.9% in 
the total patient cohort and 4.6% in the ALSPAC cohort. The genotype frequencies 
observed in the other diagnostic groups must be interpreted with caution due to the 
small sample sizes. The solid tumour patients have been combined but this means that 
they form a group of very diverse diseases which cannot be interpreted as a 
homogenous group. In 2002, Schmiegelow et al reported an increased frequency of 
MBL deficiency among children with ALL (Schmiegelow et al., 2002). The frequency 
of MBL variant allele homozygosity was 8.8% in the patients (n=137) compared to 
2.2% in an adult blood donor population (n=250). Their explanation for this finding was 
based on the ‘Two hit’ model, where individuals have an underlying genetic mutation 
(present in utero) which when combined with a second hit, which may be an infection, 
they develop childhood leukaemia (Greaves, 1999). Schmiegelow proposed that 
children with MBL mutations suffering from more frequent and/or severe infections 
experienced more proliferative stress on their developing immune system, potentially 
leading to critical leukaemogenic DNA damage. This is in contrast to the original 
hypothesis by Greaves that proposed that exposure to common infections in early 
childhood may protect against ALL by promoting normal maturation of the immune 
system. Lack of early exposure to infection rendered the immune system unmodulated. 
Subsequent infection with common microbes that occurs in a biologically abnormal 
timeframe for which the immune system is inappropriately programmed, leaves such 
children at risk of leukaemogenesis (Greaves, 1997). To support this a large UK case- 
control study looking at day care and social activity during the first year of life as a 
measure of potential exposure to infection supports the hypothesis that early exposure to 
infection reduces the risk of subsequent ALL (Gilham et al., 2005). Our data is not in 
agreement with Schmieglow’s findings. The frequency of exon 1 variant allele
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homozygosity in all the diagnostic groups; ALL, other haematological malignancies and 
solid tumours, is similar or lower compared to the ALSPAC cohort.
With regard to solid tumours, a study of Polish adults has reported that the HYD 
haplotype is specifically associated with gastric cancer risk and the authors suggest that 
this may be related to the influence of MBL on Helicobacter pylori infection (Baccarelli 
et al., 2006). There has also been data published which suggests that MBL may 
influence breast cancer risk (Bemig et al., 2007). We did observe an overrepresentation 
of MBL variant alleles in the solid tumour group but this was small, the group was 
heterogenous and we would be wary to draw any firm conclusions from uncontrolled 
data. Larger homogenous groups are required to investigate the role of specific variant 
haplotypes in predisposition to paediatric solid tumours.
In summary we have performed detailed genotyping of the MBL2 gene on 283 
paediatric oncology patients utilising two techniques giving concordant results. 
Differences in genotype frequencies were observed between the patients and a healthy 
paediatric cohort which reflect the ethnic variation within the two groups. The 
distribution of MBL genotypes in ALL patients was in keeping with the general 
population but assessment of other diagnostic groups was limited by small patient 
numbers. This study group is investigated in more detail in following chapters.
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Chapter 5
Influence of MBL on infectious complications in children with
cancer
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5.0 Introduction
The role of MBL in defence against infection following chemotherapy remains unclear 
(Klein and Kilpatrick, 2004). Studies to date have reported conflicting findings but their 
differing designs and size have made comparisons difficult, fuelling the ongoing debate. 
Oncology patient populations are heterogenous. Their underlying disease and 
subsequent treatment renders them immunosuppressd but to differing degrees (Graubner 
et al., 2007). Such differences are compounded further by variability in treatment 
intensity and supportive care measures employed such as use of colony stimulating 
factors and prophylactic antibiotics (predominantly used in adult practice).
It remains important to establish whether MBL has a role in some or all of these 
complex patients. Such information may be particularly useful in FN risk assessment 
and for the selection of patients who may benefit from MBL replacement therapy in the 
future.
A drawback of studies investigating the role of MBL in oncology patients to date has 
included their lack of applicability because the majority have been conducted in single, 
specialist oncology centres. Our study was multicentred and designed to capture all FN 
episodes in both POCs and POSCUs, hoping to provide a true reflection of the burden 
of infection in these patients. The study was run in parallel with the PINE project 
described in Chapter 3 which provided the clinical data used in the analysis. The aims 
of this study were to explore the influence of MBL genotype on FN frequency and 
severity in a large paediatric cohort by recruiting all children on active treatment for 
cancer in the South East of England over a one year period.
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5.1 Methods
5.1.1 Patient population
The patients recruited into this study are described in Section 4.1.1. Clinical information 
(age, sex, diagnosis and ethnic status) was obtained on all patients and in addition to 
this, information on RS criteria (Figure 3.1) and outcome measures (Figures 3.5 and 
3.6) was collected on the subset of patients admitted with FN during the study period 
through the PINE project (Chapter 3).
The MBL and Lectin pathway studies were approved by the Research Ethics 
committees of the 4 POCs, section 2.1. Permission was sought from the Caldicott 
Guardians at each Paediatric Oncology Shared Care Unit (POSCU) in order to access 
data collected for audit purposes for use in research.
5.1.2 Definitions
FN was defined as neutrophils <1.0 x 109/L and fever >38°C for more than 4h or on 2 
occasions at least 4h apart or fever >38.5°C on one occasion or clinical suspicion of 
sepsis in the absence of fever e.g. unexplained abdominal pain or generally unwell. 
Episodes where there was clinical evidence of infection (including radiological 
evidence) as assessed by the attending clinician, and/or microbiological evidence of 
infection are termed clinical/microbiological infections. Episodes where there was no 
clinical or microbiological evidence of infection are termed fever of unknown origin 
(FUO). Episode duration refers to the number of inpatient nights.
5.1.3 Outcome measures
The primary endpoint was frequency of documented clinical/microbiological infections 
in relation to MBL genotype. The secondary endpoints were; a) duration of FN episode, 
b) Paediatric Intensive Care Unit (PICU) admission and c) death, in association with 
MBL genotype.
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5.1.4 Data collection and analysis
Data was collected on FN episodes as part of the PINE project. In addition, a review of 
patient records was conducted in order to assess the accuracy of the PINE data and also 
collect information on any FN episodes not captured through the PINE project. 
Information collected on these additional episodes of FN was not always complete and 
did not include details about risk stratified management. Data were analysed on the 
number of episodes for which specific information was available and therefore this 
number varied for different parameters.
5.1.4.1 MBL genotype
All analyses have compared the influence of MBL genotype on different outcome 
variables. Data have been analysed using exon 1 genotype alone and heterozygotes and 
homozygotes have been grouped together owing to the small number of homozygotes, 
giving an abbreviated genotype, AO/OO.
Patients and episodes have also been grouped in different analyses as follows:
5.1.4.2 By Episode- Subjects experienced different numbers of FN episodes during the 
study period which may not have all been independent of each other. In order to 
examine the data on a per patient basis both the first and longest FN episodes were 
analysed. The same episode was included in each analysis (first and longest) for those 
patients who experienced only one episode of FN.
5.1.4.3 By Diagnosis- In order to explore the effect of MBL on FN in different 
diagnostic groups, patients were separated into the ALL group and Non ALL group. 
The ALL group includes patients with ALL and T-NHL because of similarities in their 
treatment protocols. The Non-ALL group includes patients with other haematological 
malignancies and solid tumours (Table 4.5).
5.1.4.4 By Risk- Clinicians risk stratified patients according to clinical criteria (Figure 
3.1), both on admission and at 48h which dictated their subsequent management as
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either low or standard risk as described in Chapter 3. The ‘Exclusions’ group refers to 
patient episodes automatically excluded from low risk management by virtue of an 
underlying diagnosis/treatment regime or patient age <lyr, that rendered the patient at 
higher risk of adverse outcome. In the analysis of the influence of MBL genotype on 
episode duration the ‘Exclusions’ episodes are compared to all other episodes termed 
‘No exclusions’.
5.1.5 Statistical analysis
In order to detect a 20% difference in infection rate between patients with MBL WT 
(AA), and those with one or more variant alleles (AO and OO) with 90% power and 5% 
significance we required a sample size of 300. This was based on previous research, and 
assumes a prevalence of 58% of patients with an AA genotype, and an estimated sepsis 
rate of approximately 40% (Neth et al, 2001).
Frequencies between groups were compared by the Mann Whitney U and Chi square 
tests, where appropriate. Linear by linear chi square tests were used to test for a trend in 
frequency of outcome across ordered exposure variables. If the number was smaller 
than five in any cell a Fisher’s exact test was performed.
5.2 Results
5.2.1 Patient characteristics
Of the 283 patients recruited into the study, 269 were eligible for analysis. Fourteen 
patients were excluded from the analysis because clinical data were not available. A 
total of 513 FN episodes were analysed from 211 subjects (zero episodes were 
identified in 58 subjects), of which 421 (72%) were PINE episodes and 92 (28%) were 
traced from clinical notes. Table 5.1 shows details of the patient cohort. 57% (153) of 
subjects were wildtype (AA), 39% (104) were heterozygous for variant alleles (AO) and 
4% (12) were homozygous for variant alleles. The hetero and homozygotes were
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analysed together. The cohort consisted of 148 boys and 121 girls whose median age at 
recruitment was 5.34 years. Both age and sex distributions were independent of 
genotype as shown in Table 5.1.
Total group 
n=269
AA 
n=153 (57%)
AO/OO 
n= 116 (43%)
p value
between 
AA & AO/OO
Age
Median (years) 5.3 5.2 5.7 0.254
Range 0.6-16.6 0.6-16.6 1-16.6
Sex
Male 148 (55%) 84 (54.9 %) 64 (55.2%) 0.965
Female 121 (45% 69 (45.1 %) 52 (44.8%)
Diagnosis
ALL (+ T NHL) 178 (66%) 101 (66%) 77 (66%)
0.552Other Haem 24 (9%) 17(11%) 7 (6%)
Solid tumours 67 (25%) 35 (23%) 32 (28%)
Months on 
treatment (median) 8 8.2 8.3 0.919
Ethnicity
White 194 (72.1%) 109 (71.2%) 85 (73.3%)
0.570
Black 18 (6.7%) 10 (6.5%) 8 (6.9%)
Asian 35 (13%) 18(11.8%) 17(14.7%)
Chinese 5 (1.9%) 3 (2%) 2(1.7%)
Mixed 12 (4.5%) 10 (6.5%) 2(1.7%)
Other 5 (1.9%) 3 (2%) 2 (1.7%)
Table 5.1 Patient characteristics of the total group and according to MBL genotype
170 (63%) subjects had ALL and have been grouped together with 8 T cell-NHL 
patients for the purposes of the analysis. This ‘ALL’ group accounted for 66% of 
patients. The remaining patients formed the ‘Non ALL’ group; 22 (9%) had other 
haematological malignancies and 69 (25%) had solid tumours. Median time on 
treatment at recruitment into the study was 8 months (IQR 15 months). No association 
between diagnosis or ethnicity and abbreviated MBL genotype was evident (Table 5.1).
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5.2.2 MBL genotype and frequency of FN
In order to investigate the effect of MBL genotype on susceptibility to infection, the 
number of episodes per patient over the study period was analysed. FN signifies 
infection until proven otherwise and approximately 50% of episodes would be expected 
to have no evidence of either clinical or microbiological infection, i.e. fever of unknown 
origin (FUO). For this reason the number of FN episodes has been analysed as a total 
(Table 5.2) and also separated by type i.e. clinical/microbiological infection or FUO 
(Table 5.3 and 5.4) respectively. Of the 269 subjects, 58 (21.6%) had no FN episodes 
during the study period. Of these 37 (24.2%) were AA and 21 (18.1%) AO/OO.
Total group 
n(% )
AA 
n (%)
AO/OO
u(% )
p value
between 
AA & AO/OO
Number of FN 
episodes (n=269)
0-1 131 (48.7) 82 (53.6) 49 (42.2)
2-4 126 (46.8) 66 (43.1) 60 (51.7) 0.048
> 5 12 (4.5) 5 (3.3) 7(6.1)
Median (range) 2 (0-8) 1 (0-6) 2 (0-8) 0.074
Table 5.2 Total FN episode frequency stratified by MBL genotype
Overall, patients in possession of MBL variant alleles were found to experience more 
FN episodes than wildtypes, with a median number of 2 compared to 1 (p=0.074). As 
the number of FN episodes per patient increased the distribution of MBL genotypes 
shifted. An increased proportion of wildtype individuals had zero or one episode 
compared to individuals in possession of variant alleles who appeared more likely to 
experience multiple episodes, p=0.048, shown graphically in Figure 5.1.
Analysis of the number of episodes with documented clinical and/or microbiological 
evidence of infection, a subset of the total FN episodes, revealed a similar trend. A 
higher proportion of MBL hetero- and homozygotes experienced multiple infections,
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e.g. 14.6% (AO/OO) compared to 8% (AA) with three or more infections. This trend is 
illustrated in Figure 5.2.
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FN episodes
Figure 5.1 MBL genotype distribution and frequency of FN
Number of Clinical 
/ Microbiological 
infections (n=240)
Total group
n (%)
AA 
n (%)
AO/OO
n (%)
p value
between 
AA & AO/OO
0 103 (42.9) 64 (46.7) 39 (37.9)
1 75 (31.3) 44 (32.1) 31 (30.1) 0.045
2 36(15) 18(13.1) 18(17.5)
>  3 26(10 .8) 11(8) 15(14.6)
Median (range) 1 (0-5) 1 (0-4) 1 (0-5) 0.064
Table 5.3 Clinical/Microbiological infection frequency stratified by MBL genotype
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Figure 5.2 MBL genotype distribution and frequency of clinical and/or 
microbiological infection
In contrast, no significant relationship was found between the number of FUO episodes 
and MBL genotype (Table 5.4).
Total group
n (%)
AA 
n (%)
AO/OO
n (% )
p value
between 
AA & AO/OO
Number of FUO 
episodes (n=240)
0 125 (52.1) 76 (55.5) 49 (47.6)
1 67 (27.9) 36 (26.3) 31 (30.1) 0.349
2 33 (13.8) 16(11.7) 17(16.5)
> 3 15(6.3) 9 (6.6) 6(5.8)
Median (range) 0 (0-5) 0(0-5) 1 (0-4) 0.262
Table 5.4 FUO episode frequency stratified by MBL genotype
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Patients were also analysed according to diagnosis, i.e. the ALL group and the Non 
ALL group (Tables 5.5 and 5.6 respectively). In the ALL group, 36 (20.2%) patients 
had no FN episodes during the study period, of which 24 (23.8%) were AA and 12 
(15.6%) AO/OO. There was a trend towards an increased number of episodes in 
AO/OO compared to AA for both total FN episodes and clinical/microbiological 
episodes. The proportion of AO/OO patients with > 2 clinical/microbiological infections 
was 29.8% compared to 17.2% AA.
Total group 
n (%)
AA 
n (%)
AO/OO
n(% )
p value
between 
AA & AO/OO
ALL patients
Number o f FN 
episodes (n=178)
0-1 88 (49.4) 55 (54.5) 33 (42.9)
0.1132-4 84 (47.2) 43 (42.6) 41 (53.2)
> 5 6 (3.4) 3(3) 3 (3.9)
Number o f Clinical 
/  Microbiological 
infections (n=154)
0 66 (44.2) 42 (48.3) 26 (38.8)
0.1091 51 (33.1) 30 (34.5) 21 (31.3)
2 22 (14.3) 9(10.3) 13 (19.4)
> 3 13 (8.4) 6 (6.9) 7(10.4)
Table 5.5 Episode frequency stratified by MBL genotype in the ALL group
There was also a similar weaker trend in Non ALL patients, e.g. the proportion of 
AO/OO patients with > 2 clinical/microbiological infections was 36% compared to 28% 
for AA patients. These differences did not reach statistical significance for either 
diagnostic group. In the ALL and Non ALL groups no association was found between 
the number of FUO episodes and genotype (p=0.363 and p=0.520, data not shown).
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Total group 
n (%)
AA 
n (%)
AO/OO 
n (%)
p value
between 
AA & AO/OO
Non ALL patients
Number of FN 
episodes (n=269)
0-1 43 (47.3) 27 (51.9) 16(41)
0.2162-4 42 (46.2) 23 (44.2) 19(48.7)
> 5 6 (6.6) 2 (3.8) 4(10.3)
Number of Clinical 
/ Microbiological 
infections (n=240)
0 35 (40.7) 22 (44) 13 (36.1)
0.2871 24 (27.9) 14 (28) 10(27.8)
2 14(16.3) 9(18) 5 (13.8)
> 3 13(15.1) 5(10) 8 (22.2)
Table 5.6 Episode frequency stratified by MBL genotype in the Non-ALL group
Findings reported in the next chapter (Chapter 6) suggest that MBL from YAYD 
individuals exhibited functional activity which was similar to wildtype MBL. For this 
reason the total group were re-analysed with the YAYD individuals combined with AA 
individuals and compared to all other AO/OO subjects. Although similar trends were 
observed (Table 5.7) they did not reach significance when compared to the original
analyses shown in Tables 5.2 and 5.3.
Total group 
n(% )
AA + YAYD 
n (%)
AO/OO  
n (%)
p value
between 
AA & AO/OO
Number of FN 
episodes (n=269)
0-1 131 (48.7) 89 (51.4) 42 (43.8)
0.1022-4 126 (46.8) 79 (45.7) 47 (49)
> 5 12(4.5) 5 (2.9) 7 (7.3)
Median (range) 2 (0-8) 1 (0-6) 2 (0-8) 0.140
Number of Clinical 
/ Microbiological 
infections (n=240)
0 103 (42.9) 72 (46.5) 31 (36.5)
0.0991 75 (31.3) 49 (31.6) 26 (30.6)
2 36(15) 18(11.6) 18(21.2)
> 3 26 (10.8) 16(10.3) 10(11.8)
Median (range) 1 (0-5) 1 (0-4) 1 (0-5) 0.080
Table 5.7 Episode frequency stratified by MBL genotype, AA + YAYD compared 
to all other heterozygotes and homozygotes, AO/OO.
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5.2.3 MBL level and frequency of FN
The influence of MBL level on episode frequency was also explored in the subset of 
patients for whom serum samples were available. Three groups were analysed, those 
with levels >1000ng/ml, 500-1000ng/ml and <500ng/ml. The results were comparable 
to analysis by genotype group (Table 5.2, Figure 5.1), i.e. patients with lower levels of 
MBL (most likely to be AO/OO) were more likely to experience multiple episodes of 
FN during the study period, (Table 5.8 and Figure 5.3). A similar relationship was also 
observed for Clinical/Microbiological infections, except in the group experiencing > 3 
episodes, who appeared to have higher MBL levels (Table 5.8 and Figure 5.4). No 
relationship between the number of FUO episodes and MBL level was demonstrated 
(data not shown).
Total
group
N (%)
>1000ng/ml 
n (%)
500-1000 
ng/ml 
n (%)
<500 ng/ml 
n (%)
p value
Number of FN 
episodes (n=180)
0-1 79 (43.4) 52 (49.5) 10 (37.0) 17(35.4)
0.0362-4 89 (49.4) 48 (45.7) 16(59.3) 25 (52.1)
> 5 12 (6.7) 5 (4.8) 1 (3.7) 6 (12.5)
Clinical /  Micro
infections
(n=162)
0 67(41.4) 48 (50.0) 7(31.8) 12 (27.3)
0.0451 49 (30.2) 26 (27.1) 7(31.8) 16 (36.4)
2 23 (14.2) 9 (9.4) 4(18.2) 10 (22.7)
> 3 23 (14.2) 13 (13.5) 4(18.2) 6(13.6)
Table 5.8 Episode frequency stratified by MBL level
145
MBL and FN 5
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Total group 0-1 2-4 >5
FN episodes
Figure 5.3 MBL level distribution and frequency of FN episodes
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Figure 5.4 MBL level distribution and frequency of clinical/microbiological 
infections
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In agreement with the previous findings, median MBL levels decreased as number of 
FN episodes increased (Figure 5.5).
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Figure 5.5 MBL levels stratified by FN episodes group (median indicated by a line, 
boxes represent interquartile range and bars represent outliers)
Median MBL also decreased as the number o f Clinical/Microbiological episodes 
increased except in those experiencing > 3 infections (Figure 5.6).
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Figure 5.6 MBL levels stratified by Clinical/Microbiological infections group 
(median indicated by a line, boxes represent interquartile range and bars 
represent outliers)
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5.2.4 MBL genotype and FN management
In order to examine the data on a per patient basis both the first and longest FN episodes 
were analysed. The same episode was included in each analysis (first and longest) for 
those patients who experienced only one episode of FN (n=73). Using the new FN 
protocol patients were managed according to risk (low or standard). In order to enable 
interpretation of clinical outcome data and the influence of MBL genotype it was 
important to establish that risk management was independent of genotype, as this alone 
could influence outcome. Table 5.9 shows the distribution of MBL genotypes between 
low and standard risk episodes. Although a higher proportion of AO/OO episodes were 
managed as standard risk there was no statistically significant difference in the 
distribution of episodes managed as low and standard risk between the AA and AO/OO 
subjects in both the first and longest episodes. This was also the case for the number of 
‘Exclusions’ episodes i.e. those excluded from low risk management by virtue of their 
age (under lyr) or diagnosis/treatment regimen (e.g. AML, B-NHL) (Table 5.9). The 
proportion of patient episodes excluded was very similar in the genotype groups in both 
the first and longest episodes (p=l and 0.965, respectively). Actual numbers and 
proportions of ‘No exclusions’ episodes are not shown.
Total group 
n (%)
AA  
n (%)
AO/OO  
n (%)
p value
between 
AA & AO/OO
Risk management
First (n=182)
0.697Low 43 (23.6) 25 (25.3) 18(21.7)
Standard 139 (76.4) 74 (74.7) 65 (78.3)
Longest (n=182)
0.580Low 34(18.7) 21 (20.6) 13 (16.3)
Standard 148 (81.3) 81 (79.4) 67 (83.7)
Exclusions’
group
First (n=208) 55 (26.4) 30 (26.5) 25 (26.3) 1
Longest (n=209) 52 (24.9) 29 (25.4) 23 (24.2) 0.965
Table 5.9 FN episode risk adapted management and MBL genotype
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5.2.5 MBL genotype and clinical outcome measures
Differences were observed in clinical outcome measures between the first and longest 
episodes for the total cohort which reflect the need for longer inpatient stays when 
patients are more unwell or have a microbiologically defined infection, shown in Table 
5.10. During longest episodes: fluid bolus requirement (a surrogate measure of 
circulatory system compromise), frequency of positive blood cultures, change/addition 
of antibiotics, CVL removal and PICU admission were higher than in the first episodes 
analysed. MBL genotype did not appear to influence the majority of these outcome 
measures.
Positive blood cultures were present in 29.4% and 33.8% of the first and longest 
episodes respectively. Interestingly when analysing the episodes by genotype, wildtype 
individuals had more episodes with positive blood cultures than AO/OO individuals and 
this reached significance in the longest episodes, p=0.044. Gram positive organisms 
accounted for approximately 2/3rds of blood culture isolates (63-71%), which is in 
keeping with previous reports (Hann et al., 1997). However, a higher proportion of the 
common gram positive isolates {Staphyloccus epidermidis and Coagulase negative 
staphylococcus) were isolated in AA compared to AO/OO individuals. The remaining 
isolates consisted of predominantly gram negative isolates (27-31%) and a small 
proportion of fungal organisms (2-5.6%). There were a higher number of both gram 
positive and negative isolates in AA episodes, in line with the higher proportion of 
positive blood cultures but this was not statistically significant.
When patients remain febrile for 96h they are commenced on antifungal agents as part 
of routine management. No difference was observed between the need for antifimgals 
and MBL genotype in either first or longest episodes (p=0.822 and 0.719, respectively). 
Changes or additions to first line antibiotics are made in episodes with positive blood 
cultures, dependent on antibiotic sensitivities and resistances, or in those not responding
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Total group AA 
n (%)
AO/OO
n(% )
p value
between 
AA & AO/OO
Fluid bolus required 
at admission
First (n=182) 6 (3.3%) 4 (4.0%) 2 (2.4%) 0.844
Longest (n=181) 15 (8.3%) 11 (11.0%) 4 (5.0%) 0.230
Positive blood culture
First (n=194) 57 (29.4%) 36 (34.3%) 21 (23.6%) 0.141
Longest (n=195) 66 (33.8%) 43 (40.6%) 23 (25.8%) 0.044
Gram +ve isolate
First 42 (71.0%) 26 16 0.437
Longest 45 (63.4%) 29 16 0.238
Gram -v e  isolate
First 16 (27.0%) 11 5 0.377
Longest 22 (31.0%) 16 6 0.114
Fungal isolate
First 1 (2.0%) 1 0 -
Longest 4 (5.6%) 2 2 1.0
Antifungal commenced
First (n=188) 26(13.8%) 15 (14.9%) 11 (12.6%) 0.822
Longest (n=187) 45 (24.1%) 23 (22.5%) 22 (25.9%) 0.719
Change of 1st line 
antibiotics required
First (n=188) 85 (45.7%) 49 (48.0%) 37 (43.0%) 0.589
Longest (n=188) 112(59.6%) 62 (60.2%) 50 (58.8%) 0.967
CVC removed
First (n=202) 4 (2.0%) 3 (2.7%) 1 (1.1%) 0.744
Longest (n=202) 10 (5.0%) 5 (4.5%) 5 (5.5%) 1
Transfer from 
POSCU to POC for 
FN
First (n=210) 7 (3.3%) 5 (4.3%) 2 (2.1%) -
Longest (n=210) 13 (6.2%) 7 (6.0%) 6 (6.3%) -
PICU admission
First (n=210) 3 (1.4%) 2 (1.7%) 1 (1.1%) 1
Longest (n=211) 7 (3.3%) 5 (4.3%) 2 (2.1%) 0.615
Table 5.10 Clinical outcome measures and MBL genotype
to first line treatment (including addition of antifimgal agents). No differences were 
observed in the requirement for change of first line antibiotics between the genotype 
groups. The number of patients requiring CVC removal and/or transfer from POSCU to 
POC because of FN was relatively low in the episodes recorded and there was no over 
representation of individuals with variant MBL genotypes.
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In this study no relationship between MBL variant genotype and PICU admission was 
demonstrated. Numbers were small but of the 7 admissions during the longest episodes, 
5 were in wildtype individuals. Overall there were a total of 9 PICU admissions in 269 
subjects, 7 AA and 2 AO/OO. No deaths during the study period were related to FN 
episodes.
5.2.6 MBL genotype and FN duration
Duration of inpatient (IP) stay was used as a surrogate measure of the severity of FN 
and analysed for both the first and longest episodes. The whole group were analysed 
and also divided into the two diagnostic categories: ALL and Non ALL. Within the 
whole group and the two diagnostic categories all episodes were subsequently analysed 
together and also separated into the ‘Exclusions’ group (those automatically excluded 
from low risk by virtue of age or underlying diagnosis) and the ‘No exclusions’ group 
(all other episodes which may have been managed as low or standard risk for clinical 
reasons at the time of admission). Longer inpatient stays were observed in the 
‘Exclusions’ group in all analyses reflecting the prolonged neutropenia experienced 
when treated on intensive treatment protocols (Table 5.11).
Longer IP stays were observed in AO/OO compared to AA individuals in the majority 
of analysis groups, predominantly in the longest episodes. The differences between the 
genotype groups were greatest in the ‘Exclusions’ group, specifically in the Non-ALL 
patients, but none of these differences reached statistical significance.
The influence of MBL genotype on episode duration in ALL patients was minimal. 
When the group was analysed as a whole, AO/OO patients spent one night longer in 
hospital than AA in both the first and longest episodes. When the group was separated 
into ‘No Exclusions’ and ‘Exclusions’ this difference was lost (first episodes) or 
reduced (longest episodes) which may reflect the many confounding variables that can
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IP nights First episode Longest episode
AA AO/OO p value AA AO/OO p value
Total group (n=) 108 89 109 91
Mean 6.5 7.5 7.6 9.2
Median 5 6 0.301 6 6 0.190
‘No exclusions’ (n=) 78 63 80 69
Mean 5.3 5.5 6.2 7.4
Median 4 4 0.609 5 6 0.211
‘Exclusions’ (n=) 30 24 29 22
Mean 9.6 11.7 11.6 15.1
Median 7.5 10.5 0.155 12 14.5 0.223
A L L  (n=) 72 61 72 62
Mean 5.7 7.1 6.6 8.3
Median 4 5 0.120 5 6 0.100
‘No exclusions’ (n=) 59 47 62 50
Mean 5.2 5.8 6.2 7.2
Median 4 4 0.281 5 5.5 0.184
‘Exclusions’ (n=) 13 14 10 12
Mean 7.9 11.2 8.9 12.9
Median 7 7 0.306 8.5 9 0.390
Non A L L  (n=) 36 28 37 29
Mean 7.9 7.9 9.6 11.2
Median 6 6 0.849 8 10 0.650
‘No exclusions’ (n=) 19 18 18 19
Mean 5.6 4.7 6.1 7.8
Median 5 4 0.407 5.5 6 0.760
‘Exclusions’ (n=) 17 10 19 10
Mean 10.7 13.8 12.9 17.6
Median 8 12.5 0.217 13 15.5 0.198
Table 5.11 Mean and median (bold) IP nights for different patient groups stratified 
by MBL genotype
contribute to length of IP stay, independent of risk, which may mask any effect of MBL 
genotype. In contrast, the Non ALL group consists of patients with a wide range of 
diagnoses. Solid tumour patients vary considerably in their risk and severity of FN. 
Within this group are also AML and B NHL patients who are rendered significantly 
immunosuppressed by their treatment regimes and subsequently experience prolonged
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A comparison of median inpatient stay for all episodes for the different diagnostic 
groups is illustrated in Figure 5.7, and highlights the variability between different 
diagnoses and the two genotype groups. It should be noted that not all diagnoses were 
represented in each of the two genotype groups.
AA e p iso d e s  AO/OO ep iso d es
D iagnosis
Figure 5.7 Median inpatient nights for all captured episodes stratified by diagnosis 
and genotype
Overall the Non ALL group contained diagnoses/patients some of which were at very 
high risk and some at relatively lower risk of adverse outcome which could explain the 
lack of difference between IP nights in the total group, first episode where they are 
likely to even each other out. The Non ALL/’No exclusions’ group represents lower risk 
episodes and the shorter IP stays in AO/OO in the first episodes may be due to 
confounding factors. The Non ALL ‘Exclusions’ group predominantly consists of 
patients with AML, infant ALL, B NHL and those post peripheral blood stem cell 
Transplant (e.g. Stage IV Neuroblastoma). Due to sample sizes there was no statistically 
significant difference between genotype groups but the results do suggest that MBL 
may be exerting a greater effect in these higher risk episodes where AO/OO subjects 
spent on average 4.5 days longer in hospital than AA individuals.
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Number of antibiotic days was also used as a surrogate measure of FN severity. Trends 
were similar to those for IP nights but the effect of MBL deficiency was less 
pronounced (data not shown). The data are generally more difficult to interpret as they 
do not necessarily reflect whether the patient was unwell. A number of clinically well 
patients would have continued antibiotics at home e.g. intravenous Teicoplanin for 
uncomplicated line infections or oral Augmentin in low risk patients, which would have 
affected the results. The largest differences were in the Non ALL exclusions group 
where antibiotic days for AA individuals were 7 and 12 in the first and longest episodes, 
respectively, compared to 11.5 and 14.5 in AO/OO individuals. These differences did 
not reach significance.
5.2.7 MBL genotype and low risk management
Patients managed on the low risk protocol were eligible for discharge from hospital at 
48h to continue oral antibiotics at home until their fever resolved. Patients who 
deteriorated clinically or had persistent fever at 96h were readmitted at any point post 
early discharge. It was hypothesised that MBL deficiency may be a risk factor for 
readmission. Of the 421 PINE episodes, 115 (27%) were managed as low risk and only 
9 (7.8%) required readmission. These readmissions were in 5 AA and 4 AO/OO 
individuals. The reasons given for readmission included ongoing fever, clinical 
deterioration and parental concern, of which the latter is assumed to be MBL 
independent.
5.3 Discussion
This study was designed to explore the role of MBL in FN episodes in a paediatric 
oncology population. The principle aim was to investigate the effect of MBL genotype 
on susceptibility and severity of FN. This is the largest study of its kind to date in terms
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of both patient numbers and participating centres which included both oncology units 
and shared care/district general hospitals. We have shown that individuals in possession 
of MBL variant alleles suffer more episodes of FN compared to wildtype (Table 5.2). 
These episodes are generally of longer duration with the most notable differences 
observed in patients with diagnoses and/or treatment regimens which render them at 
increased risk of severe infection i.e. the ‘Exclusions’ group.
Our data indicates that MBL deficiency may increase susceptibility to FN, as the 
proportion of individuals experiencing multiple episodes of FN was higher for AO/OO 
than AA patients (Figure 5.1). More specifically it appears to influence frequency of 
actual clinical and/or microbiological infections as opposed to FUO episodes i.e. MBL 
appears to be important in protection against bacterial infections. Our initial analysis 
stratified patients by genotype i.e. AA Vs AO/OO but we were also able to demonstrate 
similar findings when analysing by MBL level in the subpopulation of patients for 
whom serum was available (Table 5.8, Figure 5.3). This is in agreement with 
Schlapbach et al who observed that patients with very low levels of MBL were at 
increased risk of FN caused by severe bacterial infections (Schlapbach et al., 2007). 
They categorized their patients by MBL level into three groups; <100ng/ml, 100- 
lOOOng/ml and > lOOOng/ml, different from this study. They reported that when 
compared to individuals with MBL levels of lOO-lOOOng/ml, patients with very low 
(<100ng/ml) and normal levels (>1000ng/ml) had more episodes of FN which were of 
longer duration. They also reported that children with MBL levels >1000ng/ml were 
more frequently hospitalized for FN due to episodes of FUO. This study involved 94 
patients of whom 10 had levels <100ng/ml and they were heterogenous in terms of 
patient age, diagnosis and chemotherapy intensity.
Findings reported in the next chapter (Chapter 6) suggested that individuals in 
possession of the YAYD genotype had MBL levels and function which were more
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similar to wildtype than other heterozygotes. Interestingly when the YAYD individuals 
were analysed with the wildtype group and compared with the other heterozygotes and 
homozygotes the trend was weaker implying that the YAYD group behave clinically 
more like other heterozygotes.
MBL appears to not only influence susceptibility to FN but also how an individual 
handles an infection i.e. their duration of illness. Neth et al reported an effect of MBL 
on duration of fever during neutropenic episodes, with AO/OO individuals spending 
twice as many days with fever and neutropenia over the first six months of cancer 
treatment compared to AA. Our study also supports a role for MBL in modulating 
duration of FN episodes. We used IP nights as a surrogate measure of FN duration 
because capturing information on actual fever duration is difficult, particularly in a 
multicentre setting. We were unable to collect such detailed information due to the 
involvement of over 40 hospitals. The data are subject to a number of confounding 
variables which are complicated further in a multicentre study. There may be a number 
of reasons why patients undergoing treatment for malignancy experience a prolonged 
inpatient stay for FN e.g. Hospital staff may have different levels of experience in 
caring for such patients and hence different levels of confidence in decision making 
regarding discharge which may contribute to prolonged admissions and parental 
confidence may vary at different points during treatment and influence the duration of 
inpatient treatment. Essentially using the new protocol, patients were discharged when 
clinically well +/- afebrile dependent on RS. Despite the potential effects of the 
confounding factors discussed which may dilute any biological effect we did find a 
difference in the number of IP nights when comparing AA and AO/OO individuals 
although this did not reach statistical significance. This was a secondary analysis and 
our study was not powered to detect differences in duration of episode. MBL deficient 
patients generally spent longer in hospital with their FN but the differences were less
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pronounced than those demonstrated by Neth for fever days because we used IP nights 
however this may be a more relevant measure from the patient’s perspective.
Identifying within which patient groups MBL exerts its (most significant) effect is 
important when considering which patients may gain most benefit from replacement 
therapy. Previous studies have been criticised for failing to consider the intensity of 
chemotherapy regimens when analysing patient episodes. It has been proposed that 
MBL could prove to be most beneficial in those patients at lower risk of infection 
whose capacity for granulocyte recovery is better (Klein and Kilpatrick, 2004). This 
theory was supported by Schlapbach et al who showed that very low MBL levels were 
most relevant to FN outcome under transiently myelosuppressive chemotherapy e.g. 
treatment for solid tumours and ALL (Schlapbach et al., 2007). The issue of 
chemotherapy intensity was analysed by separating episodes by diagnosis (ALL Vs Non 
ALL) and the presence or absence of Exclusion criteria which selects out patients on the 
most intensive regimes. The data suggest that MBL may be operating in ALL patients 
but its effect was not dramatic. This may reflect the fact that ALL patients, especially 
during maintenance treatment, do not generally suffer from severe infections and 
commonly present with mild upper respiratory tract infections which are viral in nature. 
Differences in the recognition and binding of MBL to different pathogens may in part 
explain these findings. Evidence therefore indicates that MBL deficiency (as assessed 
by genotype) may be most important in those patients at highest risk of severe FN e.g. 
AML and B NHL patients who experienced longer FN episodes than their MBL 
sufficient peers. This is in contrast to findings reported by Bergmann et al who studied 
80 adult AML patients for 28 days post induction chemotherapy. They found no effect 
of MBL deficiency on frequency of severe infections or duration of fever but it should 
be noted that only 16/80 patients were considered deficient (Bergmann et al., 2003). 
They hypothesised that the effect of MBL was overshadowed by the profound
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disturbance in phagocytic function experienced in these patients. This explanation 
implies that the main role of MBL is initiation of opsonophagocytosis but this may not 
be its only function. Its role in the modulation of inflammation may also be important, 
particularly in the resolution of episodes.
Analysis of ALL patients alone demonstrated a trend towards an increased frequency of 
FN episodes which were generally longer in the AO/OO group compared to AA (Table 
5.5, Table 5.11). Lausen et al retrospectively analysed FN data on 137 children during 
their first 3 months of induction therapy for ALL (Lausen et al., 2006). In this 
homogenous group they reported that MBL deficiency did not influence frequency of 
infections. In the present study 178 patients were investigated including 170 children 
with ALL who were grouped together with T NHL patients due to similarities in 
treatment protocol and subsequent risk of FN. FN episodes captured during both the 
first and last few months of their treatment (which spans up to 3 years) were 
investigated. The first few months are when patients are deemed at highest risk of 
infection but this does vary from patient to patient throughout their treatment (Graubner 
et al., 2007). Interestingly our data from first FN episode captured during the study 
period showed no difference in duration for AA and AO/OO subjects. A proportion of 
these episodes would have been from patients at the time of diagnosis and may reflect 
the relatively standard length of IP admission for a newly diagnosed ALL patient. 
Current protocols require a repeat bone marrow aspirate on day 8 after diagnosis and 
most patients remain an inpatient until this time. The current one year study period has 
provided a more global overview of the influence of MBL deficiency in children with 
ALL which may have been overlooked by Lausen et al when focussing on just the first 
three months of treatment.
The duration of the study period may well be important when assessing the true 
influence of MBL on infection morbidity in such patients. Previous studies that have
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reported an effect of MBL deficiency on infection outcome (Peterslund et al., 2001; 
Neth et al., 2001; Mullighan et al., 2002; Horiuchi et al., 2005; Schlapbach et al., 2007) 
have generally included longer follow up periods than those who have found no effect 
(Kilpatrick et al., 2003; Bergmann et al., 2003; Frakking et al., 2006) with the study by 
Peterslund et al being the exception. As previously discussed the studies have asked 
different questions of their heterogenous groups of patients making comparisons 
difficult but it can be said that the studies of longer duration have been more 
informative. The only study to demonstrate an effect of MBL on infections after 
chemotherapy in a single patient episode was conducted by Peterslund and colleagues 
which simply compared the severity of infections. The impact of this study was great as 
it highlighted oncology patients as potential beneficiaries of MBL replacement therapy 
and has fuelled the development of recombinant MBL.
One of the weaknesses of this study was its cross-sectional design. We aimed to capture 
patients on active treatment during a one year period rather than following individual 
patients prospectively for a year. Some patients were diagnosed before the study started 
and some patients were diagnosed during the one year period which meant that some 
patients started and/or finished their treatment during the study period i.e. did not have 
FN episodes for the full year period and we have made the assumption that they balance 
each other out. If patients were not equally distributed we may have introduced bias into 
our sample and skewed our findings in either direction, potentially diluting the effect of 
MBL deficiency. Different diagnostic groups receive different management e.g. patients 
with ALL receive 2-3 years of treatment (predominantly as an out-patient) during which 
the degree of treatment related immunosuppression varies compared to patients with 
AML who receive 6 months of intensive treatment which requires inpatient admission 
and patients with solid tumours who receive treatment of differing duration and 
intensity. Patients from most of the diagnostic groups were present in our sample with
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no marked difference between the wild type and variant populations. Of note 11 of the 
15 patients with AML possessed a wildtype genotype. The advantage of this study 
design was that it enabled us to recruit a large number of patients who had many FN 
episodes over the one year period which were available for analysis. Frakking et al were 
unable to demonstrate an effect of MBL deficiency in their study of a mixed group of 
paediatric oncology patients which may be due to the fact that they analysed a single FN 
episode from just 66 patients (Frakking et al., 2006). This meant that there were only 39 
patients in their high MBL genotype group and 26 in the medium/low group making 
analysis and interpretation limited.
MBL genotype did not appear to influence the type of bacterial infection that patients 
experienced which is in keeping with a number of other studies. The finding of more 
episodes of bacteraemia in wildtype subjects is in keeping with the results of a recent 
study of adults with community acquired pneumonia (Perez-Castellano et al., 2006). A 
greater risk of developing bacteraemia was reported in wildtype subjects with the 
authors hypothesising that MBL may favour entry of bacteria via the bloodstream. The 
number of reported fungal infections was low in our population preventing any 
meaningful analysis. Choi et al were unable to demonstrate an association between 
MBL polymorphisms and chronic disseminated candidiasis in adult leukaemia patients 
(Choi et al., 2005) but MBL deficiency was found to be a predictive factor for invasive 
fungal infection in adults after stem cell transplantation (Granell et al., 2006). Viral 
infections are currently poorly investigated and reported and therefore no comment can 
be made on whether MBL is important. It remains unclear how many episodes 
classified as FUO may be viral in origin. A relationship between MBL deficiency and 
intensive care admission in the paediatric oncology population has never been 
convincingly demonstrated. Of the 9 episodes requiring transfer to PICU in this study, 7 
were in AA subjects which is in keeping with two other studies (Frakking et al., 2006;
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Schlapbach et al., 2007). This is in contrast to findings of Neth et al who reported that 3 
out of 4 patients who went to PICU were AO/OO individuals (Neth et al., 2001). These 
divergent findings do not correlate with work demonstrating an effect of MBL 
deficiency on incidence of SIRS in intensive care patients and are likely to reflect the 
multifactorial reasons for PICU admission in oncology patients in which MBL may play 
only a part (Garred et al., 2003; Dalton et al., 2003; Fidler et al., 2004).
The final question of this study was whether MBL genotype would be a useful addition 
to RS to aid the accurate identification of patients suitable for low risk management. It 
was hypothesised that MBL deficiency may contribute to the need for readmission 
following early discharge but we have been unable to conclusively answer this question. 
Of those patients who did require readmission, 5 were AA and 4 were AO/OO but the 
reasons for readmission make interpretation difficult. As previously discussed the new 
protocol was introduced and audited from the outset. Confidence in the low risk 
management protocol differed between hospitals and parents as did the practicalities of 
its use which may have resulted in inappropriate or under use and the subsequent need 
for readmission. MBL genotype may form part of the RS process in the future but larger 
studies are required to delineate its specific role.
In conclusion, this large multicentre study has demonstrated that MBL genotype (and 
protein level) appears to influence both frequency of FN and duration of IP stay for FN 
in children with cancer. It has highlighted that MBL genotype may be most important in 
patients at risk of severe FN but due to relatively low patient numbers in some analysis 
groups this finding must be interpreted with caution. Previous studies that have 
dismissed a relationship between MBL and infections in cancer patients have often 
involved inadequate numbers of patients from which to draw such conclusions. It 
remains unclear exactly how MBL is exerting its effect in oncology patients with 
different diagnoses and therefore further analysis of large homogenous groups is
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required to answer such questions. MBL deficiency may contribute to susceptibility but 
may have most impact on modulation of inflammation and subsequent resolution of 
these episodes. It may be most suited as an adjunct to infection management with the 
aim of accelerating recovery and reducing potential interruptions in treatment. It must 
be remembered that MBL is just one component of the lectin pathway and further 
studies are required in order to clarify the role of the other components e.g. MASPs and 
Ficolins, in infection susceptibility in children with cancer.
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Chapter 6
MBL structure and lectin pathway function in children with
cancer
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6.0 Introduction
Investigation of the lectin pathway 6
Assessment of MBL ‘deficiency’ has been the focus of many studies over the last 17 
years but the methodology used has differed. Many studies have relied on genotype data 
alone but this may be considered an over simplified measure of this complex pathway. 
More detailed characterisation of the pathway is of importance, particularly with the 
prospect of selecting patients for MBL replacement therapy. MBL, at least in terms of 
complement activation, does not function in isolation and identification of other defects 
within the pathway would prevent inappropriate use of recombinant MBL in potential 
subjects.
Identification of the most clinically relevant measure is obviously paramount when 
conducting and analysing disease association studies and in the case of MBL has led to 
the development of a number of assays (Petersen et al., 2001; Kuipers et al., 2002; 
Seelen et al., 2005). Measurement of MBL ‘functional activity’ is complement specific 
and should improve our understanding of its disease specific actions. However it should 
be noted that MBL has other functions which are not quantified by these assays 
(Dommett et al., 2006).
The contribution of individual MASPs to lectin pathway function can also be assessed 
using functional assays (Sorensen et al., 2005). Polymorphisms in the genes encoding 
these serine proteases have been identified and their clinical importance is currently 
under investigation (Stengaard-Pedersen et al., 2003; Lozano et al., 2005; Thiel et al., 
2007). The involvement of Ficolins in this system is an evolving story, and to date, our 
understanding of ficolin deficiency and disease remains in its infancy.
The aim of this work was to characterise components of the MBL lectin pathway and 
their combined functional activity in children with cancer. Firstly, potential associations 
between MBL genotype, protein levels and functional activity were assessed.
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Investigation of MBL structure, specifically the presence of higher order oligomers,
added to this global assessment. Unexplained functional deficiencies in some
individuals further led to investigations of their MASP levels and function.
6.1 Methods
6.1.1 Patient population
The patients used in this study are a subset of those described in Section 4.1.1, which 
were recruited at Great Ormond Street Hospital. An additional sample of whole blood 
was collected and centrifuged (2500rpm, 15min). Serum was aliquoted and stored at 
-80°C until required. Blood samples were taken when the subjects were clinically well, 
i.e. not during an acute infective episode. Actual sampling took place either on the day 
of admission for inpatient chemotherapy when patients were well enough to commence 
treatment or when they were attending the outpatient department for routine follow up. 
All investigations were performed using a fresh aliquot of serum.
6.1.2 Measurement of MBL concentration
The ELISA method described in Section 2.4.3.1 was used to determine the MBL levels 
in serum.
6.1.3 Wieslab total complement screen
The Wieslab total complement screen method described in Section 2.4.4.4 was used to 
investigate lectin (Figure 6.1), classical and alternative pathway function.
6.1.4 Western blotting of MBL in serum
This method was developed and optimised as part of this study. The final method used 
in these studies is described in Section 2.4.5.
165
Investigation of the lectin pathway 6
6.1.5 Measurement of MASP2 levels
The TRIFMA method described in Section 2.4.3.2 was used to determine the MASP2 
levels in serum.
6.1.6 Genotyping of MASP2
Analysis of the D105G SNP was performed by Innogenetics, Belgium using a multi 
probe assay system similar to that used in the INNO-LiPA MBL2 assay.
6.1.7 Measurement of MASP3 levels
The TRIFMA method described in Section 2.4.3.3 was used to determine the MASP3 
levels in serum.
6.1.8 MBL/MASP2 complex activity /C4b deposition
The C4b deposition assay described in Section 2.4.4.1 was used to investigate 
MBL/MASP2 complex activity (Figure 6.1). Recombinant MBL (rMBL) was added to 
a number of samples with low activity. rMBL was a gift from Natlmmune A/S, 
Copenhagen, Denmark and was prepared as previously described (Vorup-Jensen et al., 
2000). For reconstitution studies rMBL was added to serum at a concentration of 
lOOOng/ml.
6.1.9 C3 cleavage activity/C3b deposition
The C3 assay described in Section 2.4.4.2 was used to investigate activation of C3 by 
MBL/MASP2 and MBL/MASP1 complexes (Figure 6.1). rMBL was added to a number 
of samples prior to assessment of C3 cleavage activity.
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MBL-MASP1
M A S P 3
Figure 6.1 Schematic of MBL lectin pathway and its components assessed by the 
different functional assays utilised in this study. The blue bar (C4) corresponds to the 
components assessed by the MBL/MASP2 complex activity or C4b deposition assay, 
the yellow bar (C3) corresponds to components assessed by the C3 assay and the red bar 
(Wieslab) corresponds to components assessed by the Wieslab MBL Lectin pathway 
screening assay.
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6.2 Results
Serum samples were analysed from 183 subjects recruited from Great Ormond Street 
Hospital.
6.2.1 Relationship between MBL levels and Exon 1 genotype
The mean MBL level for the entire cohort was 2322ng/ml (SD 2220, median 
1808ng/ml) as measured by sandwich ELISA. Mean MBL levels (SD, median) for the 
different exon 1 genotype groups are shown in Table 6.1.
Exon 1 
genotype
N mean SD median
All
subjects
183 2322 2220 1808
AA 103 3684 2047 3328
AO 73 623 615 451
AB 36 336 208 327
AC 13 477 209 576
AD 24 1134 917 982
OO 7 19 12 19
Table 6.1 Mean, SD and Median MBL levels (ng/ml) stratified according to MBL 
Exon 1 genotype.
A significant difference between serum levels in the WT, heterozygotes and 
homozygotes was observed (p<0.001). Comparison amongst the heterozygotes showed 
AD individuals to have the highest levels, followed by AC and AB (Table 6.1).
6.2.2 Relationship between MBL levels and promoter genotype
The XY promoter has the most profound effect on serum levels and its influence in both 
WT and heterozygotes is illustrated in Figure 6.2.
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Figure 6.2 MBL serum concentration stratified according to Exon 1 and XY 
promoter genotype (median indicated by a line, boxes represent interquartile 
range and bars represent outliers).
The median MBL levels in YAYA, XAYA and XAXA individuals were 4484, 2989 
and 1692 ng/ml respectively. In heterozygous individuals the presence of the YY 
promoter is associated with increased average levels in all groups compared to those in 
possession o f the XY promoter and this effect is most pronounced in the AD individuals 
(AD, YY=1466 ng/ml and XY= 245ng/ml, AC 579 and 96, AB 443 and 127 ng/ml 
respectively). When combining the heterozygotes, the median levels in the YAYO 
group were 576ng/ml compared to 138ng/ml in the XAYO group. When stratified by 
full haplotype combination a good correlation was observed with MBL levels (Figure 
6.3). The majority o f WT individuals had levels above lOOOng/ml and the highest levels
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were in individuals in possession of the HYPA haplotype. Most marked variation was
noted in the LXPA/LXPA individuals where levels ranged from 235-2453ng/ml.
HYPD/HYPA individuals (and the one LYQA/HYPD subject) also had levels above
lOOOng/ml in contrast to other heterozygotes in possession of the YY promoter.
Heterozygotes (except YAYD individuals) generally had levels between 100 and
lOOOng/ml and homozygotes and compound heterozygotes possessed levels of less than
lOOng/ml.
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Figure 6.3 MBL serum levels and full haplotype combination.
Black dashed lines delineate WT and YAYD individuals from other heterozygotes and 
compound heterozygotes or homozygotes. Red lines represent mean levels.
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6.2.3 Relationship between MBL level and function
Functional assessment of the MBL lectin pathway was initially investigated using the 
Wieslab MBL lectin pathway screen which assesses the ability of MBL complexes to 
activate complement as determined by detection of terminal components of the 
pathway, C5b-9. Individuals exhibiting <10% activity compared to the positive control 
were deemed deficient (Seelen et al., 2005). The MBL lectin pathway activity stratified 
by exon 1 (Table 6.2) and XY promoter genotypes is shown in Figure 6.4. Deficient 
activity was observed in 82% (60/73) of heterozygotes and all homozygotes. Thirteen 
heterozygotes had activity above the 10% level and of these 11 possessed the YAYD 
genotype combination, with MBL levels above 1000 ng/ml.
Exon 1 
genotype
Wieslab MBL lectin 
pathway activity 
% (of positive control)
n mean range
All
subjects
183 36 0-193
AA 103 56 0-193
AO 73 12 0-133
AB 36 2 0-10
AC 13 4 0-19
AD 24 30 0-133
OO 7 1 0-3
Table 6.2 Mean and range values for Wieslab MBL lectin pathway activity 
stratified according to MBL exon 1 genotype.
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Figure 6.4 MBL lectin pathway activity (median indicated by a line, boxes 
represent interquartile range and bars outliers) stratified according to exon 1 and 
XY promoter genotype.
There is no agreed definition of MBL deficiency but WT subjects generally exhibit 
MBL levels >1000ng/ml as shown in Figure 6.3. When MBL lectin pathway activity 
was plotted against MBL level (Figure 6.5), AA subjects were predominantly found in 
the upper right area i.e. >10% activity and MBL level >1000ng/ml. The AO subjects 
were mainly seen in the middle lower area, i.e. <10% activity and MBL levels between 
lOO-lOOOng/ml. The 0 0  individuals were observed in the lower left area, i.e. <10% 
activity and MBL levels <100ng/ml.
The data identified a subset (n=20) of WT individuals with low lectin pathway activity 
i.e. <10%. Of these, 5 subjects had MBL levels below lOOOng/ml but 15 had levels 
>1000ng/ml and warranted further investigation.
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Figure 6.5 MBL levels plotted against MBL lectin pathway activity. The horizontal 
dashed line marks 10% activity. The vertical dashed lines mark MBL levels of 
lOOng/ml and lOOOng/ml.
Whether the lack of activity was due to a defect in the MBL lectin component of the 
pathway or due to a defect in the terminal pathway was unclear. In order to clarify this 
both classical and alternative pathway were screened in these individuals as these also 
rely on an intact terminal pathway.
Results for the entire cohort for the classical and alternative pathway assays stratified by 
MBL exon 1 genotype are shown in Table 6.3. Mean pathway activity was relatively 
uniform between the MBL genotype groups. There was no relationship between 
classical and alternative pathway function and MBL level as illustrated in Figure 6.6.
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Classical pathway (%) Alternative pathway (%)
n mean range mean range
AA 103 86 4-137 86 33-113
AO 73 88 43-127 89 13-117
OO 7 83 32-133 82 54-100
Table 6.3 Classical and Alternative pathway activity stratified by MBL exon 1 
genotype
1000 -
100 -
1 0 -
10 100 1000 100001
£  1000-
# A A
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#00
100-
10 -
10 100 1000 100001
MBL (ng/ml) MBL (ng/ml)
Figure 6.6 MBL levels plotted against Classical and Alternative pathway activity.
Red arrow indicates individual with deficient classical pathway activity.
One MBL2 WT individual exhibiting low lectin patheway function also showed 
deficiency in classical pathway activity (4%, highlighted by red arrow in Figure 6.6) but 
not alternative pathway activity. This suggests a defect common to both the MBL lectin 
and classical pathways e.g. this could occur at the C2/C4 level. As all other individuals 
had no detectable deficiency in either the classical or the alternative pathways using this 
screening tool, deficiency in lectin specific components was assumed.
Our next line of investigation was to examine MBL structure. Differences in MBL 
oligomeric structure which correlate with functional activity have been demonstrated in
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hetero and homozygotes (Dean et al., 2005) however detailed structural analysis in WT
individuals has not been performed.
6.2.4 Relationship between MBL structure and function
To explore the influence of MBL structure on complement activating function, the 
presence of MBL higher order oligomers (trimer and above) was analysed by non­
denaturing SDS-PAGE followed by Western blotting. As evidence suggests that MBL 
tetramers (and above) are required for complement activation (Super et al., 1992; 
Yokota et al., 1995), lower order oligomers were not the focus of this study.
6.2.4.1 MBL oligomeric structure and genotype 
Wildtype
On the basis of ELISA, serum containing lng of MBL was analysed by western 
blotting. Interestingly, marked interindividual differences were observed. Figure 6.7 
shows band patterns for WT individuals with a YY promoter in the top panel and XY or 
XX promoter in the bottom panel. Purified MBL (positive control) yielded bands 
presumed to represent trimer, tetramer, pentamer and hexamer at approximately 288, 
384, 480 and 576 KDa, respectively. The tetramer band was the most abundant. In some 
samples a band was also noted between the trimer and tetramer at ~320 KDa, whose 
structure is unclear. Due to the low band intensity seen for pentamers and hexamers, 
when compared to trimers and tetramers, the blots were exposed for different durations 
in order to visualize these bands optimally. The gel images shown represent one 
exposure time and individuals with the same genotype were run on the same gel to 
enable direct comparison.
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Figure 6.7 SDS-PAGE separation of MBL oligomers followed by blotting with 
anti-MBL and development by ECL. Examples from 18 individuals are shown with 
their corresponding MBL genotype, level and functional activity as measured by the 
Wieslab assay. Purified MBL is shown for comparison and bands corresponding to 
trimers (x3), tetramers (x4), pentamers (x5) and hexamers (x6) are indicated.
176
Investigation o f the lectin pathway 6
Heterozygotes
Analysis o f lng o f MBL protein from exon 1 heterozygotes revealed differences in 
oligomer patterns compared with WT. MBL from HYPD/HYPA individuals showed 
closest resemblance to WT and contained mainly trimers and tetramers corresponding 
with good complement function (Figure 6.8). One LYQA/HYPD subject appeared to 
produce some tetramer but exhibited low function (Lane 3; Figure 6.8). Weak bands of 
tetramer size were observed in AD subjects with a XY promoter (Figure 6.8) and other 
heterozygotes with a YY promoter which corresponded with markedly low complement 
function (Figure 6.9). The results o f samples from heterozygotes with a XY promoter 
(except XAYD, Figure 6.8), with very low MBL concentration were the most difficult 
to interpret due to poor clarity o f the trimer band (Figure 6.9). Uninterpretable results 
were obtained from homozygotes (data not shown).
x4
x3
d  . «  • «  m -
Haplotype
combination
HYPD
HYPA
LYQA
HYPD
LXPA
HYPD
MBL level 
(ng/ml)
2601 2332 1414 519 843 664
Wieslab 
function (%)
70 121 2 2 21 7
Figure 6.8 MBL oligomers from subjects with an AD genotype.
Corresponding MBL level and functional activity is shown for 6 individuals.
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Figure 6.9 MBL oligomeric structure in MBL2 variant allele heterozygotes.
Corresponding MBL level and functional activity is shown for 10 individuals.
Overall, with the exception o f Y A YD heterozygotes, the absence of tetramer correlated 
very well with low complement activating function as assessed by the Wieslab screen 
(Lanes 4-6 Figure 6.8 and Figure 6.9). The presence o f a strong trimer band however 
was not indicative o f good functional capacity.
6.2.4.2 Analysis of MBL2 WT individuals with MBL level > lOOOng/ml but low 
functional activity as assessed by the Wieslab assay
Figure 6.10 shows MBL oligomer structure in WT individuals who exhibited low 
functional activity. MBL tetramers were observed in all samples tested. Trimer and 
tetramer bands were clearly saturated making quantification impossible. The MBL 
oligomer patterns observed in these individuals did not appear to explain their low 
functional activity unlike the patterns observed in certain heterozygotes.
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MBL lectin 
pathway (%)
A HYPA/HYPA 2240 0.5
B LXPA/LYQA 1104 0.9
C LYQA/HYPA 5569 1.0
D LYQA/HYPA 1990 1.0
E LXPA/HYPA 1421 1.1
F LXPA/LYPA 1120 2.2
G LXPA/HYPA 1419 4.0
H LXPA/LYQA 2689 6.5
I LXPA/HYPA 2525 7.5
J HYPA/HYPA 3098 8.5
K HYPA/HYPA 2377 8.5
L HYPA/HYPA 6189 8.8
M LXPA/HYPA 3761 9.5
N LXPA/HYPA 1646 9.8
O LXPA/HYPA 2806 10
Figure 6.10 MBL oligomeric structure in exon 1 WT individuals (MBL protein 
level >1000ng/ml) with low Wieslab functional activity.
This prompted the investigation o f other components o f the lectin pathway which may 
be contributing to the low functional activity. As discussed, MBL works in concert with 
MASPs. At present, there is no assay available for MASP1 quantification; assays are 
available for MASP2 and MASP3. The role or significance o f the latter is unclear, 
although there is a suggestion that it may act as a competitive inhibitor o f MASP1 and 
MASP2 activity (Dahl et al., 2001; Moller-Kristensen et al., 2007). Additional 
functional assays were also used to assess function at different levels in the MBL lectin 
pathway in order to investigate the influence o f specific MASP deficiencies and assess 
their correlation with the results obtained using the Wieslab screen.
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6.2.5 Relationship between MASP2 levels and genotype
Levels of MASP2 in relation to MBL exon 1 genotype are shown in Table 6.4. The 
mean MASP2 level for the cohort was 442 ng/ml. 20 (11%) individuals had MASP2 
levels <200ng/ml.
Exon 1 
genotype
MASP2
(ng/ml)
N Mean Range
All
subjects
183 442 54-1474
AA 103 378 54-1294
AO 73 527 115-1474
AB 36 584 138-1252
AC 13 483 222-839
AD 24 465 116-1474
OO 7 496 239-834
Table 6.4 Mean and range MASP2 levels stratified by MBL exon 1 genotype
MASP2 levels were noted to be lower in the MBL2 WT individuals when compared to 
the hetero and homozygotes but this was not statistically significant. No clear 
relationship was observed between MBL and MASP2 levels (r2=0.04) (Figure 6.11).
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Figure 6.11 MBL serum concentrations plotted against MASP2 levels.
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Of note, mean MASP2 levels in the 15 MBL2 WT subjects with low Wieslab function
were 197ng/ml, compared to 378ng/ml in the total WT group.
6.2.5.1 MASP2 SNP analysis
The total patient population (n=283) as described in Chapter 4 was genotyped for a well 
known SNP in exon 3 of the MASP2 gene, D105G. This work was performed in 
collaboration with Innogenetics NV, Belgium. This SNP prevents MASP2 forming 
complexes with MBL and the ficolins (Sorensen et al., 2005). There were no 
homozygotes found but 15 heterozygotes were identified, giving an allele frequency of 
5.3%.
Serum samples were available on 6 of the 15 heterozygotes and their mean MASP2 
level was 129ng/ml (range 83-162) compared to 452 ng/ml (range 54-1474) in the 
MASP2 D105G WT individuals. Of the 6 MASP2 D105G heterozygotes in this study 
population, 3 were MBL2 WT and 3 were heterozygotes. Two of the MBL2 WT 
individuals had low MBL lectin pathway function and one had very high function.
When the MBL2 WT/D105G heterozygotes were excluded from the group of MBL2 WT 
individuals with low function, mean MASP2 levels for the group remained low 
(215ng/ml) compared with other MBL2 WTs. This group included one subject who had 
a very low MASP2 level of 54ng/ml.
6.2.6 MASP3 levels
The mean MASP3 level in the entire cohort was 6518 ng/ml.
No clear relationship was observed between MBL and MASP3 levels (r2=0.067) (Figure 
6 .12).
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Figure 6.12 MBL serum concentrations plotted against MASP3 levels.
When stratified by MBL exon 1 genotype the highest MASP3 levels were noted in the 
MBL2 WT individuals and the lowest in the homozygotes, in contrast to MASP2 (Table 
6.5). Mean MASP3 levels in the 15 MBL2 WT subjects with low function were 
7302ng/ml, compared to 6975ng/ml in the total MBL2 WT group.
Exon 1 
genotype
MASP3
(ng/ml)
n mean Range
All
subjects
183 6518 2089-15880
AA 103 6975 2445-15638
AO 73 6014 2088-15880
AB 36 6197 2088-15880
AC 13 4973 2806-9150
AD 24 6305 3725-9162
OO 7 5035 3452-6520
Table 6.5 Mean and range MASP3 levels stratified by MBL exon 1 genotype
182
Investigation of the lectin pathway 6 
No relationship between MASP2 and MASP3 levels has been previously reported and
no correlation was observed between MASP2 and MASP3 levels in this population
(r2=0.052) (Figure 6.13).
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Figure 6.13 MASP2 levels plotted against MASP3 levels
6.2.7 MBL/MASP2 complex activity- C4b deposition assay
This assay assesses the first step in MBL complement activation i.e. whether 
MBL/MASP2 complexes in serum are able to cleave complement component C4, 
reported to be unaffected by lack of MASP1 and MASP3 (Moller-Kristensen et al., 
2007). The results shown in Table 6.6 are from MBL2 WT subjects and a subset of 
heterozygotes with sufficient MBL levels. The levels o f activity followed a similar trend 
to MBL levels, i.e. AA>AD>AC>AB. The additional influence of the XY promoter is 
illustrated in Figure 6.14.
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Exon 1 
genotype
MBL/MASI 
activity- C4b 
(munil
>2 complex 
deposition
ts/ml)
n mean range
All
subjects
156 694 54-3476
AA 102 872 138-3476
AO 54 357 54-2870
AB 23 218 54-440
AC 12 266 62-394
AD 19 581 68-2870
OO -
Table 6.6 Mean and range values for MBL/MASP2 complex activity stratified by 
MBL exon 1 genotype
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Figure 6.14 MBL/MASP 2 complex activity (median indicated by a line, boxes 
represent interquartile range and bars outliers) stratified according to Exon 1 and 
XY promoter genotype
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Marked variation in activity was observed among WT individuals and activity in
YAYD individuals was noted to be higher than other heterozygotes with the YY
promoter. A scatterplot of MBL level against C4b deposition shows good correlation
(r2=0.817) between level and activity (Figure 6.15).
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Figure 6.15 MBL serum levels plotted against MBL/MASP2 complex activity. A 
line of best fine is shown
This assay is reliant on a sufficient concentration of MBL in the sample for activation of 
C4. Assessment of MBL/MASP2 activity was therefore hindered in samples of low 
MBL concentration and rMBL (lOOOng/ml) was added to MBL deficient samples to 
enable analysis. Results for the remaining heterozygotes, homozygotes and one WT 
individual whose MBL levels were low requiring addition of rMBL are shown in Table
10000
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6.7. The levels of activity observed in the homozygotes were similar to heterozygote
levels shown in Table 6.6.
Exon 1 
genotype
MBL/MASP2
deposition
complex activity- C4b 
munits/ml) +rMBL
MBL level (ng/ml)
n= Mean Range mean range
AA 1 542 - 235 -
AO 19 454 182-800 179 4-843
OO 7 382 314-536 19 1-37
Table 6.7 MBL/MASP2complex activity in individuals with low MBL levels
rMBL was also added to 3 WT (all with MBL levels <1000ng/ml) and 16 heterozygote 
samples which had low level activity on initial investigation and the assay was repeated. 
In all cases activity increased, with mean activity on the initial assay of 128 munits/ml 
(range 54-192) increasing to 454 munits/ml (range 306-642), implicating low MBL as 
the limiting factor.
Correlation between the C4b deposition assay and the Wieslab assay was good, r2=0.76 
(Figure 6.16). Of the 15 MBL2 WT individuals with low Wieslab lectin pathway 
function, mean C4b deposition was 466munits/ml, compared to 872munits/ml in the 
total WT population. The plot (Figure 6.16) clearly identifies a WT individual with low 
Wieslab activity but high C4b deposition (872munits/ml); this is the individual with low 
classical pathway activity (marked with a red arrow). This confirms that MBL/MASP2 
complex activity is good and that the defect is likely to be at the C4/C2 level. When this 
individual is removed from the analysis the mean C4b deposition remains low 
(437munits/ml) for the MBL2 WT/low Wieslab cohort.
Interestingly poor correlation was noted between MASP2 levels and C4b deposition, 
r2=0.028, data not shown.
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Figure 6.16 X/Y plot comparing MBL/MASP2 complex activity versus Wieslab 
MBL lectin pathway activity.
The vertical dashed line marks 10% activity as measured by the Wieslab assay. A line 
of best fit is shown. The red arrow represents individual with presumed deficiency at 
C4/C2 level.
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6.2.8 C3 cleavage assay- C3b deposition
This assay assesses the ability of MBL complexes to cleave C3, detected by the 
presence of C3b, reflecting the influence of MASP2 and also MASP1 within the lectin 
pathway. It is newly developed and as yet there is no published data utilizing this assay. 
C3 cleavage stratified by MBL exon 1 genotype is shown in Table 6.8 with the highest 
levels of activity observed in WT individuals and the lowest in homozygotes implying 
that MBL protein level is also important in this assay.
Exon 1 
genotype
C3 cleava 
(munit
ge assay 
ts/ml)
n mean Range
All
subjects
183 743 169-2064
AA 103 994 188-2064
AO 73 496 169-1704
AB 36 352 188-627
AC 13 440 222-681
AD 24 705 169-1704
OO 7 226 181-279
Table 6.8 Mean and range values for C3 cleavage stratified according to MBL 
exon 1 genotype
The additional effect of the XY promoter is illustrated in Figure 6.17. Marked 
variability in levels of activity was observed in WT individuals. In the heterozygotes, 
the XY promoter had the most profound effect in AD individuals, in keeping with 
results from the other assays.
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Figure 6.17 C3 cleavage activity (median indicated by a line, boxes represent 
interquartile range and bars outliers) stratified according to Exon 1 and XY 
promoter genotype
Potential relationship between MBL level and C3 cleavage is shown in Figure 6.18 
(r2=0.65). The scatter plot displays two WT outliers with relatively high MBL levels but 
low C3 activity who were not identified by the C4b deposition assay. This implies that 
their MASP2 function is adequate but that they may be MASP1 deficient.
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Figure 6.18 MBL levels plotted against C3 activity on a log scale. The vertical 
dashed lines mark MBL levels of lOOng/ml and lOOOng/ml. Outliers are marked 
with an arrow.
rMBL was also added to 66 samples with low C3 cleavage activity to override the 
influence of low MBL within the assay system. The majority of these samples were 
from homo and heterozygotes but also included 10 of the 15 MBL2 WT subjects with 
low Wieslab lectin pathway activity. Figure 6.19 shows the change in C3 cleavage 
following the addition of recombinant MBL. The mean percentage increase in C3 
cleavage was 55% (IQR 45-67).
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Figure 6.19 C3 cleavage assay results pre and post addition of recombinant MBL. 
The red and blue dashed lines represent MBL2 WT subjects with low function.
Interestingly 2 of the 10 WT individuals with low function showed minimal increments 
following the addition of rMBL (red and blue dashed lines). In particular the subject 
identified as having low lectin and classical pathway activity showed no increase at all 
(shown as a red dotted line). The blue dashed line represents a subject who may be 
MASP1 deficient. These individuals are also highlighted as outliers (marked with red 
and blue arrows, respectively) when the C4b deposition assay was plotted against the 
C3 cleavage assay results, r2=0.77 (Figure 6.20). Interestingly, these individuals would 
not have been detected using the C4b deposition assay alone. The yellow arrow 
identifies the individual with a low MASP2 level who was not heterozygous for the 
D105G polymorphism who also has relatively low C3 cleavage activity and C4b 
deposition.
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Figure 6.20 X/Y plot comparing results obtained from the MBL/MASP2 complex 
activity assay and the C3 cleavage activity assay. A line of best fit is shown. The 
yellow, red and blue arrows highlight MBL2 WT subjects of interest.
On review of the cumulative results of the different assays utilized we were able to 
propose a reason for deficient function in 8 of the 15 MBL2 WT subjects with low 
Wieslab function (Table 6.9).
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Subject MBL
genotype
MBL
level
Wieslab MASP2 MASP3 C4b C3b Defect
LP CP AP
B LXPA
LYQA
1104 0.9 50 76 54 5527 260 293 Low MASP2
C LYQA
HYPA
5569 1.0 4 68 225 4648 872 254 C2/C4, low 
classical
D LYQA
HYPA
1990 1.0 63 99 83 10946 300 407 D105G
J HYPA
HYPA
3098 8.5 64 77 223 9015 748 188
■Lfidefcl
L HYPA
HYPA
6189 8.8 38 61 154 7898 648 470 Low MASP2
M LXPA
HYPA
3761 9.5 99 95 83 6942 412 504 D105G
heterozygote
N LXPA
HYPA
1646 9.8 47 72 146 5955 400 563 Low MASP2
0 LXPA
HYPA
2806 10 66 93 181 7641 396 417 Low MASP2
Table 6.9 Reasons for deficient lectin pathway function in MBL2 WT subjects
6.3 D iscussion
In this series of experiments we investigated the interaction between components of the 
lectin pathway in a population of children receiving treatment for malignancy. We used 
different assays to quantify and investigate the activity o f various components which 
has enabled detailed evaluation of potential ‘deficiencies’ in the lectin pathway. We 
found MBL to be a major contributor and our results also highlight other deficiencies 
that can compromise MBL’s activity.
MBL levels for the study group were in keeping with other paediatric populations 
(M.Johnson, Institute of Child Health, London [personal communication], Neth et al., 
2001). Marked differences in MBL levels were observed between individuals in 
possession of WT and variant MBL alleles which influenced subsequent function. We 
also confirmed the influence of the XY promoter (Madsen et al., 1995; Minchinton et 
al., 2002). Its effect was evident on both protein levels and functional activity and of 
particular note in AD individuals where the largest differences were seen between the
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YY and XY groups (Figure 6.2 & 6.4). The influence of the H/L and P/Q
polymorphisms was minimal in comparison.
The Wieslab total complement screen assay enabled us to assess MBL lectin, classical 
and alternative pathway activity simultaneously, thus offering greater insight into 
potential deficiencies of complement components which participate in more than one 
pathway. The semi-quantitative nature of the Wieslab assay is a major disadvantage and 
at present should be viewed primarily as a ‘screening’ methodology. Despite lack of 
sensitivity a relationship between MBL lectin pathway functional activity and MBL 
levels was observed, further variability in functional activity between MBL2 exon 1 WT 
individuals was of particular interest. We identified a group of individuals who in the 
majority of studies to date would have been presumed to have good MBL activity as 
assessed by genotype and/or protein level. This study showed that despite a WT 
genotype and MBL level of >1000ng/ml, deficiency in MBL lectin pathway 
complement function can exist (Figure 6.5), thus highlighting deficiencies in other 
components of the pathway e.g. MASPs (Figure 6.21). Our findings are in agreement 
with Carlsson et al who also noted marked variation in pathway activity in MBL 
sufficient control and diseased individuals (Carlsson et al., 2005). However the data 
contrast with results from another study of adult blood donors where all individuals with 
MBL levels >1000ng/ml had >10% pathway activity (Seelen et al., 2005). Analysis of 
the classical and alternative pathways allowed us to identify one MBL2 WT subject with 
low function who also had apparent deficiency in the classical pathway implicating a 
defect at the C2/C4 level. However, more individuals with a similar phenotype need to 
be identified to confirm our findings of one individual. The majority of subjects had 
sufficient classical and alternative pathway activity which may be compensating for 
MBL deficiency. We were interested to explore the sensitivity of the three assays and
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Figure 6.21 Flow chart illustrating investigation of MBL2 WT subjects with low 
lectin pathway activity as assessed by the Wieslab screen.
Subjects with low MASP2 levels are also shown.
195
Investigation of the lectin pathway 6 
performed a number of preliminary experiments in order to investigate this. A non­
linear relationship was observed in all three pathway assays. Focussing on the lectin 
pathway, the addition of purified MBL to an MBL deficient serum (20ng/ml) resulted in 
a dose response effect on lectin pathway function. The addition of serum from MBL 
deficient and sufficient subjects to the assay resulted in enhanced function indicating the 
contribution of other serum proteins e.g. MASPs from the MBL deficient subject. 
Structural analysis of MBL from our patient population revealed the effect of variant 
alleles on the presence of higher order oligomers. Marked differences in the intensity of 
higher bands were observed between WTs and heterozygotes and an effect of the XY 
promoter was demonstrated, as previously described (Dean et al., 2005). Our focus on 
the higher order structures, considered crucial for complement activation (Wallis and 
Drickamer, 1999), was technically challenging. We utilized purified MBL for 
comparison of band patterns and estimation of size, reports of which appear to vary in 
the literature. We also identified additional bands whose origin is unclear and would 
require detailed mass spectrometry analysis to elucidate their composition. Other groups 
have used purified MBL (Garred et al., 2003b) however ‘immunopurified’ proteins may 
not replicate native oligomeric species (Dean et al., 2005). Clear differences in the 
quantity of different sized oligomers in different samples were apparent. Trimer and 
tetramers were most abundant hence these bands were often saturated in our search for 
pentamer and hexamer present at lower concentrations, limiting interpretation. These 
interindividual differences in band pattern within the different genotype groups when 
lng MBL was loaded for each sample suggests that individuals show a differential 
ability in higher order oligomer formation.
Possession of the B and C variant alleles had the most profound effect on structure, 
levels and function which is in keeping with previous reports (Madsen et al., 1995; 
Minchinton et al., 2002). Codon 54 (B) and 57 (C) variants result in glycine substitution
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which disrupts the Gly-Xaa-Yaa structure in the triple collagenous helix, an effect likely
to have profound effects on protein stability (Sumiya et al., 1991; Larsen et al., 2004).
Not surprisingly this mutation also appears to influence binding of MASPs (Wallis et
al., 2004; Wallis et al., 2005). Dean et al observed differences in oligomer pattern in
heterozygotes in possession of the B allele compared to those in possession of the C
allele and proposed a unique model of their structure and effective MASP binding sites
(Dean et al., 2005). We did not observe such marked variation between our AB subjects
compared to ACs which is in agreement with other reports (Heise et al., 2000). In
contrast, individuals in possession of D variant alleles appeared to have consistently
higher MBL levels and functional capacity. Structurally at codon 52 (D), an arginine is
substituted with a cysteine which has been reported to cause the formation of
adventitious disulphide bonds (Wallis and Cheng, 1999). The size difference caused by
the substitution is also proposed to affect the stability of the molecule leading to
accelerated degradation (Madsen et al., 1994). In addition, it has been suggested that
variant D chains may combine with normal A chains enabling formation of stable
higher order oligomers (Garred et al., 2003b). This was evident in our study as serum
from some AD individuals showed tetramer and pentamer formation, but whether these
complexes are composed solely of normal A chains or a mix of A and D chains is
unknown. In AB and AC heterozygotes, the presence of trimer and minimal tetramer
was noted but whether it consists of mixed chains also remains unclear (Wallis and
Cheng, 1999).
An apparent lack of higher order oligomers did not appear to account for the low 
functional activity in the group of MBL2 WT subjects identified by the Wieslab MBL 
lectin assay. This led us to investigate the role of MASPs within the system. As 
described previously we were unable to quantify MASP1. Mean MASP2 level in the 
study population (442 ng/ml) was similar to that reported in 350 Danish blood donors
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(mean = 440ng/ml, range 125-1152, Dr S Thiel, personal communication). Studies
measuring MASP2 levels have been performed in adult populations but there are no
published cohorts of healthy children to date. Further studies are required to compare
levels to age matched controls in order to investigate any paediatric or disease specific
variation. Ytting and colleagues reported higher MASP2 levels in adults with colorectal
cancer when compared to controls (415ng/ml and 368ng/ml respectively) and somewhat
unexpectedly found that MASP2 level had independent prognostic value for survival
(Ytting et al., 2005). Like MBL, MASP2 mRNA is found primarily in the liver with
expression in the small intestine and testis also noted (Seyfarth et al., 2006). It is
unknown how levels are regulated during illness.
MASP2 binds to both MBL and Ficolins and it was therefore no surprise that we were 
unable to demonstrate a clear relationship between MBL and MASP2 levels. The use of 
a high ionic strength buffer and the presence of EDTA in the assay ensures that MASP2 
dissociates from MBL and Ficolins, i.e. to enable measurement of MASP2 in isolation 
(Moller-Kristensen et al., 2003). It is currently unknown exactly what proportion of 
MASP2 circulates free in serum (if any) (Thiel et al., 2000; Moller-Kristensen et al., 
2003) and whether it exhibits equal binding to both MBL and Ficolins. The affinity of 
MASP2 for different sized oligomers and whether it binds equally to variant chains also 
remains uncertain (Chen and Wallis, 2001; Dean et al., 2005). This would also explain 
the lack of correlation between MASP2 levels and C4b deposition in our cohort. 
Genotyping of the D105G mutation in exon 3 of the MASP2 gene revealed a variant 
allele frequency of 5.3%, comparable to an allele frequency of 3.6% reported for 
healthy Danish volunteers (Sorensen et al., 2005). Carlsson et al investigated a cohort of 
112 Swedish cystic fibrosis patients, of which 44 were under the age of 18, and reported 
an allele frequency of 6.3% in patients and 1.3% in adult blood donors (Carlsson et al., 
2005). In the same cohort minimal differences in levels were observed between the
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patients and controls for both D105G heterozygotes (157ng/ml and 166ng/ml
respectively) and WTs (380ng/ml and 352ng/ml respectively). The D105G
heterozygotes identified in our study also had markedly lower levels than WT
individuals (129ng/ml and 452ng/ml respectively).
The influence of the MASP2 D105G mutation on function using the different assays 
was variable in the 6 individuals who were heterozygous. The three MBL2 WT/D105G 
heterozygotes had C4 activity of 300, 412 and 1332 munits/ml with MBL levels of 
3761, 1990 and >10,000 ng/ml respectively. The polymorphism did not appear to 
influence activity in the subject with a very high MBL level but may have had an effect 
on MBL/MASP2 complex activity in the other two subjects who display levels similar 
to those observed in MBL heterozygotes (Table 6.6). The 3 MBL2 heterozygote/D105G 
heterozygotes had C4 activity of 178, 226 and 232munits/ml (after addition of 
recombinant MBL) with MBL levels of 451, 957 and 234ng/ml respectively. 
Interpretation of these levels is limited as numbers were small and MBL level obviously 
influenced results, making interpretation of activity from joint MBL and MASP2 
(D105G) heterozygotes difficult, warranting further studies. Overall 15 MBL2 WT 
subjects had MASP2 levels <200ng/ml, of which 6 had low functional activity. There 
were individuals with low MASP2 levels and low functional activity who were not 
heterozygous for the D105G mutation, suggesting other mutations within the MASP2 
gene may also modulate expression (Lozano et al., 2005; Thiel et al., 2007). There were 
also individuals with low MASP2 levels but good pathway function which may reflect 
the contribution from MASP1 (Moller-Kristensen et al., 2007).
Our knowledge of MASP3 function remains limited. Production of a specific 
monoclonal antibody to MASP3 has enabled measurement of serum levels but there are 
no published data on MASP3 levels. The only data available are on 350 healthy Danish
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controls (Dr S Thiel, personal communication) and on comparison, MASP3 levels were
found to be higher in our paediatric oncology cohort (mean 4193ng/ml and 6518ng/ml
respectively). These levels are approximately 10 fold higher than MASP2 levels,
reasons for which are unknown. Measurement of MASP3 in other populations is
required in order to attempt any interpretation of our finding. No clear relationship was
observed between MASP2 and 3 levels; there may be a relationship between their
function if MASP3 is involved in inhibition of MASP2 activity, but current assays
cannot confirm this. A relationship between MASP2 and MASP1 enzyme activity has
been reported, implicating an inverse relationship between the two (Mayilyan et al.,
2005). Evidence for the presence of separate populations of MBL/MASP complexes
which may also have unique MASP binding sites is growing (Teillet et al., 2007). The
interaction between the three MASPs and also MApl9 and their affinity for MBL
requires further investigation.
Assessment of complement activation by MBL using the C4b deposition assay has long 
been the method of choice for quantifying MBL functional activity, but the assay only 
assesses the first step in the activation pathway, providing no information on 
downstream events. C4b deposition in our WT subjects with low MBL lectin pathway 
function was also low in comparison with their WT peers, but without definitions of 
deficiency this is difficult to interpret. The C3 cleavage assay was designed to assess the 
activity of MBL, MASP2 and MASP1 (Moller-Kristensen et al., 2007). This assay 
should also reflect the potential inhibitory activity of MASP3 and therefore provides a 
more comprehensive measure than C4b deposition. Overall, good correlation between 
the three functional assays was evident. By plotting individual results together we were 
able to identify a small number of individuals with clear defects at specific levels of the 
cascade. The effect of low (or high) MASP levels in otherwise MBL sufficient 
individuals was difficult to analyse. We have identified an individual with possible
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MASP1 deficiency who had low C3b deposition (despite addition of rMBL) but good
C4b deposition. However, we are also left with a number of subjects with more subtle
‘deficiencies’ or ‘excesses’ e.g. MASP3, which are likely to be influencing the Wieslab
screening assay results. We did not measure C2, C4 or C3 levels and it is possible that
these components may also be contributing to low function in some individuals but this
would have been detected by the total Wieslab screen. It should be noted that Ficolins
also activate complement via the lectin pathway although these assays are presumed to
be MBL specific because they rely on binding to a mannan coated surface. There has
been a recent report which suggests that Ficolins may be able to bind mannan in specific
conditions (Sung et al., 2006) and further studies are required to improve our
understanding of their contribution.
The Wieslab MBL lectin pathway screen identified all patients (except 2 heterozygotes) 
with MBL levels <1000ng/ml as deficient and from our in depth investigation it also 
identified WT subjects with potentially low MASP levels as having deficient function.
In summary, in this study we attempted to gain further insight into the complexities of 
MBL lectin pathway function. Our findings raise important issues of how to classify 
patients in disease association studies as we have identified a group of MBL2 WT 
individuals with MBL levels in the normal range but yet exhibited deficient 
complement function. These results also provide evidence that MBL from AD 
individuals (specifically YAYD) behaves more like WT than other heterozygotes in the 
functional assays used. Complement activation is not the only function of MBL but in 
certain disease processes this may well be its principal role and therefore analysis using 
functional assay data may prove more relevant than genotype or MBL protein level. A 
number of questions remain unanswered in relation to the role of Ficolins in the 
pathway and the true impact of MASP deficiencies. Investigations in other healthy and
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diseased populations will improve our knowledge of these different MASP
‘abnormalites’.
0
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Chapter 7
Study of MBL structure and lectin pathway function in 
response to chemotherapy and during febrile neutropenia
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7.0 Introduction
The regulation of MBL production and function during disease remains poorly 
understood. Unlike the classic acute phase protein, CRP whose levels increase up to 
1000 fold in response to infection (Gabay and Kushner, 1999), changes in MBL level 
are minimal, increasing between 1.5 and 3 fold (Thiel et al., 1992; Van Till et al., 2006). 
A recent study investigating MBL acute phase activity in patients admitted with sepsis 
and septic shock observed that 41% of individuals maintained consistent MBL levels 
throughout their admission and 31% demonstrated an actual positive acute phase 
response (>25% increase), the majority of whom were wildtypes. The remaining 
patients demonstrated a negative acute phase response (>25% decrease) (Dean et al., 
2005).
A limited number of studies have investigated changes in MBL protein level in response 
to chemotherapy and during subsequent FN with most concentrating on its role as an 
acute phase reactant. (Neth et al., 2001; Frakking et al., 2006). Increases in MBL protein 
level were observed in children with FN, specifically in MBL2 wildtype (AA) 
individuals who showed significant increases by day 7 of their febrile neutropenic 
episode, responses that declined by day 14 (p=0.004) (Neth et al., 2001). Interestingly, 
levels in patients with variant MBL alleles (A/O, O/O) did not alter significantly and it 
has been suggested that ability to increase MBL may be essential to control infection 
during neutropenic episodes.
A number of chemotherapy drugs are known to be hepatotoxic which may influence the 
regulation of MBL during chemotherapy but interestingly MBL levels in oncology 
patients have been reported to be higher than in controls (Bergmann et al., 2003). The 
effect of liver impairment on MBL production is unclear as higher levels have been 
reported in hepatitis (Kilpatrick et al., 2003a; Brown et al., 2007). Impact of treatment 
on the oligomeric nature of circulating MBL is unknown. This may be important as
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higher order oligomers of rat MBL-A induce better complement activation (Wallis and
Drickamer, 1999). One may therefore hypothesize that during the acute phase response
increased production of higher order oligomers is likely to be beneficial, contributing to
microbial clearance, whereas a reduction in response to chemotherapy might be
detrimental.
In this chapter we investigated potential changes in MBL protein levels and in its 
oligomeric structure in response to chemotherapy and subsequent FN episodes. In 
addition the dual effect of MASP activity and MBL modulation on complement 
function was studied.
7.1 Methods
7.1.1 Patient population
This study was restricted to patients who fulfilled the inclusion criteria in section 4.1.1 
and in addition whose treatment was based solely at GOSH, where they received all 
their shared/supportive care. Serum was collected prior to commencement of 
chemotherapy, on the final day of chemotherapy and days 7, 14 and 21 (as appropriate) 
after treatment. If patients developed FN/infection they had samples taken on day 1, 7 
and 14 of the episode. Details of chemotherapy administered and neutrophil counts 
during the inpatient episode were also noted. Clinical information about FN/infections 
during the episode was recorded in conjunction with the PINE project. This study was 
approved by the Research Ethics committee at Great Ormond Street Hospital and the 
Institute of Child Health.
7.1.2 Measurement of MBL concentration
The ELISA method described in Section 2.4.3.1 was used to determine the MBL levels 
in serum.
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7.1.3 Measurement of MASP2 levels
The TRIFMA method described in Section 2.4.3.2 was used to determine the MASP2 
levels in serum.
7.1.4 Measurement of MASP3 levels
The TRIFMA method described in Section 2.4.3.3 was used to determine the MASP3 
levels in serum.
7.1.5 MBL/MASP2 complex activity /C4b deposition
The C4b deposition assay described in Section 2.4.4.1 was used to investigate 
MBL/MASP2 complex activity.
7.1.6 C3 cleavage activity
The C3 cleavage assay described in Section 2.4.4.2 was used to investigate activation of 
C3 by MBL/MASP2 and MBL/MASP1 complexes.
7.1.7 Wieslab total complement screen
The Wieslab total complement screen method described in Section 2.4.4.4 was used to 
investigate MBL lectin, classical and alternative pathway function.
7.1.8 Western blotting of MBL in serum
This method was developed and optimised as part of this study. The final method used 
in these studies is described in Section 2.4.5.
7.19 Statistical analysis
Due to small sample sizes paired data was compared using Wilcoxon signed rank tests.
7.2 Results
7.2.1 Patient characteristics
Twenty one patients were recruited into the study and monitored throughout 27 courses
of chemotherapy (episodes) in total. In 6 patients, 2 episodes of chemotherapy were
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investigated. Samples were taken pre and post chemotherapy in every patient and
additional samples were taken in those who remained as inpatients at Great Ormond
Street Hospital during the episode. The majority of patients had AML and were MBL2
wildtype (Table 7.1). Patients remained in hospital for different periods of time after
chemotherapy depending on their clinical progress and therefore the number of samples
collected differed between individuals and chemotherapy episodes. The specific
samples used for analysis were those taken, pre and post chemotherapy and on days 1, 7
and 14 of FN.
Patient
initials
Diagnosis Chemotherapy* MBL2 genotype
JM AML ADE 2 and MIDAC LYQA/HYPA
NH AML ADE 2 and MIDAC HYPD/HYPA
JC AML ADE 2 and HIDAC LYQA/HYPA
JB AML ADE 1 and ADE 2 LXPA/HYPA
AF AML ADE 2 HYPA/HYPA
KP AML ADE 2 and MACE HYPD/HYPA
JD AML MACE LXPA/HYPA
BC AML ADE 2 and MACE LYPA/HYPA
MN AML MIDAC LYQA/LYPB
GM Rhabdoid tumour Vincristine, Carboplatin, 
Cyclophosphamide, Etoposide
LXPA/LYPB
MP Wilms tumour Stage IV Etoposide, Carboplatin LXPA/HYPD
DG Hepatoblastoma Doxorubicin, Carboplatin LXPA/LYQA
SC Ectomesenchymoma VIDE LYPB/HYPA
CYY Stage IV Neuroblastoma Etoposide, Cyclophosphamide, 
Vincristine (Day 20)
LYPA/HYPA
GK Orbital
Rhabdomyosarcoma
IVA LXPA/HYPA
EG Pelvic PNET (relapsed) Etoposide, Ifosfamide LXPA/LYPB
CJ B NHL (Group B) COP ADM 2 LYQA/LYQC
SLP Ependymoma Cisplatin LXPA/LXPA
KS Pleuropulmonary
blastoma
Doxorubicin, Vincristine LYQA/HYPA 
(D105G hetero)
EMC Wilms tumour (relapsed) Carboplatin, Etoposide LXPA/HYPA
VB PNET VIDE LYQA/HYPA
Table 7.1 Diagnosis, chemotherapy regime and MBL2 genotype
* Chemotherapy drug combinations 
ADE- Daunorubicin, Cytarabine, Etoposide 
MIDAC- Mitoxantrone, Cytarabine 
HidAC- High dose Cytarabine 
MACE- Cytarabine, Amsacrine, Etoposide
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VIDE- Vincristine, Doxorubicin, Ifosfamide, Etoposide 
IVA- Ifosfamide, Vincristine, Actinomycin D
COP ADM- Cyclophosphamide, Vincristine, Prednisolone, Adriamycin, 
Hydrocortisone and Methotrexate
7.2.2 Effect of chemotherapy on the MBL lectin pathway
7.2.2.1 MBL levels
The analysis of all samples taken pre and post chemotherapy revealed no significant 
change in median MBL levels (Table 7.2). This was also the case when the AA and AO 
episodes were analysed individually.
MBL Total group AA episodes AO episodes
n median
value
(ng/ml)
P n median
value
(ng/ml)
P n median
value
(ng/ml)
P
Pre 27 2410 0.866 17 3325 0.943 10 527 0.959
Post 2487 3630 509
Table 7.2 Changes in median MBL level in response to chemotherapy.
Episodes in patients on treatment for AML receiving similar chemotherapy were also 
analysed as a separate group and no significant difference in MBL levels pre and post 
chemotherapy were observed (data not shown). Individual fluctuations in levels are 
shown in Figure 7.1, illustrating the interindividual variation. Overall, levels increased 
during 13 episodes with a mean increase of 21% (median 12, range 2-56 %) and levels 
decreased in 14 episodes with a mean decrease of 17% (median 15, range 1-41%).
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Figure 7.1 Changes in MBL level pre and post chemotherapy.
Each line represents a different patient episode.
122.2 MASP2 levels
Median MASP2 levels increased in all groups in response to chemotherapy (Table 7.3).
MASP2 Total group AA episodes AO episoc es
n median
value
(ng/ml)
P n median
value
(ng/ml)
P n median
value
(ng/ml)
P
Pre 27 346 0.001 17 307 0.003 10 390 0.037
Post 406 407 393
Table 7.3 Changes in median MASP2 levels in response to chemotherapy.
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Changes in individuals MASP2 levels are illustrated in Figure 7.2. Overall, levels
increased in 21 episodes with a mean increase of 34% (median 24, range 2-153 %),
levels decreased in 5 episodes with a mean decrease of 9% (median 8, range 4-14%) and
levels remained unchanged during one episode.
1400 
1200 
1000
f
"B> 800
CM
</) 600 <
2
400 
200 
0
Pre Post
Figure 7.2 Changes in MASP2 level pre and post chemotherapy.
Each line represents a different patient episode.
1.2.23 MASP3 levels
As discussed in Chapter 5, there is no published data on MASP3 levels in either healthy 
or diseased populations. Interestingly, MASP3 levels fell in 26 of the 27 chemotherapy 
episodes studied, irrespective of MBL genotype and in the remaining episode levels 
were unchanged (Table 7.4 and Figure 7.3). Levels decreased by a mean of 32% 
(median 33, range 2-67%).
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MASP3 Total group AA episoc es AO episoc es
n median
value
(ng/ml)
P n median
value
(ng/ml)
P n median
value
(ng/ml)
P
Pre 27 6726 <0.001 17 7918 <0.001 10 5087 0.005
Post 4215 4647 3536
Table 7.4 Changes in median MASP3 levels in response to chemotherapy.
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Figure 7.3 Changes in MASP3 level pre and post chemotherapy.
Each line represents a different patient episode
We utilized three functional assays (described in Chapter 5) to investigate the effect of 
chemotherapy on pathway function. The analysis of all samples taken pre and post 
chemotherapy revealed no significant change in functional activity irrespective of assay 
used (Tables 7.5-7.7). It should be noted that data from all three assays was not 
available for all 27 chemotherapy episodes.
Pre Post
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C4b
deposition
Total episodes AA episodes AO episodes
N median
value
(munits/ml)
P n median
value
(munits/ml)
P n median
value
(munits/ml)
P
Pre 22 779 0.733 17 874 0.723 5 500 0.893
Post 885 900 598
Table 7.5 Changes in median MBL/MASP2 complex activity - C4b deposition.
C3
cleavage
Total episodes AA episodes AO episodes
n Median
value
(munits/ml)
P n median
value
(munits/ml)
P n median
value
(munits/ml)
P
Pre 27 992 0.848 17 1380 0.768 10 439 0.508
Post 1035 1237 426
Table 7.6 Changes in median C3 cleavage activity in response to chemotherapy.
Lectin Total episodes AA episodes AO episodes
n median
activity
(%)
P n median
activity
(%)
P n median
activity
(%)
P
Pre 23 47 0.765 17 73 0.865 7 5 0.892
Post 45 79 22
Table 7.7 Changes in median MBL lectin pathway activity in response to 
chemotherapy.
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7.2.2.4 MBL/MASP2 complex activity- C4b deposition
Individual changes in MBL/MASP2 complex activity are illustrated in Figure 7.4.
Overall, activity increased in 12 episodes with a mean increase of 49% (median 15,
range 1-161%) and activity decreased in 10 episodes with a mean decrease of 12%
(median 12, range 3-31%).
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Figure 7.4 Interindividual variations in MBL/MASP2 complex activity
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213
Longitudinal study of lectin pathway 7
7.2.2.5 C3 cleavage activity
Individual changes in C3 cleavage activity are illustrated in Figure 7.5. Overall, activity 
increased in 13 episodes with a mean increase of 34% (median 16, range 3-93%) and 
levels decreased in 14 episodes with a mean decrease of 22% (median 17, range 5- 
44%).
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Figure 7.5 Interindividual variations in C3 cleavage activity in response to 
chemotherapy.
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7.2.2.6 MBL Lectin pathway activity as assessed by the Wieslab Total Complement 
Screen
Individual changes in MBL lectin pathway activity are illustrated in Figure 7.6. Marked 
fluctuations in activity were observed with activity increasing in 9 episodes, decreasing 
in 11 episodes and remaining unchanged in 3 episodes. In contrast classical and 
alternative pathway activity showed less variation (Figures 7.7 and 7.8).
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Figure 7.6 Intra- and inter- individual changes in MBL lectin pathway activity.
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re 7.7 Intra- and inter- individual changes in classical pathway activity.
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Figure 7.8 Intra- and inter- individual changes in alternative pathway activity.
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A comparison of the data obtained from all three lectin pathway assays for 20
chemotherapy episodes is illustrated in Figure 7.9. A uniform increase in activity in all
3 assays was observed during 8 episodes. A uniform decrease in activity was observed
in 7 episodes and variability in results was observed in 5 episodes. Interestingly 12 of
these episodes were from 6 subjects, i.e. patients who were investigated during 2
different courses of chemotherapy. In these individuals results were generally consistent
for the 3 assays but responses did vary between different chemotherapy episodes in two
subjects, BC and JC which may relate to the different drug regimens administered in the
different episodes.
Subject
C4b
deposition
C3
cleavage
MBL
Lectin
AF
BC a
BC b
CYY
EMC
GK
JBa
JB b
JC a
Figure 7.9 Comparison of results from 3 functional assays.
Red shading indicates increased activity, blue shading indicates decreased activity and 
yellow shading indicates no change in activity in response to chemotherapy.
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7.2.3 Analysis of MBL structure in samples pre and post chemotherapy
MBL structure was analysed as previously described (Section 6.2.4). The same dilution
factor was applied to all sequential serum samples from an individual and lng of MBL
protein was loaded for each sample and run on the same gel to permit comparison.
Differences in higher oligomer band intensity were noted in samples which were taken 
on the start and finish days of chemotherapy (Figures 7.10 and 7.11) but such results are 
semiquantitative and must be interpreted with caution. Saturation of the trimer and 
tetramer bands made interpretation difficult but there was no clear pattern identified 
between pre and post chemotherapy samples in episodes from individuals who had 
received the same chemotherapy drug combinations. It remains unknown whether 
interindividual differences in band intensity relate to the effect of different 
chemotherapy regimes.
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Subject AF BCa BCb CYY EMC GK
Haplotype
combination
HYPA
HYPA
LYPA
HYPA
LYPA
HYPA
LYPA
HYPA
LXPA
HYPA
LXPA
HYPA
Pathway
function
40 45 81 57 65 164 115 55 193 188 151 120
PRE POST PRE PO ST  PRE PO ST PRE POST PRE POST
Subject JBa JBb JCa JCb JD
Haplotype LXPA LXPA LYQA LYQA LXPA
Combination HYPA HYPA HYPA HYPA HYPA
Pathway
function
13 35 30 16 61 42 38 118 1 18
Figure 7.10 MBL structure pre and post chemotherapy during 11 episodes.
Bands corresponding to presumed trimer (x3), tetramer (x4) and pentamer (x5) are 
indicated and corresponding MBL lectin pathway activity is shown.
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PRE POST PRE POST PRE POST PRE POST PRE POST
Subject JMa JMb KS SLP VB
Haplotype LYQA LYQA LYQA LXPA LYQA
Combination HYPA HYPA HYPA LXPA HYPA
Pathway
Function
134 102 81 100 1 1 140 136 147 188
PRE POST PRE POST PRE POST PRE POST
x5
x4
x3 N H h M
Subject KPa KPb NHa NHb
Haplotype HYPD HYPD HYPD HYPD
Combination HYPA HYPA HYPA HYPA
Pathway
function
47 45 53 30 5 22 23 136
Figure 7.11 MBL structure pre and post chemotherapy during 9 episodes.
Bands corresponding to presumed trimer (x3), tetramer (x4) and pentamer (x5) are 
indicated and corresponding MBL lectin pathway activity is shown.
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7.2.4 MBL/lectin pathway activity during FN
7.2.4.1 MBL levels
Median MBL levels measured at the specific timepoints throughout FN are shown in 
Table 7.8. The number of samples at each timepoint differed and therefore the 
Wilcoxon signed rank test was used to compare differences between the available 
samples e.g post chemotherapy and day 1 FN (n=14) etc.
MBL Total group AA episodes AO episoc es
n median
value
(ng/ml)
P n median
value
(ng/ml)
P n median
value
(ng/ml)
P
Post 14 3357 0.463 9 4066 0.779 5 2337 0.686
D1 FN 2631 5100 1598
D1 FN 11 2587 0.155 7 5100 0.237 4 1607 0.465
D7 FN 3592 6326 2045
D7 FN 6 3074 0.046 4 5183 0.068 2 1128 0.655
D14
FN
2592 4206 822
Table 7.8 Changes in median MBL level during FN.
The overall trend was that median MBL levels increased between day 1 and 7 of FN but 
this difference was not significant in any group. By day 14 median levels had fallen and 
this reached significance in the total episodes and the AML episodes (data not shown). 
Individual fluctuations in levels are shown in Figure 7.12, illustrating the marked 
interindividual variation. In those episodes where samples were available at both day 1 
and day 7 FN, MBL levels increased in 8/11 (5, AA and 3 AO) and decreased in 3 (2, 
AA and 1, AO). The maximum increase was observed in a YAYD individual whose 
MBL level increased 2.4 fold or 140%.
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Figure 7.12 Changes in MBL level post chemotherapy and during FN. Each line 
represents a different patient episode.
7.2.4.2 MASP2 levels
Median MASP2 levels peaked on day 1 of FN and fell between days 1 to 7 and again 
from days 7 to 14 in the total group and in AA episodes (Table 7.9 and Figure 7.13). 
Levels in heterozygotes peaked on day 7. Changes in levels in heterozygotes were 
difficult to interpret as samples were only available from two episodes at all 4
timepoints.
MASP2 Total group AA episoc es AO episoc es
n median
value
(ng/ml)
P N median
value
(ng/ml)
P n median
value
(ng/ml)
P
Post 14 507 0.701 9 530 0.484 5 406 0.686
D1 FN 521 537 505
D1 FN 11 572 0.594 7 572 0.310 4 496 0.465
D7 FN 455 452 570
D7 FN 6 471 0.173 4 405 0.465 2 928 0.180
D14FN 436 376 817
Table 7.9 Changes in median MASP2 levels during FN
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Figure 7.13 Changes in MASP2 level post chemotherapy and during FN. Each line 
represents a different patient episode.
7.2.4.3 MASP3 levels
As discussed, mean MASP3 levels fell in 26/27 episodes in response to chemotherapy, 
and then continued to fall throughout the episode in some individuals at different rates 
but were generally increasing to pre chemotherapy levels by day 14 FN (Table 7.10 and 
Figure 7.14). MASP3 levels were generally higher in MBL2 AA individuals compared 
to the AO subset as previously observed in Chapter 6.
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MASP3 Total group AA episoc es AO episoc es
n median
value
(ng/ml)
P n median
value
(ng/ml)
P n median
value
(ng/ml)
P
Post 14 4315 0.382 9 4414 0.484 5 4164 0.080
D1 FN 4430 4823 3689
D1 FN 11 4174 0.328 7 4177 0.237 4 4187 0.465
D7 FN 4814 5674 4065
D7 FN 6 4315 0.046 4 5244 0.144 2 2851 0.180
D14FN 5542 5750 5071
Table 7.10 Changes in median MASP3 levels during FN.
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Figure 7.14 Changes in MASP3 level post chemotherapy and during FN. Each line 
represents a different patient episode.
7.2.4.4 MBL/MASP2 complex activity- C4b deposition
In all groups, median activity peaked on day 7 of FN and decreased significantly by day 
14, showing a similar trend to MBL levels (Table 7.11 and Figure 7.15). MASP2 levels
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increased in response to chemotherapy but this was not reflected by a significant
increase in C4b deposition. As discussed in Chapter 6, MASP2 does not interact solely
with MBL and C4b deposition activity correlates well with MBL levels alone.
C4b Total group AA episodes AO episodes
n median
value
(munits/ml)
P n median
value
(munits/ml)
P n median
value
(munits/ml)
P
Post 13 936 0.754 9 1052 0.575 4 662 0.715
D1 FN 924 1068 640
D1FN 10 867 0.139 7 966 0.398 2 670 0.109
D7 FN 1233 2120 1162
D7 FN 5 1162 0.042 4 1610 0.068 1 - -
D14FN 876 1172 -
Table 7.11 Changes in median MBL/MASP2 complex activity during FN
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Figure 7.15 Interindividual variations in MBL/MASP2 complex activity post 
chemotherapy and during FN
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7.2.4.5 C3 cleavage activity
A similar trend was observed in C3 cleavage activity as that for C4b deposition. This 
was expected as the two assays showed good correlation (Chapter 6). Activity peaked at 
day 7 of FN and decreased by day 14 (Table 7.12). Individual fluctuations in activity are 
shown in Figure 7.16.
C3 Total group AA episodes AO episodes
n median
value
(munits/ml)
P n median
value
(munits/ml)
P N median
value
(munits/ml)
P
Pre 27 992 0.848 17 1380 0.768 10 439 0.508
Post 1035 1237 426
Post 14 1136 0.889 9 1376 0.726 5 1035 0.500
D1 FN 916 1396 780
D1 FN 11 836 0.131 7 996 0.237 4 808 0.465
D7 FN 1531 1936 1475
D7 FN 6 1221 0.046 4 1479 0.068 2 808 0.655
D14FN 672 1058 564
Table 7.12 Changes in median C3 activity during FN
3000
Post D1 FN D7 FN D14 FN
Figure 7.16 Interindividual variations in C3 cleavage activity in response to 
chemotherapy.
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1.2 A.6 MBL lectin pathway activity as assessed by the Wieslab Total Complement 
Screen
The trend in MBL lectin pathway activity again mirrored that seen for the C4 and C3 
assays i.e. median levels peaked on day 7 of FN and fell by day 14 (Table 7.13). Similar 
trends were seen for both AA and AO episodes.
Total group AA episodes AO episodes
n median
activity
(%)
P n median
activity
(%)
P n median
activity
(%)
P
Pre 23 47 0.765 17 73 0.865 7 5 0.892
Post 45 79 22
Post 14 45 0.638 9 57 0.674 5 30 1.000
D1 FN 43 62 12
D1 FN 11 42 0.059 7 42 0.176 4 27.5 0.285
D7 FN 97 97 81
D7 FN 6 69 0.046 4 69 0.068 2 65 0.655
D14
FN
11 29 8.5
Table 7.13 Changes in median MBL lectin pathway activity during FN.
Marked intraindividual fluctuations in lectin pathway activity were observed within 
episodes, Figure 7.17. This was in contrast to classical and alternative pathway activity 
during the same episodes which showed less marked variability and generally sufficient 
activity throughout, Figures 7.18 and 7.19 respectively.
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Figure 7.17 Intra- and inter- individual changes in MBL lectin pathway activity 
post chemotherapy and during FN.
140
120
~  100
Post D1 FN D7 FN D14 FN
Figure 7.18 Intra- and inter- individual changes in classical pathway activity post 
chemotherapy and during FN.
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Figure 7.19 Intra- and inter- individual changes in alternative pathway activity 
post chemotherapy and during FN.
A marked decrease in classical pathway activity was noted in one subject on day 1 of 
FN and this was also seen for Lectin pathway activity which would imply a problem at 
the C2/C4 level at this time point because alternative pathway activity was sufficient at 
66%.
Samples taken from 6 patients with AML, all receiving similar chemotherapy drug 
combinations, of whom 4 were MBL2 AA and 2 were AO have been used to illustrate 
the overall trend in changes of MBL, MASP2 and MASP3 levels, Figure 7.20. It is 
interesting to compare the trend in MASP2 and 3 levels. As MASP2 levels increase 
MASP3 levels appear to decrease and vice versa. C4, C3 and lectin pathway activity for 
the same 6 AML patients is shown in Figure 7.21.
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Figure 7.20 Changes in MBL, MASP2 and MASP3 levels in 6 patients on 
treatment for AML (4 AA, 2 AO).
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Figure 7.21 Changes in C4, C3 and Wieslab lectin pathway activity in 6 patients on 
treatment for AML (4 AA, 2 AO (except C4 results, where only 1 AO is represented).
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7.2.5 Analysis of MBL structure in sequential samples during chemotherapy and 
FN
MBL structure was also analysed at different timepoints throughout 2 different episodes 
in the same individual. Figures 7.22-7.25 illustrate MBL structure in 4 individuals 
during 2 different episodes.
x5
MIDAC Pre Post D1 FN D7FN D14FN
Day 1 8 11 18 25
WCC/ANC 4.72/1.65 1.34/0.98 0.11/0.00 0.37/0.01 0.72/0.04
MBL level 8712 6737 7096 7398 6258
Lectin pathway (%) 81 100 110 145 113
Blood cultures taken on D1 FN grew Staphylococcus epidermidis and 
Streptococcus oralis
x3
ADE 2 Pre Post D1 FN D 7FN
WCC/ANC 5.24/3.78 1.95/1.19 0.89/0.01 3.51/0.17
Day 1 9 16 23
MBL level 10000 5860 5100 9324
Lectin pathway (%) 134 102 44 134
Blood cultures taken on I>1 FN grew Staphylococcus epidermidis
Figure 7.22 MBL structure and function in patient JM (LYQA/HYPA) undergoing 
treatment for AML during MIDAC and ADE 2 chemotherapy.
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x6  -  - .  _  _
HiDAC Pre Post D7 post 
chemo
D1 FN
Day 1 7 14 21
WCC/ANC 5.68/3.06 2.83/2.81 0.77/0.71 0.28/0.02
MBL level 3175 3952 4241 6041
Lectin pathway (%) 38 118 76 62
Febrile but not neutropenic on D1 post chemo and blood cultures 
grew Enterococcus and Staphylococcus epidermidis 
D1 FN blood cultures grew Staphylococcus epidermidis
x6
ADE 2 Pre Post D7 post 
chemo
D1 FN
Day 1 7 14 21
WCC/ANC 4.84/1.41 2.06/1.78 1.06/0.01 1.33/0.34
MBL level 3751 3630 2177 2882
Lectin pathway 
(%)
61 42 9 104
Febrile on finish day of chemotherapy, not neutropenic and negative 
blood cultures. When FN, no growth on blood cultures
Figure 7.23 MBL structure and function in patient JC (LYQA/HYPA) undergoing
treatment for AML during HiDAC and MIDAC chemotherapy.
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HiDAC Pre Post/D 1 FN D7 FN 
respiked
D14FN
Day 1 9 17 24
WCC/ANC 5.96/1.99 1.24/0.02 0.89/0.01 3.93/0.34
MBL level 6132 8054 6774 5519
Lectin pathway (%) 65 164 97 47
No growth on blood cultures throughout episode
MIDAC Pre Post D7 post 
chemo
D1 FN D7FN
Day 1 7 14 17 23
WCC/ANC 7.68/3.37 3.58/1.87 3.29/0.03 1.31/0.00 5.28/0.82
MBL level 7715 5409 7626 6443 6326
Lectin pathway (%) 81 57 132 105 117
Blood cultures taken on D1 FN grew Klebsiella aeruginosa. 
removal
)atient required CVL
Figure 7.24 MBL structure and function in patient BC(LYPA/HYPA) undergoing
treatment for AML during HiDAC and MIDAC chemotherapy.
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x6
x5
x4
x3
MACE Pre Post D1 FN D7FN
Day 1 7 10 17
WCC/ANC 3.02/0.78 1.73/0.26 0.45.0.01 1.04/0.00
MBL level 2264 2349 1616 3881
Lectin pathway (%) 53 30 12 99
Blood cultures taken on D1 FN grew Staphylococcus epic'ermidis
x6
ADE 2 Pre Post D1 FN D7FN
Day 1 8 16 22
WCC/ANC 4.0/1.16 2.02/1.27 0.82/0.05 1.31/0.03
MBL level 2796 2487 2675 2186
Lectin pathway (%) 47 45 73 63
Blood cultures taken on D1 FN showed no growth
Figure 7.25 MBL structure and function in patient KP (HYPD/HYPA) undergoing
treatment for AML during MACE and ADE 2 chemotherapy.
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Each individual shows different band patterns as expected from the earlier studies
described in Chapter 6, but patterns were similar for the same individual when receiving
different courses of chemotherapy. Figure 7.22 shows sequential samples for patient JM
undergoing MIDAC and ADE2 chemotherapy. During MIDAC, higher order oligomers
corresponding to presumed pentamer and hexamer are clearly observed in the sample
taken on day 1 of FN. A very weak pentamer band was evident in the pre chemotherapy
sample but was not visible in the post chemotherapy sample. This pentamer band
persisted during FN but at decreased intensity. During ADE2 chemotherapy the
pentamer band is also visible and increases in intensity, peaking again on day 1 of FN.
It is difficult to comment on changes in intensity of the tetramer band as it is saturated.
Variability in the intensity of the pentamer band and appearance of hexamer bands are
also observed in patient JC, Figure 7.23. During HiDAC chemotherapy hexamer is
visible in the post chemotherapy sample taken when the patient became febrile although
not neutropenic. This hexamer band was also evident in the two subsequent samples.
During ADE2, similar variability was observed with the hexamer band intensity highest
on the day of finishing chemotherapy which again coincided with the patient being
febrile but not neutropenic and on day 1 of actual FN. Figure 7.24 also shows changes
in higher oligomers in patient BC which correspond to FN episodes with or without any
positive cultures. Samples taken from a HYPD/HYPA individual are shown in Figure
7.25 and variability is observed in the higher order oligomers similar to that seen in the
wildtype individuals previously described. Pentamer was evident in both pre
chemotherapy samples but decreased in intensity in the post chemotherapy samples.
Hexamer and pentamer appeared most abundant in the samples taken on day 1 of FN.
Distinct higher order oligomers were not observed in all HYPD/HYPA individuals. 
Figure 7.26 shows the MBL higher order oligomers detected in samples from patient
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NH during MIDAC chemotherapy. The most prominent bands detected corresponded
with the trimer and an associated higher molecular weight band. The sample taken on
day 2 of FN shows a single low band compared to double/split bands seen at the other
timepoints. There is some signal detected at tetramer level. At this timepoint the patient
was very unwell, Streptococcus viridans was grown from blood cultures and admission
to PICU was required. This also corresponded with low lectin and classical pathway
activity. No sample was available at day 7 FN as the patient required removal o f their
CVL but by day 14 FN MBL structure appeared similar to that observed in the pre
chemotherapy sample.
x5
x4
HiDAC Pre Post D2 FN D14FN
Day 1 6 13 22
WCC/ANC 7.01/3.96 2.55/2.3 0.05/0.0 4.17/0.81
MBL level 1584 2337 1559 1153
Lectin pathway 
(%)
23 136 4 19
Classical (%) 105 110 12 103
Alternative (%) 99 100 66 102
Blood cultures taken on day 1 FN grew Streptococcus viridans
Figure 7.26 MBL structure and complement function in patient NH undergoing 
HiDAC chemotherapy.
In total 14 episodes o f FN were analysed and an increase in higher order oligomer band 
intensity was apparent in 10 of these episodes coinciding with the onset of FN.
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Sequential samples from healthy volunteers were also analysed to act as controls for
comparison. Figure 7.27 shows samples from 2 MBL2 wildtype individuals taken at
weekly intervals during which time individuals were well and at work. Two different
exposures of each blot are shown to demonstrate the lack o f variability between
different samples.
Volunteer 1 Volunteer 2
Day 0 14 21 28 14 21 28
x5
x4
x3
Day 0 7 14 21 28 0 14 21 28
Figure 7.27 MBL oligomers in serial samples taken from two healthy volunteers.
Long and short exposures (top and bottom panel respectively) are shown for 
comparison.
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7.3 Discussion
The work presented in this chapter represents the most detailed study to date 
investigating changes in MBL structure and MBL lectin pathway function in response 
to chemotherapy. Patient numbers were small and there was no control group which 
does limit interpretation but a number of interesting findings warrant further 
investigation and could be important when selecting patients for MBL replacement 
therapy.
Our findings suggest that median MBL levels are not significantly affected by a number 
of different chemotherapy combinations (Table 7.2). In those patients who went on to 
develop FN, average MBL levels increased between day 1 and 7 but this did not reach 
significance. However median levels did decrease significantly from day 7 to 14. These 
results are in agreement with previous paediatric studies which have shown minimal 
changes in levels in response to chemotherapy and increases during FN (Neth et al., 
2001; Frakking et al., 2006). We did not observe dramatic increases in levels during the 
‘acute phase’ (maximum 2.4 fold) supporting the view that MBL is not a classic acute 
phase protein. The timing of sampling may be crucial to the detection of any acute rise 
in levels but other studies using more frequent sampling do not suggest that this is the 
case (Ytting et al., 2006).
There are no published studies investigating changes in MASP levels in response to 
chemotherapy or during FN episodes. Our data suggests that MASP2 levels increase 
after chemotherapy and peak on day 1 of FN, decreasing thereafter. Changes in levels 
by up to 400% were observed in some subjects. MASP2 has not been proposed as an 
acute phase reactant (Moller-Kristensen et al., 2003) but our data suggest that a single 
level taken at diagnosis is not predictive of changes observed during times of stress. 
MASP2 levels have been measured in adults undergoing surgery for colorectal cancer 
and a mean increase of 10% was noted on day 8 post surgery when compared to pre-
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operative levels (Ytting et al., 2006). In contrast, MASP3 levels decreased in all
subjects in response to chemotherapy (p<0.001) and had increased again by the end of
the episode. MASP2 and MBL are predominantly hepatic in origin unlike MASP3
which has been detected in a number of different tissues (Seyfarth et al., 2006). The
results presented would suggest that MASP3 levels may be affected by chemotherapy
and that reduced levels could be implicated in susceptibility to infection but the
significance of this finding remains unknown.
Functional activity of MBL and the lectin pathway in sequential samples assessed by 
the C4b deposition, C3 and Wieslab assays showed similar trends. This was expected as 
the results of the different assays showed good correlation with each other (Chapter 6). 
Median functional activity generally peaked on day 7 of FN and decreased thereafter 
(Figure 7.8). This may suggest that the lectin pathway was operating in response to FN 
and activity increased when required most. Marked fluctuations in MBL/lectin pathway 
activity were observed in some individuals (Figures 7.5-7.7). Interestingly, classical and 
alternative pathway activity was more consistent throughout the episodes which may 
reflect increased stability of their components or increased sensitivity of the lectin 
pathway assays.
The analysis of MBL structure in sequential samples using western blotting has 
revealed some interesting findings. Interindividual variation was noted in response to 
chemotherapy but (presumed) trimer and tetramer remained markedly intact. The 
detection of higher bands at the start of a FN episode was somewhat unexpected and we 
can only speculate on its significance. One hypothesis is that at this time of presumed 
infection i.e. FN, the production of higher order MBL2 oligomers, which are reported to 
be more efficient at complement activation, would be beneficial to the host in 
combating infection. Detectable MBL levels do not appear to increase significantly at 
these times but the ability to regulate oligomer formation may be more important to the
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host. Such differences in band pattern were not observed in sequential samples taken
from healthy volunteers. The control of oligomer formation and whether such tight
control is even possible are currently unknown. It is understood that MBL matures post
translationally into higher order oligomeric forms within the endoplasmic reticulum
prior to secretion (Heise et al., 2000). Evidence from work investigating rat MBL A
suggests that formation of higher oligomers occurs over a number of hours but the
degree of regulation of this process has not been investigated. A number of chaperone
proteins have been shown to interact with collagenous proteins during their assembly
but it is unclear if they can influence the higher oligomeric forms. One other
explanation may be that body temperature influences the process. The changes in higher
oligomers correspond to febrile episodes which may affect the maturation of the protein.
Such differences were not observed in healthy subjects over similar time periods.
Alternatively the higher bands detected on the immunoblot may purely relate to a
change in size of oligomer e.g. tetramer, which is then bound to a target organism in the
bloodstream. A recent study has demonstrated that conformational changes occur in the
quaternary structure of MBL upon binding to surface immobilized ligands (Dong et al.,
2007).
We should also consider the issue of degradation which may affect the band patterns 
detected. Previous studies have suggested that both large and small oligomers are more 
prone to degradation and that middle sized oligomers are more stable and therefore 
crucial to complement activation (Yokota et al., 1995). In our study the higher bands 
were clearly visible at specific timepoints and no obvious degradation was observed. 
There are a number of technical issues which must be considered when interpreting the 
results. The detectable bands are presumed to correlate with MBL trimer, tetramer, 
pentamer and hexamer but actual quantification is difficult. A band detected between 
the trimer and tetramer in some individuals at -325 KDa remains of unknown origin
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and detailed mass spectrometry of this specific band would be required to identify it.
The small number of samples investigated were predominantly from MBL-2 AA
subjects and just two YAYD subjects and an increased sample size would be required to
confirm the findings. The comparison of sequential samples was possible because an
equal amount of MBL was loaded for each timepoint calculated from the MBL
concentration measured by ELISA. The accuracy of the ELISA measurements could
therefore affect the interpretation of the Western blot.
In the current study we have demonstrated variability in the activity of the MBL lectin 
pathway of complement in response to chemotherapy and FN in a small group of 
children on treatment for cancer. Investigations into MBL structure at these times 
suggest that higher order oligomers are more abundant at the onset of FN in some 
individuals and the reasons for this are currently unknown. The changes in complement 
function are presumed to be influenced by the combination of changes in both MBL and 
MASP levels and potentially MBL structure. Our small and heterogenous sample limits 
further interpretation of these findings but future work will be important in deciphering 
the role of replacement therapy after chemotherapy treatment.
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Chapter 8
Transcriptional regulation of MBL
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8.0 Introduction
Transcriptional regulation of MBL 8
Although the potential role of MBL during various infectious and inflammatory 
diseases has been studied in great detail, our current understanding of the regulation of 
MBL remains severely limited. MBL is a soluble protein produced mainly by 
hepatocytes, though extrahepatic transcription has been reported in the small intestine, 
testis tissue and in mononuclear cells (Downing et al., 2003; Seyfarth et al., 2006). It is 
well established that polymorphisms in the MBL2 gene result in variation in the amount 
and/or function of the protein. For example: three point mutations in exon 1 impair 
formation of functional oligomers and the ability to activate downstream events. In 
conjunction with exon 1 polymorphisms, MBL expression is regulated by 
polymorphisms in the promoter region, with the XY polymorphism exerting the most 
profound effect.
Data presented in Chapter 7 show interindividual variation in MBL protein levels in 
response to chemotherapy and during FN which indicates that non-genetic 
mechanism(s) may influence its regulation. MBL is also suggested to be an acute phase 
reactant, adding further complexity to its regulation. An acute phase reactant is defined 
as a protein whose levels change by at least 25% in response to a stimulus e.g. 
inflammation (Morley and Kushner, 1982). An acute phase response is a systemic 
reaction to disturbances in homeostasis due to infection, tissue injury/trauma, surgery, 
neoplastic growth or an immunological disorder. The acute phase response (APR) is 
orchestrated by the release of cytokines (especially IL6) and activation of vascular and 
inflammatory cells. These in turn influence the production of acute phase reactants, such 
as C reactive protein (CRP), by hepatocytes (Kushner, 1993; Gabay and Kushner, 
1999).
Characterisation of the MBL2 gene and its promoter region has revealed similarities 
common to other acute phase reactants. Sequence analysis also highlights homology
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with regions of the Drosophila heat shock consensus sequence, three regions similar to
glucocorticoid-responsive elements and a sequence present in a cytokine responsive
element found in serum amyloid A protein (SAA) (Sastry et al., 1989; Taylor et al.,
1989). The MBL promoter was first characterised by Naito and co-workers and they
found hepatocyte-specific nuclear factor (HNF)-3 sites within the sequence (Naito et al.,
1999). Binding of transcription factor to these sites resulted in up regulation of MBL
transcription; in contrast, activation of the glucocorticoid responsive elements resulted
in down regulation. IL-6 responsive elements were also identified but their role in MBL
transcriptional regulation needs further characterisation. Using the Huh7 hepatoma cell-
line Arai et al found IL-6, dexamethasone and heatshock increased MBL gene
expression (Arai et al., 1993). Investigations into the effect of other pro-inflammatory
cytokines revealed that IL-1 inhibited transcription with minimal effect of TNFa and
IFNy. More recently, Sorensen et al reported thyroid and growth hormones can also
influence MBL synthesis (Sorensen et al., 2006).
In vivo studies have reported a 1.5 to 3 fold increase in MBL serum levels following 
major surgery and compared this response to changes in CRP levels. A dramatic 1000 
fold increase in CRP levels was noted, whereas MBL levels increased modestly and 
slowly as previously seen for C3 and ceruloplasmin (Thiel et al., 1992). Due to the very 
modest increase in MBL levels, defining MBL as an acute phase reactant may be an 
oversimplification.
Our knowledge regarding MBL’s regulation during infection and inflammation remains 
limited and the purpose of the present series of experiments was to gain further insight 
into MBL transcriptional regulation.
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8.1 Methods
8.1.1 Cell culture
Cell lines were maintained as described in Section 2.5.1. Cells were grown to 
confluency prior to stimulation studies (Section 2.5.2).
8.1.2 Reverse Transcription Polymerase Chain Reaction (RTPCR)
RNA was isolated from cell preparations prior to reverse transcription and then used in 
PCR. PCR products were visualised on agarose gels and semi-quantitative analysis was 
performed using densitometry. Specific details of the techniques used are detailed in 
Sections 2.5.3-2.5.5.
8.1.3 Cloning of the MBL promoter
The stepwise approach used to clone the MBL promoter is described in full in Section 
2.5.6.
8.1.4 Transient transfection studies
The MBL promoter/luciferase construct was transiently transfected into liver cell-lines 
prior to stimulation studies. On termination of the experiments, luciferase activity was 
measured and normalised to Renilla. Full details are described in Section 2.5.7. The IL- 
8 promoter construct was used as a positive control for the cell-line.
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8.2 Results
8.2.1 MBL gene expression in Hepatoma cell-lines
Initial experiments were conducted to confirm the genotype of the two hepatoma cell- 
lines. Genotyping (using the heteroduplexing method) revealed the HepG2 cell-line was 
heterozygous for a mutation in codon 54 (A/B) and the Huh7 cell-line was homozygous 
for wildtype alleles (A/A) (Figure 8.1). This is in agreement with a previous study 
(Dumestre-Perard et al., 2004). Both cell-lines were homozygous for the Y promoter 
(not shown) and their full haplotype combinations analysed using the INNO-LiPA assay 
were HYP A/HYP A, normally associated with high MBL levels and LYPB/HYPA, 
associated with medium to low levels.
HepG2 Huh7
AB AA
Figure 8.1 Exon 1 heteroduplexing results for HepG2 and Huh7 hepatoma cell- 
lines
MBL mRNA was detected in both cell-lines and also in primary hepatocytes (kindly 
provided by Dr P Smith, Institute of Child Health, London). The two cell-lines 
investigated showed constitutive MBL expression with the wild type Huh7 cells 
expressing at least 3 fold more mRNA when compared to the Hep G2 cell-line, 
measured by densitometry. This confirmed the influence of genotype on MBL mRNA 
expression as expected (Figures 8.2 and 8.4).
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Cytokines that are produced at inflammatory sites, predominantly by macrophages and
monocytes, are the chief stimulators of the production of acute phase proteins. 
Therefore we wished to understand how this cytokine milieu in an ongoing 
inflammatory episode may influence MBL expression. The potential effect of pro- 
inflammatory cytokines including IL-1 p, TNFa, INFy and IL-6 on MBL mRNA 
expression was investigated. IL-10 and IL-22 were chosen as representative of ‘anti­
inflammatory’ responses. E.coli LPS was used to mimic the effect of Gram-negative 
sepsis.
Expression of MBL in response to the various stimuli in both Huh7 and HepG2 cell- 
lines is shown in Figures 8.2-8.5. In the Huh7 cell-line a significant reduction in IL-lp 
mediated mRNA expression was noted 24h post stimulation. A trend for decrease in 
MBL expression was also noted in response to TNFa. IL-6 and IL-10 had minimal 
effect on expression however an increase was noted in response to IL-22 which was 
greater at 8h compared to 24h. In contrast in Hep G2 cell-line effects of IL-lp on MBL 
mRNA expression were modest, reaching no statistical significance. IL-6 had the 
greatest effect on MBL expression in the HepG2 cell-line and a trend for increase in 
MBL expression was also noted for TNFa and IL-22. Minimal effect of IL-10 was 
observed but LPS did modulate expression at 24h.
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Figure 8.2 Expression of MBL in Huh7 cell line
RNA from Huh7 cells was amplified by RT-PCR with primers specific for MBL and 
GAPDH. The constitutive expression of MBL in this cell line was found to be further 
modulated by cytokines. Results shown are representative data from 3 experiments 
performed at 8hrs and 24hrs.
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Figure 8.3 Regulation of MBL mRNA expression in Huh7 cells
Graphical representation of the mean MBL mRNA expression at 8 and 24h. Data shown 
are from three independent experiments and results are presented as mean ± S.E.
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Figure 8.4 Expression of MBL in HepG2 cell line
RNA from HepG2 cells was amplified by RT-PCR with primers specific for MBL and 
GAPDH. MBL gene expression was constitutive and further modulated by cytokines. 
Results shown are representative data from 3 experiments performed at 8 and 24hrs.
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Figure 8.5 Regulation of MBL mRNA expression in HepG2 cells
Graphical representation of the mean MBL mRNA expression at 8 and 24h. Data shown 
are from three independent experiments and results are presented as mean ± S.E.
Due to contrasting findings noted in the two cell-lines, we wished to further confirm our 
data using the more sensitive methodology of promoter-luciferase assays. This required 
cloning of the MBL promoter.
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8.2.2. Cloning of the MBL promoter
The MBL promoter of choice was from an individual with the HYPA/LYPA haplotype 
combination. Primers were designed with restriction enzyme sites tagged at the 5’ end 
of both sense and antisense primers to enable specific amplification of a 2933bp 
fragment 5’ of the ATG codon, as described by Naito et al. Figure 8.6 illustrates the 
purified 2.93KB PCR product.
Figure 8.6 Genomic DNA MBL promoter PCR product.
Lane 1, Lambda DNA/Hind III marker. Lane 2, 2.93KB MBL promoter PCR product
Enzyme digestion o f the MBL promoter and a promoterless luciferase reporter vector, 
the pGL3 basic vector, was performed using Hind III and Ncol restriction enzyme 
(Figure 8.7).
A B « C
Figure 8.7 Restriction digest products.
Lambda DNA/Hind III marker shown. Lane A- uncut vector, Lane B- cut vector -5KB, 
Lane C- cut PCR product 2.93KB.
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This step was followed by successful ligation of the PCR product into the vector,
observed by the presence of higher molecular weight bands (lanes G and H) (Figure
8 .8).
Figure 8.8 Ligation results.
Lambda DNA/Hind III marker shown (KB). Lane A&B- Vector, Lane C&D single cut 
Hindlll and Ncol respectively, Lanes E&F double cuts, Lanes G&H ligation product.
Transformation was performed using competent JM109 E.coli cells and subsequent 
colonies were screened for the presence of the MBL promoter insert (Figure 8.9).
Figure 8.9 PCR results confirming presence of MBL promoter construct in 9 
colonies.
Lambda DNA/Hind III marker shown (KB).
Double digests were subsequently performed to confirm the presence of the insert in the 
cloned vector. Figure 8.10 shows the results of the double digests of four independent 
colonies. All four showed the presence of the correct sized fragments for vector and 
insert. A third higher band represents uncut plasmid DNA.
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Figure 8.10 Double digests of 4 colonies showing presence of vector and insert in 
cut samples. A third higher band in the cut samples represents uncut plasmid DNA.
Sequencing of plasmid DNA using commercial primers spanning the vector was 
performed at the UCL core facility. Analysis of over 600bp confirmed complete 
homology with the published sequence and, specifically, all three MBL promoter 
polymorphisms were present.
8.2.3 Preliminary transfection studies
Once cloned, preliminary studies were performed to establish the optimum promoter 
concentration that would be used in transfection experiments. Both Huh7 and HepG2 
cell-lines were studied, with the HepG2 cell-line providing better transfection 
efficiency. All subsequent studies were conducted in HepG2 cells. Following 
transfection cells were stimulated for 8 and 24h with cytokines and LPS alone and/or in 
combination.
8.2.4 MBL promoter/luciferase studies
IL-1 (3, IL-6 and LPS showed a slight propensity for MBL promoter activation, between
1.2 and 1.5 fold induction during the first 24h (Figure 8.11). None of these effects were 
statistically significant. TNFa was the most potent cytokine tested with at least 2-fold
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induction at 8h increasing to 4 fold at 24h. In contrast IFNy showed a slight reduction
when compared to control.
As in-vivo, cytokines are likely to act in concert, we hypothesised greater effects on 
MBL gene expression in the presence of combinations of stimulants (Figure 8.12). 
Interestingly IL-6 in combination with IL-1 and LPS showed an additive effect on MBL 
transcription. No additive effect of IL-6 was noted in the presence of TNFa. 
Importantly, addition of a third stimulant in any form did not enhance MBL gene 
expression, highlighting the tight transcriptional regulation of this critical innate 
immune molecule.
The IL-8 promoter was used as a positive control for the cell-line and over 50 fold 
induction was observed following IL-1 stimulation (data not shown).
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Figure 8.11 MBL promoter activity in response to cytokine/LPS stimulation in 
HepG2 cells.
Promoter luciferase activity was assessed by normalisation to Renilla luciferase. Data 
are expressed as n-fold changes in luciferase activity when compared with unstimulated, 
control cells. Error bars indicate ± S.E. of values representative of 3 experiments 
conducted in triplicate.
258
Transcriptional regulation o f  MBL 8
® 1.5
t  0.5
Control IL-6 + IL-6 + IL-6 + IL-6 + IL-6 + IL-6+ IL-6 + IL-6 +
IFNy TNFa + TNFa + LPS TNFa + TNFa + TNFa + 
IL-1 IFNy LPS LPS IL-1 +
+IFNy LPS
Figure 8.12 MBL promoter activity in response to stimulation with cytokine/LPS 
combinations in HepG2 cells.
Promoter luciferase activity was assessed by normalisation to Renilla luciferase. Data 
are expressed as n-fold changes in luciferase activity when compared with unstimulated, 
control cells. Error bars indicate ± S.E. of values representative of 3 experiments 
conducted in triplicate (where error bars are not shown experiments had been performed 
only once).
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8.3 Discussion
To date there have been a limited number of studies investigating MBL transcriptional 
regulation with only one study investigating promoter function. The work presented in 
this chapter was undertaken to further delineate the regulation of MBL gene expression 
and its potential role as an acute phase reactant.
We investigated the regulation of MBL gene expression in two hepatocellular 
carcinoma cell-lines exhibiting different MBL genotypes. We found higher (3 fold) 
constitutive expression of MBL in the wild-type Huh7 cell-line when compared to the 
HepG2 cell-line which is heterozygous for a variant allele, confirming that genotype 
influences MBL mRNA expression. We were unable to confirm this finding by 
measuring MBL in the supernatant using the MBL ELISA described in Chapter 2 but a 
recent study utilising a more sensitive MBL assay (TRIFMA) with a detection limit of 
30pg/ml reported higher MBL levels in supernatant from Huh7 cells when compared to 
Huhl cells, another heterozygous liver cell line with the LYPB/LYQA haplotype 
combination (Sorensen et al., 2006).
Few studies have investigated the potential role of cytokines implicated in sepsis in 
regulating MBL. The RT-PCR experiments in the Huh7 and HepG2 cell-lines revealed 
contrasting findings. These may relate to genuine differences between the cell-lines, the 
limited sensitivity of the technique and/or their markedly different levels of constitutive 
MBL expression which influences interpretation of results. IL-6, IL-1 and TNF-a were 
chosen as pro-inflammatory cytokines and the observed upregulation in response to IL- 
6 and down-regulation with IL-1 is in agreement with a previous report (Arai et al., 
1993). The effect of IL-6 on MBL gene expression was greatest in the HepG2 cell line. 
TNF-a also modulated MBL expression in the HepG2 cell line. IL-10 has anti­
inflammatory effects and IL-22 is a member of the same cytokine family. IL-22 has 
previously been reported to up-regulate mRNA expression of acute phase reactants
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(serum Amyloid A, al-antichymotrypsin and haptoglobin) (Dumoutier et al., 2000). For
this reason, we also wished to investigate if IL-22 and IL-10 influenced MBL
expression. We found IL-22 induced MBL expression in a time dependant manner with
greater effects noted in HepG2 cells but IL-10 exerted no observable effect on MBL
transcriptional regulation. An effect of E.coli LPS was only observed in the HepG2 cell
line at 24h. A recent study by Sorensen et al was able to detect MBL in culture
supernatants of Huh7 cells stimulated with IL-6 for 3 days (Sorensen et al., 2006). A
dose dependent increase in MBL was observed with a maximum two fold increase in
cells stimulated with 1 pg/ml IL-6 which is above levels normally used in experiments
investigating acute phase activity and it could also be argued that 3 days is beyond the
time of an innate response.
Promoter studies in HepG2 cells revealed upregulation with TNF-a and IL-6. 
Interestingly the only other study investigating the promoter reported no significant 
effect of IL-6, TNF-a or IFN-y on MBL transcriptional activity (Naito et al., 1999). 
Naito et al used deletion constructs to conclude these findings in contrast to the 
stimulation experiments reported. Of note, when using combinations of cytokines and 
LPS, TNF-a alone remained the most potent stimulant.
Detailed analysis of the promoter sequence identifies one potential NFkB binding site
through which you would expect IL-1, IL-6 and TNF-a cytokines to be operating but
there is no published data from deletion construct studies to confirm this (Dr M Haston,
Institute of Child Health, London, personal communication). Synergistic effects were 
0
observed when some cytokines were combined and generally effects were greater at 24 
than 8h. IL-1 appeared to exert a mild inhibitory effect in some combinations as did 
IFN-y. This IL-1 effect may be time dependent as it has previously been noted to down 
regulate gene expression at 12 and 24h but upregulate it at 48h (Arai et al., 1993).
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Overall, promoter activity (fold induction) observed with the different stimulants was
relatively low. In contrast, the IL-8 promoter was used as an internal control for the cell
line and over 50 fold induction was observed in response to IL-1 stimulation. Naito et al
made deletion constructs which enabled identification of a number of both negatively
and positively acting elements within the promoter sequence implicating a complex
system which responds to a variety of stimuli (Naito et al., 1999). The construct utilized
in the current study contained all of these elements and results are likely to represent
their combined overall effect. Variation in MBL levels observed in individuals in
response to infection has been reported to be up to 3 fold (Thiel et al., 1992). Murine
MBL acute phase responses have also been studied and in response to LPS stimulation,
MBL A levels were reported to increase two fold (after 32h) but no increase in MBL C
was observed (Liu et al., 2001). The protein is also subject to a number of post
translational modifications and therefore the relevance of such findings to the in-vivo
situation remains unclear. Measurement of actual protein levels may be the most useful
measure of the acute phase response in future studies. Our use of 8 and 24h timepoints
may have been too early to assess the maximum response but as already discussed we
would argue that these would reflect an innate response and longer timepoints would
not.
This work adds support to the idea of a complex system of regulation involved in MBL 
expression which varies in individuals depending on their exposure to specific stimuli. 
Further work cloning different promoters, e.g. LXP/LXP, would be very useful to 
enable a comparison of the response to the stimuli used in this series of experiments, to 
further delineate individual variations in response. Gene deletion/directed mutagenesis 
experiments may also enable identification of novel transcription factor binding sites.
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9.0 General discussion and future prospects
The successful treatment of cancer in children comes at a price. Both disease and 
treatment render children immunosuppressed and susceptible to infection which causes 
significant morbidity and mortality. Treatment related infection is the second 
commonest reason for admission to hospital during treatment for cancer and has 
significant implications for both the health service and the quality of life of the patient 
and their family. Work to improve the treatment of infection is ongoing, specifically the 
ability to identify people at lower risk of infection who may be suitable for less 
intensive treatment with the goal of spending less time in hospital. What remains clear 
is that children with the same disease, treated on the same protocol vary in their 
susceptibility to infection. Identifying the reasons for this variability could prove critical 
to optimising management. Focus on the immune system may hold the key to this 
variation. It has been proposed that the innate immune system, our first line of defence 
against infection, may assume greatest importance at such times. MBL has been 
proposed in a number of studies to play a role in infection susceptibility. Genetically 
defined deficiency has been investigated but the findings of such studies have been 
variable leading to controversy in the field. MBL has warranted greater interest because 
recombinant protein has been produced and the oncology population have been 
proposed as potential candidates for therapy. However, a number of questions remain 
unanswered which are paramount to delineating the role of MBL replacement therapy in 
the future.
To address the issues remaining in the field we have undertaken a number of studies in 
a population of children with cancer. In collaboration with the 4 specialist oncology 
centres in London we have developed a new management strategy for FN which has 
been introduced in over 40 hospitals. Our cohort has provided us with the largest group 
of children with cancer in whom MBL gene polymorphisms have been studied in
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relation to infection susceptibility to date. MBL genotyping has been performed using 2 
different techniques and the benefits of these have been compared for their potential use 
in large scale studies. Protein work has been performed on a subgroup of these patients 
to explore MBL and MASP protein levels and functional activity of the lectin pathway 
of complement. Techniques have been developed to explore changes in MBL structure 
in response to both chemotherapy and during FN episodes. We have also explored the 
effects of chemotherapy and infection in a longitudinal manner enabling us to question 
the mechanisms behind MBL’s potential protective effect. The regulation of MBL 
expression is largely unknown and we have also investigated transcriptional control 
mechanisms.
9.1 The role of risk stratification (RS) in FN management in children
RS is not a new concept but it is relatively under used in paediatric populations because 
there are no universally agreed definitions. We were able to introduce of a new protocol 
(Chapter 3) which now enables approximately 20% of patients to be discharged after 
48h in hospital compared to previous median stays of 5 days for uncomplicated FN. 
Safe introduction of such a protocol into multiple centres with differing experience and 
confidence in the management of these children was the main priority. The data in this 
study represented the first year of its introduction and with time we would expect 
confidence in the application of the low risk policy to improve. Acceptance of the new 
management strategy by patients and their families is equally important. Studies have 
suggested that parental anxiety may limit uptake of outpatient FN management 
strategies, emphasising the need for good support and education (Sung et al., 2004, 
Laddie and Chisholm, 2007).
Our RS methodology concentrated on clinical variables and the patients underlying 
disease and treatment. Work is ongoing to improve the accuracy of the process and the
265
Discussion 9
inclusion of potential immune modifiers or genetic information about our immune 
system may optimise this further. The use of cytokine measurements such as IL8 has 
been reported and Oude Nijhuis et al described a cohort of patients treated for FN as 
outpatients selected using a combination of clinical data and IL8 measurements (Oude 
Nijhuis et al., 2005). At present such work is limited to research centres as these 
measurements are not routinely undertaken. The advantage of genetic information is 
that it can be obtained at the time of diagnosis of cancer and utilised in future RS 
processes. Figure 9.1 represents a proposed hierarchy of RS criteria utilising potential 
innate immune modifiers. These include patient specific factors that remain relatively 
constant throughout treatment (shown in blue) and episode specific factors that further 
influence the decision making process in any given FN episode (shown in red).
Clinical
wellness
Microbiology 
Neutrophil count
IL-8, IL-6, Procalcitonin 
levels at admission
Co-existing medical condition 
requiring hospitalisation
Social issues influencing compliance
INNATE IMMUNE GENETIC PROFILE
Patient age
Disease and treatment protocol
Figure 9.1 Hierarchy of factors influencing RS.
Base of pyramid (blue) represents patient specific factors, top of pyramid represents 
episode specific factors (red).
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9.2 Does MBL deficiency predispose children to cancer?
It has been proposed that MBL deficiency may predispose people to cancer. For this 
purpose MBL2 genotyping was performed (Chapter 4). Our data represents the largest 
population of children with cancer studied to date. We did not observe marked 
differences between our population and a similar paediatric cohort (Mead et al., 1997); 
any differences observed related to ethnicity and could not be explained by underlying 
disease. A link between MBL deficiency and childhood ALL has been reported but this 
work has not been supported by further studies (Schmiegelow et al., 2002). As expected 
our largest single disease group was ALL and the population was similar to the total 
group. The aetiology of childhood leukaemia remains unknown but an abnormal 
immune response to a common infection in a previously unexposed individual is 
proposed (Greaves 2006). With this regard MBL deficiency may actually have a 
protective role as individuals may have been exposed to more infective insults in early 
life, deemed essential to the development of a healthy immune response. This may also 
support the high incidence of MBL deficiency in the general population.
9.3 Does MBL deficiency influence infection susceptibility and severity 
during treatment for cancer?
As discussed above (Chapter 1) paediatric studies to date have been unable to answer 
this question due to study design and patient numbers. Our study was designed to 
capture a larger cojiort and study patients over a longer time course. The group was 
heterogenous and the data was not truly prospective but the overall information suggests 
unequivocally that patients heterozygous or homozygous for MBL mutations 
experienced more FN episodes with a median of 2 versus 1 compared to wild type and 
these FN episodes were more likely to represent clinically or microbiologically defined 
infections. This supports the concept that MBL is likely to be important in bacterial
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infections, however the individual infections found in the present study did not 
implicate a propensity for specific infections within our MBL deficient group (Chapter 
5). The duration of hospitalisation, used as a surrogate marker of severity of FN, was 
prolonged in patients deemed MBL deficient. Our analyses identified that this effect 
was most profound in patients at higher risk of severe infection by virtue of their 
underlying disease or treatment. Such endpoints are subject to a number of 
confounding variables but our findings were relatively consistent between groups, i.e. 
that the MBL deficient patients spent longer in hospital with FN compared to their MBL 
sufficient peers.
As the name suggests FN encompasses neutropenia in a febrile patient and implies a 
state of infection until proven otherwise. The contribution of MBL to this process is not 
in prevention of neutropenia or from a patient becoming febrile. Our data suggest that 
MBL sufficiency/deficiency influences the incidence of documented infection. If this is 
the case it may prevent infection developing or simply modify the clinical consequences 
e.g. lower the risk of prolonged/severe infection. Such an effect is supported by animal 
studies which have demonstrated that neutropenic MBL WT mice were able to clear 
their bacterial load faster than their MBL deficient litter-mates (Shi et al., 2004). The 
interpretation of data relating to paediatric intensive care unit admission in our 
population and in previously studied populations remains unclear. It may be 
inappropriate to extrapolate our findings to this cohort as there are often many reasons 
why patients get admitted to PICU (Meyer et al., 2005) which do not purely reflect their 
ability to respond to infection.
The use of MBL gene status in RS was inconclusive (Chapter 5) due to the group size. 
We hypothesised that MBL deficient patients would be more likely to require 
readmission to hospital following early discharge however the safety of our protocol 
resulted in very low readmission rates overall. Further work would be required in order
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to answer this question studying a larger cohort over a longer follow up period. It may 
be more useful in future studies to select patients from specific diagnostic groups at 
specific stages in their treatment for management with oral antibiotics from the outset. 
One such group would be children with ALL on maintenance therapy who are less 
likely to have a clinically or microbiologically defined infection and less likely to 
require prolonged hospital admission.
The heterogeneity of patients, in terms of diagnosis and treatment over the one year 
study period is likely to affect the validity of our findings. The potential use of MBL 
status in FN management is dependent on the definition of ‘risk’ and it is important to 
accept that this will vary over time. The influence of MBL during such episodes is also 
likely to differ depending on the degree of immunosuppression. This is explained by the 
concept of environmentally determined genetic expression (EDGE), i.e. genetically 
encoded differences in expressed proteins react differently under increasingly extreme 
environmental conditions. The resulting phenotype or pathology is determined through 
a combination of the functional magnitude of the genetic change and the severity of the 
environmental stimulus. Rare genetic disorders represent one extreme resulting in a 
phenotype while extreme environmental conditions represent the other and the majority 
of diseases lie between these two extremes (Figure 9.2).
This concept supports studies suggesting that the MBL gene is relatively redundant in a 
healthy host and implies that the environmental stimulus of different chemotherapy 
regimes coupled with MBL deficiency will inevitably result in different phenotypes 
over time. When interpreting our results we have compared patients with differing 
levels of risk in terms of developing FN or severe infection and despite this we have 
observed a relationship with MBL status. Using ALL as an example we have compared 
patients undergoing intensification with those on maintenance, two very different states 
of immuno-competence. Further prospective studies of disease specific populations are
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Figure 9.2 The EDGE concept.
Differing phenotypes or pathologies are reached through a combination of the severity 
of the genetic change and the severity of the environmental stimulus (Kallianpur, 2005).
warranted in order to prove the influence of MBL deficiency on infection burden during 
treatment for cancer.
9.4 Assessment of MBL or Lectin Pathway deficiency?
Our disease association studies utilised MBL genotype and levels (Chapter 5) but the 
question remains as to whether MBL genotype/level is the most clinically relevant 
measure to use. MBL does not work in isolation and the concept of one gene one effect 
would be somewhat surprising, hence our studies progressed to explore other 
components of the Lectin Pathway (Figure 9.3). Assessment of the functional activity of 
the three complement activation pathways identified a group of MBL2 WT subjects with 
protein levels in the normal expected range (>1000ng/ml) who were deficient in 
function. This group was able to form higher order oligomers (Figure 6.10), therefore 
structural differences did not explain the observed defect in function. We hypothesised 
that downstream components, the MASP enzymes may be responsible for the lack of 
activity in this group.
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Figure 9.3 Investigation of MBL specific lectin pathway activation
Blue boxes represent parameters analysed in the current study. Yellow boxes represent 
additional investigations which would contribute valuable information to future studies 
of abnormal pathway function.
Very little data is available on MASP levels in paediatric or diseased populations. 
Polymorphisms in the MASP2 gene have been reported which correlate with low 
protein levels. We investigated the MASP2 D105G polymorphism and a number of 
heterozygotes were identified with corresponding low protein levels. Other 
polymorphisms are likely to be responsible for low MASP2 levels observed in a number 
of other individuals. MASP3 was found to be present at high levels when compared to 
MASP2, the reason for this is unknown. Assessment of the different steps in the
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pathway using the C4 and C3 assays provided interesting results and showed good inter 
assay correlation. One subject with a potential MASP1 deficiency was identified. The 
present study highlighted that utilisation of MBL genotype or protein level alone is 
inadequate in reflecting the functional capacity of the lectin pathway in disease 
association studies. Future work to establish the contribution of the other MASPs and 
the influence of different MASP SNPs is warranted. More comprehensive MASP2 SNP 
analysis is available but the genetics of maspl/3 remains poorly understood. Such 
information could improve our understanding of the contribution of MASP1 and 
MASP3 to pathway dynamics.
9.5 Does chemotherapy affect MBL and the Lectin Pathway function 
and how is this pathway modulated during FN?
Clinical studies to date have assumed association between MBL deficiency and 
infection by extrapolating data from a number of sources. Our longitudinal study of a 
small subset of patients throughout chemotherapy and FN has provided insight into 
potential mechanism(s) that may be involved. We found chemotherapy did not 
markedly affect MBL production and this is in agreement with previous findings (Neth 
et al., 2001). Marked individual variation was observed during different episodes of 
chemotherapy which may relate to different chemotherapy drugs used. There was also 
no obvious effect of chemotherapy on higher order oligomer structure. Variation was 
seen from sample to sample but due to saturation this was difficult to interpret.
Our study is the first to investigate MASP levels in this context and maybe an important 
component contributing to changes in functional activity. Increase in MASP2 levels 
and marked decreases in MASP3 were observed in response to chemotherapy; in fact 26 
out of 27 patients showed a decrease in MASP3 levels (Figure 7.3). Current 
understanding of MASP3 function is limited. It is present in a variety of tissues and is
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not just hepatic in origin. Despite dynamic changes in MASP2 and MASP3 protein 
levels marked changes in functional activity with chemotherapy were not observed. 
Interpretation of these findings is limited by different durations of chemotherapy 
courses and different combinations of drugs used.
In contrast, differences in MBL structure and functional activity throughout FN 
episodes were observed. MBL higher order oligomers rather than the amount of total 
protein may be critical during FN. During a number of episodes (and consistent within 
the same individual) an additional higher band was identified on the first day of FN. 
One may hypothesise that patients suffering from infections respond by increasing 
production of higher order oligomers which have enhanced complement function. Of 
the two HYPD/HYPA subjects studied, one also showed the presence of higher 
oligomers on day 1 of FN. Further studies are required to explore how MBL 
heterozygotes respond to infection.
MBL pathway function appeared to peak on day 7 of the FN episode implying that it 
was playing a role within the resolution of these episodes. As the majority of our 
subjects in the study were MBL WT we were unable to test the hypothesis that 
heterozygotes were unable to increase their functional activity and hence suffered 
prolonged episodes. Variability in classical and alternative pathway function was less 
apparent throughout the period post-chemotherapy. This may relate to the sensitivity of 
assays utilised or may imply that components of these pathways are less affected by 
treatment and disease. The significant reduction in MASP3 levels during chemotherapy 
returned to pre-chemotherapy levels during the episode and MASP2 levels peaked on 
the first day of FN, falling thereafter. Results from Chapter 7 highlight the variability in 
MBL during stress but also imply that changes in other components of the pathway e.g. 
MASP2 are likely to influence function. Further work is required to delineate the 
complex control of these proteins and their interactions.
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Very little attention has been given to the transcriptional control of the MBL gene 
unlike other APRs e.g. CRP. Findings from Chapter 8 investigating the transcriptional 
regulation of the MBL protein using promoter studies revealed complex regulation of 
the system. Promoter activity was relatively low in keeping with changes observed in 
MBL protein levels in response to infection or inflammation. The influence of IL-6 and 
IL-22 with known effects on liver homeostasis was apparent and the signalling 
pathways involved are currently under investigation. Our results are in agreement with 
previous studies i.e. that MBL does not behave like a classical acute phase reactant such 
as CRP.
9.6 MBL replacement therapy
The work presented supports a role for MBL and the lectin pathway of complement in 
the regulation of infections in children with cancer and highlights the pitfalls of defining 
MBL deficiency by genotype or protein level alone. The question remains of how and 
when MBL replacement therapy may be a viable option. The present study emphasizes 
the need for potential candidates to undergo full assessment of lectin pathway function 
prior to consideration for therapy as we found patients who were WT for MBL 
genotype with normal expected MBL protein levels but an inactive lectin pathway. The 
identification of individuals with MASP2 deficiency is of particular relevance as 
administration of additional MBL would be fruitless in such subjects. Further work to 
identify subjects with other MASP deficiencies is also important in order to optimise the 
effects of rMBL in the most appropriate subjects. In terms of disease groups it seems 
most relevant to target those at increased risk of clinically significant infection on 
highly immunosuppressive drug regimens. Previous studies have suggested that any 
effect of MBL is overshadowed in such situations and that patients who are less 
immunocompromised by treatment may benefit more (Bergmann et al., 2003; Klein and
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Kilpatrick, 2004). Our data, using inpatient stay as a proxy measure of severity suggest 
that MBL deficiency assumes greatest relevance in patients at higher risk of clinically 
significant infection by virtue of their disease or treatment protocol but our numbers 
were too small to show significance. Improvements in supportive care and the universal 
use of broad spectrum antibiotics has resulted in the vast majority of patients recovering 
from FN without significant complications. We must await proof of concept studies in 
order to answer the question of who would benefit most.
Issues regarding patient selection rely somewhat on the decisions regarding 
administration. Phase I trials suggest that rMBL has a half life of ~31 hours and repeat 
infusions are required to maintain adequate plasma concentrations (>1000ng/ml) 
(Petersen et al., 2006). Whether MBL should be used as a prophylactic measure or a 
rescue treatment is open to debate. Our data suggest that MBL deficient patients suffer 
more episodes of FN with specifically clinically or microbiologically defined infections. 
This is in agreement with adult studies which have linked MBL deficiency with severe 
infections in similar patients (Peterslund et al., 2001; Horiuchi et al., 2005; Molle et al., 
2006; Vekemans et al., 2007). The administration of MBL replacement throughout 
chemotherapy treatment is unfeasible and would be very costly. The use of MBL 
replacement as rescue treatment is the alternative but the same issues remain i.e. 
frequency, duration and cost. Similarities can be drawn with the use of G-CSF in such 
patients. The practicalities of administration i.e. duration and frequency of infusions and 
the overall cost of the procedure may limit use in the long run.
The safety of any such procedure is of paramount importance in an already vulnerable 
population. The use of recombinant protein has overcome a number of safety concerns 
inherent to a plasma purified product which may originate from a number of donors 
with the risk of transinfection. Another risk with any recombinant protein is the 
development of antibodies but data suggests that this is not an issue with either
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recombinant or plasma purified products (Valdimarsson et al., 2004; Petersen et al., 
2006). MBL has a number of functions and there appear to be advantages and 
disadvantages to its replacement in an MBL deficient subject (Dommett et al., 2006) 
(Figure 9.4).
ADVANTAGEOUS 
TO HOST ? Protection against 
Leishmania and 
other intracellular
Protection against:
Infection 
Myocardial infarction
Modulation of inflammation 
(111,116, IL10)
DISADVANTAGEOUS 
TO HOST
Increased susceptibility to
Infectious diseases 
Autoimmune disease 
Sepsis/SIRS
Increased susceptibiity to: 
Leishmania and other
LOW HIGH
MBL level
Figure 9.4 Schematic representation illustrating how both high and low serum 
MBL levels may impact the health of a given host.
Lack of complement activating function is obviously undesirable in terms of infection 
management but equally enhanced complement activation can be deleterious to the host, 
e.g. ischaemia reperfusion injury (Hart et al., 2005; Walsh et al., 2005). Phase I studies 
using rMBL report no nonspecific complement activation following reconstitution to 
normal plasma MBL levels as measured by C3d concentrations. Overall no safety or 
tolerability concerns were raised when using rMBL in healthy subjects (Petersen et al.,
2006). The results of Phase II and III trials which may modify our future practice are 
eagerly awaited.
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9.7 Unanswered questions and future direction
The present project set out to address whether MBL gene status is the right indicator to 
influence our management of FN using RS. Our results suggest that MBL status does 
influence infection risk but that MBL status alone is an oversimplified measure of this 
system. Our studies imply that the lectin pathway is active within our patient population 
using the functional assays available. Further work to investigate the clinical 
relevance/applicability o f these measures is warranted. These assays incorporate the role 
of MASPs but it must be remembered that these enzymes also work in concert with 
Ficolins which in turn also activate the lectin pathway. Future work should include the 
investigation of Ficolins within the pathway in order to delineate their role and 
contribution to host defence as they may assume greater importance (Hummelshoj et al,
2007) (Figure 9.5).
Gene
MBL
LECTIN
ATHWAY
FicolinsM A S P s
FunctionProtein
Figure 9.5 Illustration of components of the lectin pathway.
Future studies should incorporate genetic, protein and functional analysis of the 
MASPs, Ficolins and MBL.
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Our current understanding o f the role of MBL higher order oligomers to MBL function 
remains limited. If MBL deficient patients are unable to increase production of higher 
order oligomer in order to fight infection MBL replacement at such a time may be very 
valuable. Variation between the YAYD individuals also warrants further studies as 
these individuals are obviously a unique population who can raise their levels to that of 
WT but clinically behave like other heterozygotes.
The role o f a lectin pathway genetic profile incorporating MBL, MASP and Ficolin 
polymorphisms may be most informative to future practice. Identifying pathway 
deficiencies within patients at the beginning of their treatment for cancer and modifying 
their infection management accordingly may improve both quality of life for the patient 
and also improve the efficacy o f their chemotherapy treatment preventing interruptions 
and delays in therapy (Figure 9.1). The use o f MBL replacement as a supportive 
measure in infection management is an exciting prospect. The practicalities of its use 
and the cost effectiveness o f such an intervention remain under investigation. We 
should be mindful that manipulation of the immune system can have positive and 
negative effects and it is imperative that the benefits of replacement therapy outweigh 
any risks to our patients.
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Abbreviations
A Angstrom
AA MBL2 Exon 1 wildtype
ALL Acute Lymphoblastic Leukaemia
AML Acute Myeloid Leukaemia
AMPs Antimicrobial Peptides
ANC Absolute Neutrophil count
AO MBL2 Exon 1 heterozygote
ATP Adenosine triphosphate
BIR Baculoviral inhibitor-of-apoptosis-protein repeat
BMT Bone Marrow Transplant
bp Base pair
C Cysteine
CARD Caspase-recruitment domain
cDNA Complementary DNA
CRD Carbohydrate recognition domain
CRP C reactive protein
CVC Central venous catheter
D Aspartic acid
DC Dendritic cell
DNA Deoxyribonucleic acid
dNTPs deoxynucleotide triphosphates
DTT Dithiothreitol
EGF Epidermal growth factor
ELISA Enzyme linked immunosorbent assay
FCS Fetal Calf Serum
FN Febrile Neutropenia
G Glycine
GAPDH Glyceraldehyde-3 phosphate dehydrogenase
GI Gastrointestinal
hBD Human beta defensins
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HIV
HRP
IFN-y
IL
IRAK
KDa
LBP
LDL
LPS
LRR
LTA
P
MAC
MAMPs
MAP
MARCO
MASP
MBL
MCP
mM
mRNA
MW
NAIP
NALP
NF-kB
NHL
NK
nM
NOD
OD
OO
P
Human immunodeficiency virus 
Horse radish peroxidase 
Interferon gamma 
Interleukin
IL-1 receptor-associated protein kinase 
Kilodalton
Lipopolysaccharide binding protein
Low-density lipoprotein
Lipopolysaccharide
Leucine rich repeat
Lipoteichoic acid
micro
Membrane attack complex
Microbe associated molecular patterns
Mitogen-activated protein
Macrophage receptor with collagenous structure
MBL associated serine protease
Mannose Binding Lectin
Membrane cofactor of proteolysis
millimolar
Messenger ribonucleic acid 
Molecular weight
Neuronal apoptosis inhibitor protein
NACHT, LRR, PYD containing protein
Nuclear factor-xB
Non Hodgkins Lymphoma
Natural killer
Nanometre
Nucleotide binding oligomerization domain protein 
Optical density
MBL2 Exon 1 homozygote or compound heterozygote 
Pico
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PAGE Polyacrylamide gel electrophoresis
PAMPs Pathogen associated molecular patterns
PBMCs Peripheral blood mononuclear cells
PBS Phosphate buffered saline
PBSC Peripheral blood stem cell
PCR Polymerase chain reaction
PINE Paediatric infections during neutropenic episodes
PKR Double stranded RNA (dsRNA)-activated protein kinase
POC Paediatric Oncology Centre
POSCU Paediatric Oncology Shared Care Unit
PRRs Pattern recognition receptors
rMBL Recombinant Mannose Binding Lectin
RPM Revolutions per minute
RS Risk stratification
RT Room temperature
SAP Serum Amyloid protein
SCT Stem cell transplant
SDS Sodium dodecyl sulfate
SIRS Systemic Inflammatory Response syndrome
SLE Systemic Lupus Erythematosus
SNP Single Nucleotide Polymorphism
SP-A Surfactant protein A
SP-D Surfactant protein D
TBS Tris buffered saline
TLR Toll like receptor
TNF-a Tumour necrosis factor alpha
TPOC Thames Paediatric Oncology Centre
TRAF6 Tumour necrosis factor receptor-activated factor 6
UHG Universal Heteroduplex generator
UV Ultra violet
P micro
WT Wildtype
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